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Arginine methylation is catalyzed by the protein arginine methyltransferase 
(PRMT) family of enzymes, which transfer a methyl group from S-adenosylmethionine 
(SAM) to the guanidinium group of an arginine residue.  This reaction first produces 
monomethylated arginine (MMA) that can then be further methylated to produce either 
asymmetrically dimethylated arginine (ADMA) or symmetrically dimethylated arginine 
(SDMA).  There are nine PRMT family members described to date, with PRMT1 as the 
predominant member, suggested to be responsible for ~85% of asymmetric 
dimethylation.  In addition, PRMT1-dependent methylation likely plays a significant role 
in a plethora of diseases (e.g., cancer, heart disease, and ALS).  These observations 
render it imperative that the isozyme be more thoroughly characterized and suggests that 
potent and selective inhibitors may be useful as therapeutics.  
 Herein we describe our efforts to decode PRMT1-dependent methylation by 
investigating the catalytic mechanism, the effects of post-translational modifications and 
protein-protein interactions on activity, the development of potent and selective inhibitors 
and inactivators, as well as examining crosstalk between arginine methylation and 
phosphorylation.  Using site-directed mutagenesis and unnatural amino acid 
incorporation, we have identified key active site residues that are critical for catalysis 
and/or substrate binding, and have determined the effects of phosphorylation, if any, on 




knowledge of the regulation of PRMT1 activity by protein-protein interactions.  The use 
of MS/MS analysis aided in the identification of the site of modification for a potent 
inactivator of the isozyme, C21, and has led to the design of new inhibitors and 
inactivators that will likely be more potent and selective for not only PRMT1, but 
PRMT5 as well.  Finally, using a peptide based model, we began to investigate crosstalk 
between arginine methylation and serine/threonine phosphorylation within kinase 
consensus sequences and hypothesize that it is an important means of regulation in 
regards to cell signaling.  Overall, the results presented in the following chapters have 
enhanced our understanding of PRMT1-dependent methylation and have opened doors 




Table of Contents 
Dedication .......................................................................................................................... iii 
Acknowledgements ............................................................................................................ iv 
Abstract .............................................................................................................................. vi 
List of Tables ..................................................................................................................... xi 
List of Figures .................................................................................................................. xiii 
Chapter 1. Introduction ........................................................................................................1 
1.1 Post-Translational Modifications ...............................................................................1 
1.2 Modification of Histones ............................................................................................1 
1.3 Crosstalk Between Post-translational Modifications .................................................4 
1.4 Arginine Modifications ..............................................................................................6 
1.5 Protein Arginine Methyltransferase Family .............................................................10 
1.6 Role of PRMT1 in Disease .......................................................................................20 
1.7 Conclusion ................................................................................................................28 
Chapter 2. Mechanistic Studies on PRMT1 .......................................................................29 




2.2 Materials and Methods .............................................................................................33 
2.3 Results & Discussion ...............................................................................................39 
2.4 Conclusions ..............................................................................................................64 
Chapter 3. Regulation of PRMT1 by Post-translational Modifications .............................69 
3.1 Introduction ..............................................................................................................69 
3.2 Materials and Methods .............................................................................................75 
3.3 Results & Discussion ...............................................................................................81 
3.4 Conclusions ..............................................................................................................89 
Chapter 4. Regulation of PRMT1 by Protein-Protein Interactions ....................................91 
4.1 Introduction ..............................................................................................................91 
4.2 Materials and Methods .............................................................................................94 
4.3 Results & Discussion ...............................................................................................98 
4.4 Conclusions ............................................................................................................102 
Chapter 5. Development of PRMT1 Inhibitors................................................................104 
5.1 Introduction ............................................................................................................104 
5.2 Materials and Methods ...........................................................................................111 
5.3 Results & Discussion .............................................................................................116 
5.4 Conclusions ............................................................................................................123 
Chapter 6. Crosstalk Between Methylation and Phosphorylation ...................................126 
6.1 Introduction ............................................................................................................126 
6.2 Materials and Methods ...........................................................................................143 




6.4 Conclusions ............................................................................................................153 
Chapter 7. Conclusions & Future Directions ...................................................................157 
References ........................................................................................................................162 






List of Tables 
Table 2.1. Peptide Sequences.............................................................................................40 
Table 2.2. Kinetic parameters of PRMT1 mutants for the AcH4-21 peptide. ...................40 
Table 2.3. Kinetic parameters of PRMT1 mutants for SAM. ............................................41 
Table 2.4. SAH Inhibition Studies. ....................................................................................42 
Table 2.5. Solvent Isotope Effects (SIE) and Solvent Viscosity Effects (SVE). ...............60 
Table 3.1. Observed modifications of PRMT1. .................................................................72 
Table 3.2. Kinetic parameters of PRMT1 mutants for the AcH4-21 peptide. ...................82 
Table 3.3. Kinetic parameters of PRMT1 mutants for SAM. ............................................82 
Table 3.4. Kinetic parameters of PRMT1 mutants for the AcH4-21 peptide. ...................86 
Table 3.5. Kinetic parameters of PRMT1 mutants for SAM. ............................................86 
Table 3.6. Percent activity of select protein kinases with PRMT1. ...................................88 
Table 5.1. IC50 values for PRMT1 inhibitors and inactivators. .......................................109 
Table 5.2. Kinetic parameters of PRMT1 mutants for the AcH4-21 peptide.. ................118 
Table 5.3. Kinetic parameters of PRMT1 mutants for SAM. ..........................................118 
Table 5.4. IC50 values for C21 .........................................................................................119 




Table 6.1. Tested Substrates for PRMT1 and Akt. ..........................................................141 
Table 6.2. PRMT1 and Akt Crosstalk Predictions. ..........................................................142 
Table 6.3. Peptide Sequences...........................................................................................148 
Table 6.4. Kinetic parameters of PRMT1 for the FOXO1 peptide substrates. ................148 
Table 6.5. Kinetic parameters of PRMT1 for the FOXO1 peptide substrates. ................151 
Table 6.6. Kinetic parameters of PAD4 for the FOXO1 peptide substrates. ...................151 

















List of Figures 
Figure 1.1. Selected post-translational modifications of arginine, lysine, serine, threonine, 
and tyrosine. .........................................................................................................................2 
Figure 1.2. Post-translational modifications of histones. .....................................................3 
Figure 1.3. Crosstalk scenarios. ...........................................................................................5 
Figure 1.4. PAD catalyzed reaction. ....................................................................................7 
Figure 1.5. Role of PAD4 in NET formation.......................................................................8 
Figure 1.6. PRMT catalyzed reactions. ................................................................................9 
Figure 1.7. Structure of PRMT1 family members. ............................................................11 
Figure 1.8. PRMT1 splice variants. ...................................................................................12 
Figure 1.9. Proposed model of an ERα-dependent role of PRMT1 in breast cancer. ........22 
Figure 1.10. Proposed model of the role of PRMT1v2 in breast cancer. ..........................23 
Figure 1.11. Proposed model of the role of PRMT1 in leukemia. .....................................24 
Figure 1.12. Proposed model of the role of PRMT1 in heart disease. ...............................26 
Figure 1.13. Proposed model of the role of PRMT1 in ALS. ............................................27 
Figure 2.1. Active site of PRMT1. .....................................................................................31 




Figure 2.3. Amino acid analysis of PRMT1-dependent methylation products..................46 
Figure 2.4. Processivity of WT PRMT1 and M155 mutants. ............................................47 
Figure 2.5. D51 and H293 interaction. ..............................................................................52 
Figure 2.6. pH profiles of WT PRMT1 with SAM. ...........................................................55 
Figure 2.7. pH profiles of WT PRMT1 and mutants with the RGG3 peptide. ..................58 
Figure 2.8. Processivity of WT PRMT1 and mutants. .......................................................61 
Figure 3.1. Structural comparisons between the PRMTs and contrast between amino acid 
side chains ..........................................................................................................................73 
Figure 3.2. Structure of PRMT1 and structural contrast of amino acid side chains ..........74 
Figure 3.3. Immunoprecipitation of PRMT1 .....................................................................83 
Figure 3.4. Synthesis of pCMF  .........................................................................................84 
Figure 3.5. Incorporation of pCMF into PRMT1 ..............................................................85 
Figure 3.6. Expression and purification of PRMT1(Y291pCMF) .....................................85 
Figure 3.7. MS/MS Analysis of PRMT1(Y291pCMF)  ....................................................86 
Figure 4.1. Enzyme regulation scenarios of PRMT1 by CAF1 and BTG1  ......................93 
Figure 4.2. Effect of interacting proteins on PRMT1 activity at high concentrations of 
substrate  ............................................................................................................................99 
Figure 4.3. Effect of interacting proteins on PRMT1 activity at low concentrations of 




Figure 4.4. Effect of interacting proteins on PRMT1 activity at low concentrations of 
substrate  ..........................................................................................................................101 
Figure 4.5. Summary of the effects of CAF1 and BTG1 on PRMT1 activity .................102 
Figure 5.1. Structures of selected PRMT inhibitors discovered from library screenings 105 
Figure 5.2. Structures of selected PRMT inhibitors discovered from virtual screenings 106 
Figure 5.3. Structures of SAM analogues and selected bisubstrate PRMT inhibitors  ....107 
Figure 5.4. Mechanism of PRMT1 inhibition by AAI  ...................................................108 
Figure 5.5. Structures of haloacetamidine based inhibitors and inactivators  .................109 
Figure 5.6. Possible mechanisms of inactivation of PRMTs  ..........................................110 
Figure 5.7. MS/MS of the site of modification of PRMT1 with (A) Cl-amidine and (B) 
C21 ...................................................................................................................................117 
Figure 5.8. Dialysis experiments of WT PRMT1 and the C101A mutant with C21  ......119 
Figure 5.9. Structure of PRMT1 showing the position of the C101 residue in relation to 
SAH .................................................................................................................................120 
Figure 5.10. Synthesis of N-ethyl-aminoadenosine and Cl-acetamidino-N-ethyl-
aminoadenosine................................................................................................................121 
Figure 5.11. Dialysis experiments of WT PRMT1 with Cl-acetamidino-N-ethyl-
aminoadenosine................................................................................................................123 
Figure 5.12. Structural representation of PRMT cysteine residues around the active site 




Figure 6.1. Potential model for crosstalk between arginine methylation and 
phosphorylation ...............................................................................................................126 
Figure 6.2. Serine/Threonine Protein Kinase consensus sequences ................................127 
Figure 6.3. Structural basis for crosstalk  ........................................................................135 
Figure 6.4. Processivity of PRMT1 .................................................................................150 







1.1 Post-Translational Modifications 
Post-translational modifications (PTMs) of proteins are well-known for the 
variety of roles they play in controlling cellular functions.  With over 400 different 
experimentally determined types (Khoury et al. 2011), PTMs add to the diversity of the 
already complex nature of the proteome by influencing protein-protein interactions, the 
cellular location of proteins, and protein stability through alterations to the size, charge, 
and hydrogen bonding capabilities of the parent residues (Figure 1.1).  These processes 
are the basis for a plethora of cellular functions (e.g., transcription and signal 
transduction) that are vital to the maintenance, growth, and survival of healthy cells.  Due 
to their fundamental roles in the cell, the dysregulation of various PTMs has been 
associated with a wide range of diseases (e.g., cancer and autoimmune diseases), thus 
making the responsible enzymes attractive drug targets. 
1.2 Modification of Histones 
The most notable and well-studied group of modified proteins are the histones.      
In the nucleus, two of each of the four core histones (i.e., H2A, H2B, H3, and H4) come 
together as an octamer around which DNA is wrapped and held in place by histone H1 to 
form a complex known as the nucleosome.  Nucleosomes are further packaged into 







Figure 1.1 Selected post-translational modifications of arginine, lysine, serine, 
threonine, and tyrosine. (A) Arginine residues can be mono- and dimethylated by the 
PRMTs to form ω-MMA, ADMA, or SDMA. They can also be converted to 
citrulline by the PADs. (B) Lysine residues can be mono-, di-, and trimethylated by 
KMTs, acetylated by KATs, or ubiquitinated by ubiquitin ligases. (C) Serine, 
threonine, and tyrosine residues can be phosphorylated by kinases. 
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dictates whether genes are transcribed.  PTMs on the unstructured N-terminal tails of 
histones are responsible for switching the transcription of genes on and off using what 
has been termed the histone code (Figure 1.2). For example, specific modifications can
 
Figure 1.2 Post-translational modifications of histones. 
 
cause the destabilization of chromatin via the disruption of key interactions between 
DNA and histones (i.e., electrostatic interactions), such as in the case of acetylation of 
lysine 16 on histone H4 and the inhibition of heterochromatin formation (Shogren-Knaak 
et al. 2006 & Bannister et al. 2011).  They can also aid in the recruitment of the 
transcriptional machinery through protein domains that are capable of binding such 
PTMs (e.g., bromo-, chromo-, tudor-, and pleckstrin-homology (PH) domains (reviewed 
in Kouzarides et al. 2007).  In terms of blocking transcription, a modification can also 





tri-methylated lysine 9 of histone H3 and its recruitment of heterochromatin protein 1 
(HP1) (Canzio et al. 2011).    
1.3 Crosstalk Between Post-Translational Modifications
1
 
Over the last decade there have been several examples of crosstalk between two 
or more different post-translational modifications (PTMs), with many of these being 
observed within the context of histones.  Generally, this crosstalk is thought to modulate 
and fine-tune cell signaling cascades such that a desired outcome is achieved e.g., 
transcription of a particular gene or, alternatively, activation of one gene under the 
control of a transcription factor and repression of another.  Although crosstalk between 
two or more PTMs has predominantly been studied within the context of chromatin 
biology (Suganuma et al. 2008 and Lee et al. 2010), as one would expect, this type of 
regulatory mechanism extends to non-histone proteins as well.  Several models have been 
proposed for histone crosstalk (Fischle 2003 et al., Schreiber et al. 2002, Fischle et al. 
2008), and they are readily applied to non-histone proteins as well (Figure 1.3).  For 
example, cis crosstalk refers to communication between modifications on the same 
protein (Figure 1.3A).  Within cis crosstalk lies the possibility for adjacent crosstalk (i.e., 
between residues that are close to one another in both the primary and tertiary structures) 
or distal crosstalk (i.e., between residues that are far apart in both the primary and tertiary 
structures) (Figure 1.3A).  Trans crosstalk is also possible and occurs between 
modifications on two different proteins (Figure 1.3B).  Functionally, direct crosstalk 
refers to one PTM directly affecting the modification of a second residue (e.g., 
modification of one residue prevents the modification of another residue) (Figure 1.3C).   
                                                 
1
 Adapted with permission from Rust, H.L.; Thompson, P.R., Kinase consensus sequences: a breeding 







Figure 1.3 Crosstalk scenarios. (A) The cis-effect refers to crosstalk 
between two or more modifications located on the same protein. 
Within the same protein there can be adjacent (i.e., between residues 
that are close in both primary and tertiary structures) or distal (i.e., 
between residues that are separated in primary and tertiary structures) 
crosstalk. (B) The trans-effect refers to crosstalk between two 
modifications located on two different proteins. Functionally, 
crosstalk can be (C) direct (i.e., one modification inhibits or enhances 
the subsequent modification of the same or a different residue) or (D) 
indirect (i.e., a specific modification inhibits or enhances protein-
protein interactions leading to altered downstream effects). Note that 
while this figure depicts crosstalk involving histones, the same 
explanations can be applied to non-histone proteins. Adapted from 





Indirect crosstalk involves modulating a protein-protein interaction via the presence, 
or lack, of a PTM (e.g., a PTM enhances the binding of a transcription factor leading to 
the recruitment of other coactivators) (Figure 1.3D).  An early example of direct cis 
crosstalk (Figure 1.3A) from the histone field involves the phosphorylation of H3S10 and 
the acetylation of H3K14.  Here, stimulation of the Ras-MAPK (mitogen activated 
protein kinase) pathway (Chadee et al. 1999)
  1
 results in the Rsk-2 (ribosomal S6 kinase) 
dependent phosphorylation of H3S10 (Sassone-Corsi et al. 1999), which enhances the 
acetylation of H3K14 by generating a better substrate for the histone acetyltransferase 
Gcn5 (general control non-repressed 5) (Cheung et al. 2000, Clayton et al. 2000, and Lo 
et al. 2000).  Although this is only one example of crosstalk from the histone field, a 
plethora of others have been published (reviewed in Suganuma et al. 2008, Lee et al. 
2010, and Baek et al. 2011), including several papers that describe crosstalk in non-
histone proteins, with a particular set of crosstalk examples involving serine/threonine 
phosphorylation and the modification of neighboring arginine residues; and these 
examples will be discussed later in Chapter 6.  
1.4 Arginine Modifications 
 Arginine residues within proteins can undergo several different types of PTMs, 
some of which are more prevalent and well-studied than others.  These modifications 
include enzyme mediated modifications, i.e., citrullination, methylation, phosphorylation, 
and ADP-ribosylation, as well as non-enzymatic modifications, i.e., advanced glycation 
end-products (AGE) and carbonylation (reviewed in Slade et al. 2013).  The most 







Citrullination, also known as deimination, is catalyzed by the protein arginine 
deiminase (PAD) family of enzymes, which is comprised of PADs1-4 and PAD6.  These 
isozymes catalyze the conversion of the guanidium moiety of arginine to an ureido 
moiety via a calcium dependent hydrolytic mechanism (Kearney et al. 2005).  This PTM 
alters electrostatic interactions by changing a positively charged residue to a neutral 
residue (Figure 1.4).  In regards to histones, the in vivo sites of citrullination have been 
determined to be H2 Arg 3 (Hagiwara et al. 2005), H3 Arg 2, Arg 8, Arg 17 (Cuthbert et 
al. 2004), and Arg 26 (Cuthbert et al. 2004 & Zhang et al. 2012), and H4 Arg 3 (Wang et 
al. 2004).  Citrullination of these sites correlate with either transcriptional repression 
(e.g., citrullination of H3 Arg 17 at the pS2 promoter) (Cuthbert et al. 2004, Wang et al. 
2004) or activation (e.g., citrullination of H3 Arg 26 at ERα target genes) (Zhang et al. 
2012), depending upon the specific histone and residue.      
 
Figure 1.4 PAD catalyzed reaction. PADs catalyze the 
conversion of the guanidinium moiety of an arginine 
residue to an ureido moiety via a calcium dependent 
hydrolytic mechanism.  
 
In addition to its role in transcription, histone citrullination, specifically histone 





of the innate immune response.  NETs are comprised of decondensed chromatin, with the 
DNA and histones acting as traps for pathogens (Figure 1.5) (Neeli 2008 et al., Wang et 
al. 2009, Li et al. 2010).  Non-histone proteins, such as myelin basic protein (MPB) 
(Wood et al. 2008) and antithrombin (Chang et al. 2005), are also citrullinated by 
members of the PAD family, thus demonstrating the versatility of these isozymes.  
Citrullination has become an increasingly important PTM because of its apparent roles in 
diseases such as Rheumatoid Arthritis (RA), Multiple Sclerosis (MS), ulcerative colitis, 
Alzheimers Disease (AD), and cancer (reviewed in Jones et al. 2009).  In fact, Cl-
amidine, a pan-PAD inhibitor, was found to decrease disease severity in animal models 
of spinal cord injury (Lange et al. 2011), collagen-induced arthritis (CIA) (Willis et al. 
2011), ulcerative colitis (Chumanevich et al. 2011), and cancer (McElwee et al. 2012).     
 


















 Methylation of arginine residues is catalyzed by the protein arginine 
methyltransferase (PRMT) family of enzymes.  These isozymes transfer a methyl group 
from S-adenosylmethionine (SAM) to the guanidinium moiety of arginine residues in 
proteins, but not free arginine.  This reaction first produces an ω-monomethylarginine 
residue (ω-MMA), which in most cases is further methylated to produce either an 
asymmetrically dimethylated arginine residue (ADMA) or a symmetrically dimethylated 
arginine (SDMA) residue (Figure 1.6).  The addition of one or two methyl groups does  
Figure 1.6 PRMT catalyzed reactions. PRMTs catalyze the transfer of a methyl 
group from S-adenosylmethionine (SAM) to the guanidinium group of an arginine 
residue. Type I PRMTs produce asymmetric dimethyl arginine (ADMA), Type II 
PRMTs produce symmetric dimethyl arginine (SDMA), and Type III PRMTs only 
produce ω-monomethylarginine (ω-MMA). 
 
not alter the charge of the residue; however, it decreases the number of potential 
hydrogen bond donors, thus leaving the possibility of decreased intra- or intermolecular 





arginine demethylase has yet to be discovered.  Some have suggested the possibility that 
PAD4 may catalyze a demethylimination reaction that would convert methylated arginine 
to citrulline.  This conversion would not truly reverse the modification but may have a 
similar function.  There is conflicting evidence in vitro and in vivo however, as to 
whether this reaction actually occurs in the cell, with more evidence supporting the 
notion that it does not take place (reviewed in Thompson et al. 2006).  
1.5 Protein Arginine Methyltransferase Family 
In humans, there are nine PRMT family members including: PRMT1, -2, -3, -4, -
6, and -8 (Yang et al. 2013), which are type I PRMTs that produce ADMA; PRMT5, 
which is a definitive type II PRMT and produces SDMA (Yang et al. 2013); and PRMT7, 
which is a type III PRMT and generates only ω-MMA (Miranda et al. 2004 & Zurita-
Lopez et al. 2012) (Figure 1.6).  Note that enzymatic activity has yet to be demonstrated 
for PRMT9.  All PRMTs possess a highly conserved ~310 amino acid catalytic core that 
is responsible for methyltransferase activity.  This core consists of a SAM binding 
domain that contains a Rossmann type fold typical of Class I methyltransferases, a unique 
β-barrel domain, and a dimerization arm.  All family members possess an N-terminal 
extension and several also contain C-terminal extensions (Figure 1.7) (reviewed in Yang 
et al. 2013). 
1.5.1 PRMT1 
 PRMT1 is the most prevalent PRMT isozyme and it is thought to be responsible 
for ~85% of the asymmetrically dimethylated arginine residues in vivo (Tang et al. 2000 
& Pawlak et al. 2000).  The PRMT1 gene, located at 19q13.3 in humans (Scorilas et al. 






Figure 1.7 Structure of PRMT family members.  PRMT family members have four common 
motifs in their SAM binding domain and one motif in their unique PRMT domain.  Each 
isozyme has a distinct N-terminus with some containing common protein domains such as a 
SH3 or a Zn finger domain. Adapted from Yang et al. 2013. 
 
cerevisiae and over 90% between mammals, zebrafish, and Xenopus (Zhang et al. 2003).  
This isozyme was originally discovered as an interacting partner of the immediate-early 
gene TIS21 (Lin et al. 1996), leukemia-associated BTG1 (Lin et al. 1996), and interferon-
α receptor (IFNAR1) (Abramovich et al. 1997), as well as via sequence homology to a 
yeast homolog (Scott et al. 1998).  PRMT1 is the smallest member of the PRMT family 
and has three major human splice variants (i.e., PRMT1v1-v3) (Scott et al. 1998 & 
Goulet et al. 2007), that translate into proteins ranging from 353-371 amino acids in 
length (Scott et al. 1998 & Pawlak et al. 2000), and four minor variants (i.e., PRMT1v4-







Figure 1.8 PRMT1 splice variants.  The NES of PRMT1v2 is highlighted in green.   
 
are only beginning to understand the differences between these splice variants, the 
variation of which lies within the N-terminus (Figure 1.8), these variants 
show different tissue expression patterns and have effects on subcellular localization.  For 
example, PRMT1 is expressed in all tissues studied thus far (Scott et al. 1998, Tang et al. 
1998, Lin et al. 1996, Pawlak et al. 2000), with PRMT1v1 and –v2 found in several 
tissues, -v4 only in the heart, -v5 predominately in the pancrease, no detection of –v6, 
and -v7 mostly in the heart and skeletal muscles (Goulet et al. 2007).  In regards to 
subcellular localization, PRMT1 as a whole is located in both the nucleus and the 
cytoplasm (Tang et al. 1998, Cote et al. 2003, Frankel et al. 2002, Goulet et al. 2007).  
More specifically, PRMT1v3, -v4, -v5, and –v6 are diffuse throughout the cell (Goulet et 
al. 2007), whereas PRMT1v1 and –v7 are more nuclear (Goulet et al. 2007) and 
PRMT1v2 is primarily cytoplasmic (Herrmann et al. 2005 and Goulet et al. 2007).  In 




















2007) and was found to translocate from the nucleus, contingent on substrate methylation 
status (Herrmann et al. 2005) and catalytic activity of the enzyme (Herrmann et al. 2009).  
Interestingly, these different N-terminal tails are also important for the substrate 
specificities of PRMT1, as demonstrated by the different methylation profiles observed 
for each of the variants.  For example, known PRMT substrates such as SmB and Sam68 
were methylated to a greater extent by PRMT1v1 and –v2, but hnRNP A1 was a better 
substrate for PRMT1v5 and -6 (Goulet et al. 2007).  In addition, incubation of purified 
PRMT1 variants with extracts prepared from mouse embryonic stem cell yielded distinct 
visual differences in the proteins methylated by PRMT1v1 and –v2 (Goulet et al. 2007).  
Similar results were also observed with purified mouse PRMT1v1 and –v2 and mouse 
embryonic stem cell extracts (Pawlak et al. 2002).  Surprisingly, the addition of N-
terminal His6 tags to the two main variants abolished the differences in substrate 
specificity (Pawlak et al. 2002), thus demonstrating the uniqueness of the N-termini of 
PRMT1.  It is hypothesized that the unstructured N-terminal tail of the enzyme folds back 
and interacts with its substrates, which would account for the differences in observed 
substrate specificity (Goulet et al. 2007). 
Although vital for early postimplantation development, PRMT1 is not essential 
for cell viability (Pawlak et al. 2000).   This isozyme is involved in transcriptional 
regulation through both its methylation of Histone H4 at arginine 3 (Strahl et al. 2001 & 
Wang et al. 2001) and other proteins involved in transcription (e.g., transcription factors 
(Yamagata et al. 2008 & Jobert et al. 2009), coactivators (Teyssier et al. 2005), 
elongation factors (Kwak et al. 2003)), and RNA binding proteins (Cote et al. 2003, 





nuclear receptors (Koh et al. 2001) and transcription factors (i.e., YY1 (Rezai-Zadeh et 
al. 2003), p53 (An et al. 2004), STAT5 (Kleinschmidt et al. 2008), and AE9a (Shia et al. 
2012)), however, there are instances in which PRMT1 represses transcription 
(Kleinschmidt et al. 2008).   Interestingly, it was determined that methylation of arginine 
3 of Histone H4 enhances acetylation of lysine residues on both Histone H3 (Huang et al. 
2005) and Histone H4 (Wang et al. 2001 & Huang et al. 2005), but prior acetylation 
prevents methylation (Huang et al. 2005).   PRMT1 also plays a variety of other roles in 
the cell.   More specifically, it is involved in insulin signaling (Iwasaki et al.2007), 
estrogen signaling (Le Romancer et al. 2008), and interferon signaling (Abramovich et al. 
1997), as well as, DNA damage response pathways through methylation of MRE11 
(Boisvert et al. 2005, Dery et al. 2008, Yu et al. 2009) and 53BP1 (Boisvert et al. 2005). 
1.5.2 PRMT2 
PRMT2, the gene of which is located at 21q22.3, was discovered by Katsanis et 
al. and contains 57% nucleotide sequence homology to PRMT1 (Katsanis et al. 1997).  
The translated protein is 433 amino acids in length with an N-terminal extension that 
distinguishes it from PRMT1 (Krause et al. 2007).  This extension contains a SRC 
Homology 3 (SH3) domain, which is known to facilitate protein-protein interactions 
(Pawson et al. 1992, Mayer et al. 1993).  Interestingly, the SH3 domain is required for 
PRMT2’s interaction with E1B-AP5 (Kzhyshkowska et al. 2001) but not estrogen 
receptor alpha (ERα) (Qi et al. 2002).  Originally, methylatransferase activity for this 
enzyme could not be detected directly (Kzhyshkowska et al. 2001, Qi et al. 2002, Ganesh 
et al. 2006, Meyer et al. 2007).  It was recently discovered, however, that PRMT2 is a 





H4 in vitro (Lakowski et al. 2009) and histone H3R8 in Xenopus (Blythe et al. 2010).  
PRMT2 appears to mainly play the role of a transcriptional co-activator for a number of 
nuclear hormone receptors (e.g., androgen receptor, estrogen receptor) (Meyer et al. 
2007, Qi et al. 2002), which is unexpected because it is a cytoplasmic protein.  However, 
evidence has shown that it can be transported into the nucleus with the androgen receptor 
upon hormone stimulation (Meyer et al.2007).       
1.5.3 PRMT3 
PRMT3 is a Type I PRMT that was identified in a yeast two-hybrid screen for 
PRMT1 interacting proteins (Tang et al. 1998).  The gene is located at 11p15.1 and 
encodes a 531 amino acid protein that contains an N-terminal zinc finger domain (Krause 
et al. 2007).  This zinc finger domain was found to dictate substrate specificity and is 
vital for PRMT3’s interaction with RNA-associated proteins (Frankel et al. 2000).  
PRMT3 is located in the cytoplasm and, although the crystal structure suggests that it can 
form homodimers (Zhang et al. 2003), it was found as a monomer using gel filtration of 
rat cell extracts (Tang et al. 1998).  The major substrate of PRMT3 is the 40 S ribosomal 
protein S2 (rpS2), thus suggesting that this enzyme may play roles in the regulation of 
protein synthesis and or ribosome assembly (Swiercz et al. 2005).         
1.5.4 PRMT4/CARM1 
PRMT4, more commonly known as coactivator-associated methyltransferase 1 
(CARM1), was discovered during a yeast two-hybrid screen for proteins that interact 
with the AD2 domain of p160 coactivators (Chen et al. 1999).  The gene is located at 
19p13.2 and encodes a 608 amino acid protein in humans (Krause et al. 2007).  Although 





and C-terminal extension.  Neither of these extensions are required for enzymatic 
activity, homo-oligomerization, or p160 binding in vitro (Teyssier et al. 2002), however, 
both of them are required for the isozyme’s transcriptional coactivator function.  The N-
terminus adopts a pleckstrin homology domain (PH) fold that is typically involved in the 
formation of multiprotein complexes and the regulation of protein-protein interactions.  
The role of that this fold plays in the function of this isozyme remains to be determined 
(Troffer-Charlier et al. 2007).  Importantly, it was demonstrated that CARM1 is essential 
to life in that knockout mice die shortly after birth (Yadav et al. 2003).  CARM1 is 
known to methylate Histone H3 at arginine 2, 17, and 26 (Schurter et al. 2001), several 
splicing factors (e.g., SmB and U1C) (Cheng et al. 2007), as well as transcriptional co-
activators (e.g., SRC-3 (Feng et al. 2006), CBP (Xu et al. 2001 and Chevillard-Briet et al. 
2002), and p300 (Chevillard-Briet et al. 2002).  The identities of these CARM1 substrates 
exemplify the role of this isozyme as a coactivator involved in transcriptional regulation 
(Ma et al. 2001, Schurter et al. 2001, Chevillard-Briet et al. 2002, Feng et al. 2006). 
1.5.5 PRMT5 
Human PRMT5, originally known as Jak-binding protein 1 (JBP1), was identified 
during a search for Janus kinase 2 (Jak2) interacting proteins (Pollack et al. 1999) and 
was found to be a homologue of the previously reported Skb1 from Schizosaccaromyces 
pombe (Gilbreth et al. 1996) and HSL7 from Saccharomyces cerevisiae (Ma et al. 1996).  
It is the only known Type II PRMT and produces SDMA (Branscombe et al. 2001).  
Located at 14q11.2, the PRMT5 gene encodes a 637 amino acid protein (Krause et al. 
2007) with a large N-terminal extension that contains a TIM barrel domain (Antonysamy 





isozyme with its binding partner methylosome protein 50 (MEP50) (Antonysamy et al. 
2012).  MEP50 is a WD40-repeat containing protein that is required for PRMT5 
methyltransferase activity and aids in substrate recognition and interactions with other 
proteins, as the isozyme shows minimal activity unless it is a part of a larger multiprotein 
complex (Friesen et al. 2002).   Located in the nucleus and the cytoplasm, PRMT5 plays 
roles in a plethora of cellular processes such as transcriptional regulation (Pal et al. 2004, 
Pal et al. 2007, Wang et al. 2008), differentiation (Dacwag et al. 2007, Dacwag et al. 
2009, Mallappa et al. 2011), the synthesis of ribosomes (Ren et al. 2010), and cell 
proliferation (Pal et al. 2007 & Wang et al. 2008).  Similar to PRMT1, PRMT5 is 
essential for both embryonic development and the derivation of embryonic stem cells 
(Tee et al. 2010).  
1.5.6 PRMT6 
Discovered during a human genome search for PRMTs (Frankel et al. 2002), the 
PRMT6 gene is located at 1p13.1 and encodes a 375 amino acid protein (Krause et al. 
2007).  A type I PRMT, this particular isozyme is located exclusively in the nucleus and 
was the first PRMT discovered to be capable of automethylation (Frankel et al. 2002).  
PRMT6 plays roles in transcriptional regulation, regulation of HIV replication, base 
excision repair, and cell cycle progression via methylation of histone H2A arginine 3 
(Hyllus et al. 2007) and arginine 29 (Waldmann et al. 2011), histone H3 arginine 2 
(Hyllus et al. 2007, Guccione et al. 2007, Iberg et al. 2008), histone H4 arginine 3 (Hyllus 
et al. 2007), HIV-1 Tat (Boulanger et al. 2005), HMGA1a/b (Miranda et al. 2005 and 
Sgarra et al. 2006), DNA polymerase β (El-Andaloussi et al. 2006), and tumor suppressor 





of PRMT6 to be a rapid equilibrium random mechanism with dead end EAP and EBQ 
complexes (Obianyo et al. 2012). 
1.5.7 PRMT7 
The PRMT7 gene, which was also discovered from computational alignments of 
potential PRMT genes (Miranda et al. 2004 and Lee et al. 2005), is located at 16q22.1 
(Krause et al. 2007).  The gene encodes a 692 amino acid protein (Krause et al. 2007) that 
uniquely contains an additional but less conserved SAM binding domain at the C-
terminus (Miranda et al. 2004).  Surprisingly, the presence of both SAM binding domains 
were found to be necessary for methyltransferase activity, although SAM could only 
crosslink to the N-terminal SAM binding domain (Miranda et al. 2004), suggesting that 
only the N-terminal half of the enzyme is active and the C-terminus acts as a regulatory 
domain.  Although originally there were conflicting results regarding the final product of 
methylation, with one group suggesting a Type III enzyme and only the formation of ω-
MMA (Miranda et al. 2004) and another group suggesting a Type II enzyme and the 
formation of both ω-MMA and SDMA (Lee et al. 2005), recent evidence has supported 
the notion that it is a Type III enzyme with the latter result possibly being an artifact of 
contamination by PRMT5 (Zurita-Lopez et al. 2012).  Like PRMT1, PRMT7 is located in 
both the nucleus and cytoplasm (Lee et al. 2005).  Although one of the lesser 
characterized PRMTs, it has been suggested that this isozyme plays a role in cellular 
differentiation (Buhr et al. 2008) and the DNA damage response (Gros et al. 2006 and 
Verbiest et al. 2008). 
1.5.8 PRMT8 





protein, was originally discovered due to its 80% sequence homology to PRMT1, with 
the major variations located at the N-termini (Zhang et al. 2003).  Despite the high 
sequence homology between the two isozymes, PRMT8 expression is primarily restricted 
to brain tissue (Lee et al. 2005, Taneda et al. 2007, Kousaka et al. 2009) and it is targeted 
to the plasma membrane via myristoylation of its N-terminus at glycine-2 at its N-
terminus (Lee et al. 2005).  Interestingly, the N-terminus also plays a regulatory role in 
enzymatic activity in that the full length recombinant protein displays significantly 
decreased activity compared to a N-terminal truncated variation that more closely 
resembles PRMT1 (Sayegh et al. 2007).  The isozyme is also capable of automethylation 
via the production of ADMA on arginine 73 and ω-MMA on arginine 58, however, it is 
still uncertain as to whether this is an intra- or inter- molecular reaction, as PRMT8 is 
capable of forming homodimers (Sayegh et al. 2007).  Additionally, two proline rich 
sequences on the N-terminus have been found to bind SH3 domains of proteins, including 
the SH3 domain of PRMT2, however, the functional significance of these interactions is 
unknown as no change in PRMT8 activity was observed in in vitro assays (Sayegh et al. 
2007).  Several PRMT8 interacting proteins (e.g., TET-family of RNA-binding proteins, 
hnRNPs, and actin) were revealed via in vitro GST-pull down experiments with 
recombinant GST-PRMT8 and hypomethylated cell extracts.  Specifically, the isozyme 
co-localizes with Ewing’s sarcoma (EWS), independent of the binding partner’s 
methylation status (Pahlich et al. 2008).  The function of PRMT8 in the cell remains to be 
fully defined. 
1.5.9 PRMT9 





identified by sequence homology with other PRMT family members (Lee et al. 2005).  
No enzymatic activity has been reported and it has yet to be characterized.  Sequence 
analysis has shown that it is most closely related to PRMT7 in that it contains a second 
SAM binding domain on the C-terminus.  The N-terminus contains two tetratricopeptide 
repeats, which based on the previously reported functions of this motif (Blatch et al. 
1999), could potentially play a role in protein-protein interactions (Bedford et al. 2007).  
A controversy remains in regards to a second PRMT9, PRMT9 (2p16), which is also 
known as F-box only protein 11 (FBXO11).  This enzyme was found to produce ω-
MMA, ADMA, and SDMA (Cook et al. 2006) despite being structurally different from 
the PRMTs, which are a part of the Type I seven-β strand methyltransferase family (Katz 
et al. 2003 & Bedford et al. 2009).  A separate study demonstrated that this protein had 
no methyltransferase activity (Fielenbach et al. 2007); the production of SDMA in the 
original report may possibly be due to sample contamination by PRMT5 (Nishioka et al. 
2003).  Therefore, the methyltransferase classification of this protein has yet to be 
confirmed.         
1.6 Role of PRMT1 in Disease 
With the multitude and variety of roles that the PRMT isozymes play in the cell, it is 
conceivable that their dysregulation would be involved in the pathogenesis of one or 
more human diseases.  Our research thus far has focused on PRMT1 because it is the 
major Type I methyltransferase and would therefore logically play a greater role in the 
onset and progression of diseases compared to the other isozymes.  The following 







 A recent study of the expression levels of PRMT1 in tumors from various tissues 
revealed that the isozyme, and in some cases select splice variants, is/are significantly 
overexpressed in a variety of cancers (Yoshimatsu et al. 2011).  The results of this study 
are in agreement with several more specific studies that have shown that PRMT1 is 
overexpressed in breast cancer (Goulet et al. 2007)(Baldwin et al. 2012), colon cancer 
(Mathioudaki et al. 2008), gliomas (Wang et al. 2012), acute lymphoblastic leukemia 
(ALL) (Zou et al. 2012).  In addition, higher levels of serum ADMA is observed in 
cancer patients, an observation that is the first of its kind (Yoshimatsu et al. 2011).   
1.6.1.A Breast Cancer 
Estrogen and its receptor, estrogen receptor α (ERα), are well-known for the 
genomic roles that they play in breast cancer, demonstrated by the fact that 70% of breast 
cancers are estrogen dependent and ERα positive (Le Romancer et al. 2008).  
Surprisingly, evidence suggests that the role that PRMT1 plays in breast cancer is of 
nongenomic origin.  In the cytoplasm, the DNA binding domain of ERα is methylated by 
PRMT1 at arginine 260, in response to estrogen.  This methylation event leads to the 
formation of a multiprotein complex involving the receptor itself, Src kinase, 
phosphoinositide 3-kinase (PI3K), and focal adhesion kinase (FAK).  This complex 
ultimately activates protein kinase B (Akt) and induces cell proliferation and survival 
(Figure 1.9) (Le Romancer et al. 2008).  Interestingly, in the same study, 55% of invasive 
breast cancer tissues analyzed had high levels of methylated ERα and 45% had low levels 
(Le Romancer et al. 2008), thus demonstrating a plausible nongenomic role for PRMT1 






Figure 1.9 Proposed model of an ERα-dependent role of PRMT1 in breast cancer.
 
A second nongenomic role for PRMT1 in breast cancer has also been revealed 
(Figure 1.10).  The authors of this study had previously shown that the different splice 
variants of PRMT1 are overexpressed in breast cancer cells to varying degrees, with
PRMT1v2 having a more significant increase than the predominant PRMT1v1 (Goulet et 
al. 2007), which led them to further investigate the contribution of this particular variant 
to the disease.  RNA interference was used to abolish PRMT1v2 expression and yielded 
an increase in apoptosis and decreased cell invasion in an aggressive cell line.  
Intriguingly, overexpression of this variant caused increased invasiveness in a known 
non-aggressive cell line, that was not observed with the other PRMT variants.  The role 
of PRMT1v2 in cell motility and invasion is dependent on the localization and activity of 
the enzyme as mutations to the NES and activity site abolish the effects.  Further 
investigation into the role of this particular variant showed that it is likely involved in 
regulating β-catenin degradation, a protein involved in cell-cell adhesion, as an increase 
in phosphorylated β-catenin was observed in PRMT1v2 expressing cells (Baldwin et al. 
2012) (Figure 1.10).  This observation is in concordance with and in addition to another 





cytoplasm through regulation of Wnt signaling via methylation of Axin (Cha et al. 2011).  
 
Figure 1.10 Proposed model of the role of PRMT1v2 in breast cancer.  (A) In 
the absence of PRMT1v2, the Wnt signaling pathway targets Axin to the 
membrane, which allows β-catenin to enter the nucleus.  (B) In the presence 
of PRMT1v2, Axin is methylated, which leads to the phosphorylation of β-
catenin and subsequent degradation (Cha et al. 2011 & Baldwin et al. 2012). 
 
1.6.1.B Leukemia  
 
The mixed lineage leukemia (MLL) gene is commonly associated with ALL and 
AML in that chromosomal translocation of the gene forms fusion proteins that aberrantly 
regulate and activate the expression of genes such as class I homeobox (HOX) (Daser et 
al. 2005) and ultimately transform early myeloid progenitors and haematopoietic stem 
cells (Cozzio et al. 2003 & So et al. 2003).  PRMT1 was discovered to be a critical 
component of the MLL transcriptional complex comprised of the SH3-domain containing 
MLL-EEN oncogenic fusion protein, SAM68, an RNA-binding protein and substrate of 
PRMT1, and CREB-binding protein (CBP), a histone acetyltransferase (Cheung et al. 





binds SAM68 via its SH3-domain which leads to the recruitment of both PRMT1 and 
CBP to downstream targets of the fusion protein, in this case Hoxa9a (Figure 1.11).  
Methylation of histone H4 arginine 3 by PRMT1 leads to increased acetylation of histone 
tails by CBP and activation of gene transcription (Cheung et al. 2007).  This observation 
is in agreement with another study demonstrating cooperativity between PRMT1 and 
p300, a histone acetyltransferase related to CBP (An et al. 2004).  Other studies have 
shown that CBP interacts with wild type MLL (Ernst et al. 2001 & Daser et al. 2005) but 
recruitment of CBP alone by another MLL fusion protein, MLL-AFX, did not induce 
 
Figure 1.11 Proposed model of the role of PRMT1 in leukemia (Cheung et al. 2007).  
 
cellular transformation (So et al. 2002), thus suggesting that other factors are necessary.  
On the other hand, PRMT1 does not interact with wild type MLL, but the creation of a 
MLL-PRMT1 fusion protein transformed primary myeloid progenitor cells, thus 
demonstrating that the PRMT1 alone plays a key role in the MLL dependent leukemia 
(Cheung et al. 2007). 
In a separate but similar example, PRMT1 interacts with a splice form (AE9a) of 





isoform was identified from patient samples and rapidly induces leukemia in a mouse 
model (Shia et al. 2012).  Recruitment of PRMT1 by AE9a to the promoters of target 
genes yields activation of the genes by methylation of histone H4 and subsequent histone 
acetylation (Shia et al. 2012), as observed in in the previous example.  To further 
demonstrate the importance of PRMT1 in this pathway, knockdown of the enzyme 
decreased proliferation of AE9a leukemic cells (Shia et al. 2012). 
1.6.2 Heart Disease 
Heart disease is the leading cause of death in the United States for both men and 
women (Hoyert et al. 2012) and PRMT1 may be a contributing factor.  In addition to the 
observation that the enzyme is overexpressed in tissues of patients with this disease 
(Chen et al. 2006), free MMA and ADMA, which are products of the degradation of 
PRMT1 substrates, are competitive inhibitors of the nitric oxide synthases (NOSs), vital 
enzymes responsible for the production of nitric oxide (NO) (Valance et al. 1992).  Free 
MMA and ADMA are normally converted to citrulline by dimethylarginine 
dimethylaminohydrolase (DDAH) and can then be further broken down and used for 
protein synthesis or excreted (Vallance et al. 2004) (Figure 1.12).  An increase in PRMT1 
expression coupled with dysfunction of DDAH can cause an increase in free MMA and 
ADMA (Vallance et al. 2004) and research efforts have focused on ADMA because its 
concentration is 10 times greater than MMA in human plasma (Vallance et al. 1992 & 
Tran et al. 2003).  Elevation of free ADMA levels causes vasoconstriction (Achan et al. 
2003 & Vallance et al. 2004), due to a decrease in NO production, and its levels are 





mortality of patients suffering from end stage renal disease (Tran et al. 2003, Vallance et 
al. 2004, Leiper et al. 2002, Landim et al. 2009, Zoccali et al. 2001).       
                           
Figure 1.12 Proposed model of the role of PRMT1 in heart disease. 
 
1.6.3 Amyotrophic Lateral Sclerosis (ALS) 
 Amyotrophic lateral sclerosis is a progressive neurodegenerative disease that 
affects the entire motor system and half of patients die within 3 years of onset (Mitchel et 
al. 2007).  In the familial form of ALS, which accounts for 10% of cases (Shaw et al. 
1997), and more specifically termed ALS6, a gene fusion, i.e., fused in 
sarcoma/translocated in liposarcoma (FUS/TLS), was found to be mutated (Kwiatkowski 
et al. 2009 & Vance et al. 2009).  FUS is normally involved in transcription, RNA 
processing, and translation as a ribonuclear protein (Law 2006 et al. & Wang et al. 2008) 
and plays a crucial role in neurons regarding the formation of dendritic spines (Fujii et al. 
2005).  Although WT FUS is found mostly in the nucleus, FUS mutants appear to be 
localized in the cytoplasm (Kwiatkowski et al.  2009, Vance et al. 2009, Bosco et al. 
2010, Dormann et al. 2010, Gal et al.2011, Ito et al. 2011, Kino et al. 2011) where they 
have been observed to form inclusions and associate with stress granules (Dormann et al. 
2010, Bosco et al. 2010, Gal et al. 2011, Ito et al. 2011, Kino et al. 2011).  Two recent 






Figure 1.13 Proposed model of the role of PRMT1 in ALS.  (A) In the absence and 
presence of PRMT1, WT FUS localizes in the nucleus.  (B) In the absence of PRMT1, 
mutant FUS is capable of localizing in the nucleus, however, methylation of the mutant 
by PRMT1 leads to aggregation and formation of inclusions in the cytoplasm 
(Tradewell et al. 2012).  
 
2012, Tradewell et al. 2012) and mutant FUS (Tradewell et al. 2012) are methylated by 
PRMT1, however, methylation appears to predominantly affect the function of mutant 
FUS, as demonstrated by a PRMT1 knockout model in mouse embryonic stem cells 
(MES) and HEK293 cells, as well as methyltransferase inhibition in motor neurons.  The 
results revealed that PRMT1-dependent methylation appears to likely be a defining factor 
in the localization of mutant FUS to the cytoplasm (Tradewell et al. 2012).  Interestingly, 
the ALS linked FUS mutations are present on the C-terminus of the protein where the 
nuclear localization signal (NLS) is also located and it is hypothesized that the mutations 
may affect nuclear-cytoplasmic shuttling.  It remains unclear as to the exact role of the 





that ultimately lead to aggregation of mutant FUS in the cytoplasm and the formation of 
inclusions (Tradewell et al. 2012). 
1.7 Conclusion 
 
 The involvement of PRMT1 in the aforementioned diseases demonstrates the 
likelihood that this enzyme is a worthwhile drug target.  The close structural relationship 
between the PRMT family members presents a challenge in designing a selective 
inhibitor towards a particular isozyme.  In addition, the presence of PRMT1 splice-
variants with different substrate specificities and functions creates an additional level of 
difficulty.  There is also a lack of knowledge at this time in regards to how enzyme 
activity is regulated (e.g., PTMs or protein-protein interactions).  Herein, we will discuss 
mechanistic studies of PRMT1, potential methods of enzyme regulation, and the 
development of selective inhibitors.  We will also present evidence for possible crosstalk 




















PRMT1 shows the widest tissue distribution and highest expression, and is 
thought to be responsible for ~85% of the asymmetrically dimethylated arginine residues 
in vivo (Tang et al. 2000 & Pawlak et al. 2000).  It is located in both the nucleus and the 
cytoplasm (Herrmann et al. 2005) and is active as a head-to-tail dimer, which is formed 
by the interaction of the dimerization arm of one monomer with the SAM binding domain 
of another monomer (Zhang et al. 2003).  Our research thus far has focused on 
developing inhibitors that target this isozyme (Osborne et al. 2007, Osborne et al.2008, 
Obianyo et al. 2010, Bicker et al. 2010) due to its involvement in several diseases (e.g., 
cancer, heart disease, ALS).  Previously, we demonstrated that PRMT1 preferentially 
methylates a 21 residue peptide based on the N-terminus of histone H4 with comparable 
kinetics to the parent protein (Osborne et al. 2007).  Additionally, these studies 
demonstrated that positively charged residues present in the C-terminus of this peptide, 
which is denoted AcH4-21, are critical for the high rates of catalysis observed with this 
substrate.  We further demonstrated that PRMT1 catalyzes the methylation of the AcH4-
21 substrate in a partially processive manner, i.e., PRMT1 can rebind SAM and
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subsequently produce ADMA before the first methylation product, w-MMA, is released 
(Osborne et al. 2007).  Because ADMA formation is not obligatory, we have suggested 
that PRMT1 displays partial processivity.  The partially processive nature of this reaction 
is entirely consistent with the fact that PRMT1 uses a Rapid Equilibrium Random kinetic 
mechanism with dead-end E•SAM•w-MMA and E•AcH4-21•SAH complexes, where the 
E•SAM•w-MMA complex can undergo a second methyl transfer reaction to produce 
ADMA (Obianyo et al. 2008).   
To follow up on these studies and provide a mechanistic basis for the methylation 
of an arginine residue, which is arguably a weak nucleophile, we examined the structure 
of PRMT1 bound to SAH (Zhang et al. 2003).  Based on this structure, there are a 
number of highly conserved active site residues that likely play key roles in SAM 
recognition, substrate binding, and catalysis (Figure 2.1).  For example, in PRMT1 it has 
been suggested that R54 and E100 are involved in SAM binding by hydrogen bonding 
and forming electrostatic interactions with the carboxylate group and ribose moiety of 
SAM, respectively (Zhang et al. 2000 & Zhang et al. 2003).  The R54 residue also likely 
hydrogen bonds with the side chain of E144 to orient the γ-carboxylate of this residue for 
optimal electrostatic and hydrogen bond interactions with the Nη2 of a substrate arginine 
residue.  This interaction likely helps position Nη2 for attack on the methyl group of 
SAM.  The γ-carboxylate of E153 also likely contributes to the alignment of the substrate 
guanidinium via electrostatic and two hydrogen bond interactions with Nη1 and Nδ 
(Zhang et al. 2000 & Zhang et al. 2003), although, it should be noted that, in structures of 
PRMT1, the position of this residue does not appear to be catalytically competent as it is 





CARM1 also identified Y154, a conserved tyrosine residue that corresponds to Y39 in 
PRMT1, as potentially playing a role in PRMT catalysis.  Although Y39 is not visible in 
the crystal structure of PRMT1, the side chain phenol of this residue forms the top of the 
SAM binding pocket and is likely important for cofactor binding.  Additionally, based on 
the CARM1 structure, the phenol appears to interact with E153 (PRMT1 numbering) and 
help orient this residue, and, as a consequence, the substrate guanidinium to promote 
catalysis (Yue et al. 2007 & Troffer-Charlier et al. 2007). 
 
Figure 2.1 Active site of PRMT1. (A) Structure of PRMT1 (white) highlighting key 
residues in the active site believed to play roles in substrate binding and/or catalysis.  
Note that the PRMT1 structure is overlaid with PRMT3 (teal) because electron density of 
Y39 is not present in the crystal structure of PRMT1 and the positioning of E153 in 
PRMT1 is different from PRMT3, which is likely due to the crystallization conditions.  
This figure was prepared with UCSF Chimera using the coordinates from PRMT1 






















Also present in the active site is M155.  Although this residue is not thought to 
play a direct role in rate acceleration, it has been suggested (Branscombe et al. 2001) that 
M155 is responsible for the formation of ADMA as the end product of dimethylation, as 
opposed to SDMA, due to steric hindrance that would prevent the transfer of a methyl 
group to Nη1 after methylation of Nη2 (Zhang et al. 2000 & Branscombe et al. 2001).  
This hypothesis is supported by the fact that PRMT5, a Type II PRMT, has a serine 
residue in this position that presumably creates a more open pocket that enables 
symmetric dimethylation (Branscombe et al. 2001).  
Given that the guanidinium group is a relatively weak nucleophile, it has been 
suggested that its interaction with E153 causes a redistribution of electrons that activates 
Nη2 for an SN2-type nucleophilic attack on the methyl group of SAM (Figure 2.2) (Zhang 
et al. 2000).  This attack potentially results in the formation of a dication intermediate 
that undergoes the loss of a proton to possibly E144 or via a proton wire to H293.  
However because the formation of a dication intermediate is somewhat unfavorable, it 
 





has been suggested that PRMT1 uses a stepwise or concerted mechanism in which the 
proton is removed prior to or simultaneously with methyl transfer (Zhang et al. 2000). 
Herein we describe our efforts to characterize the catalytic mechanism of PRMT1 
using site directed mutagenesis on a number of highly conserved active site residues (i.e., 
Y39, R54, E100, E144, E153, M155, and H293), which are believed to play key roles in 
SAM recognition, substrate binding, and catalysis, as well as pH rate profiles, 
processivity studies, and the determination of Solvent Isotope Effects (SIEs).   
2.2 Materials and Methods 
2.2.1 Chemicals  
Sodium dodecyl sulfate (SDS), tris(hydroxymethyl)aminomethane (TRIS), 
tetramethylethylenediamine, acrylamide, and ammonium persulfate were purchased from 
Bio-Rad (Hercules, CA).  4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 
Tricine, dithiothreitol (DTT) were purchased from RPI (Mt. Prospect, IL).  Acetonitrile 
and methanol were purchased from Fisher Scientific (Pittsburgh, PA).  Sodium chloride 
and dimethylformamide (DMF) were purchased from Alfa Aesar (Ward Hill, MA). 
Piperidine was purchased from Sigma-Aldrich (St. Louis, MO).  Fmoc protected amino 
acids, (ethylenedinitrilo)tetraacetic acid (EDTA), and trifluoroacetic acid (TFA) were 
purchased from EMD (Gibbstown, NJ). 
14
C-labeled SAM was purchased from Perkin-
Elmer and 
14
C-labeled BSA from Sigma-Aldrich.  Mutagenic primers were purchased 
from IDT Inc. (Coralville, IA).   
2.2.2 Purification of PRMT1  
The purification of PRMT1 has been described (Osborne et al. 2007).  In brief, a 





hexa-histidine tag was transformed into E. coli BL21(DE3) cells.  One colony was used 
to inoculate 5 mL of LB media containing 50 μg/mL kanamycin and incubated overnight 
with shaking at 37 °C.  Two liters of LB media were inoculated with 20 mL of overnight 
culture containing 50 μg/mL kanamycin and grown at 37 °C and 250 rpm until OD600 = 
0.4-0.6.  Protein expression was then induced with 0.4 mM isopropyl-β-D-
thiogalactopyranoside and the cells were incubated with shaking at 22 °C overnight.  The 
next day the cells were harvested by centrifugation at 5000 rpm (4400 g) for 10 min.  The 
pellet was resuspended in 30 mL of Lysis Buffer (20 mM HEPES pH 8, 100 mM NaCl, 5 
mM imidazole pH 7.5, 0.5 mM PMSF, 5 mM 2-mercaptoethanol) and lysed using a 
French pressure cell at 20,000 psi.  The lysate was centrifuged at 13,000 rpm (20,250 g) 
for 30 min and the supernatant was applied to a Ni
2+
 Chelating Sepharose Fast Flow 
column.  The protein was eluted using a 5 mM to 500 mM imidazole step gradient in 20 
mM HEPES pH 8 and 100 mM NaCl.  Fractions were screened on a 12% SDS-PAGE gel 
and fractions containing protein were dialyzed overnight in 20 mM HEPES pH 8.0 and 
50 mM NaCl.  The next day the protein was additionally purified by FPLC using a Mono 
Q anion exchange column (GE Healthcare).  Fractions were screened on a 12% SDS-
PAGE gel and fractions containing protein were dialyzed overnight in 100 mM HEPES, 
200 mM NaCl, 1 mM DTT, 2 mM EDTA, and 10% glycerol.  The next day the protein 
was concentrated using a 10 kDa Amicon Centriplus centrifugal filter and the 
concentration was determined using a Bradford assay.  The enzyme was flash frozen in 
liquid nitrogen and stored at -80 °C. 
2.2.3 Site-Directed Mutagenesis 







(Stratagene).  The full open reading frame was sequenced for each 
mutant to ensure that only the desired mutation had been incorporated.  DNA that 
contained desired the mutation was then transformed into E. coli BL21(DE3) cells and 
purified using our established protocol for wild type (WT) PRMT1 (described above). 
2.2.4 Synthesis of Peptides 
AcH4-21 and RGG3 peptides were synthesized as previously described on a 
Rainin PS3 automatic peptide synthesizer using Fmoc chemistry on a Wang resin 
(Osborne et al. 2007).  The sequences of these peptides can be found in Table 2.1.  The 
peptides were cleaved from the resin with 95% TFA, 2.5% triisopropylsilane, and 2.5% 
water, and then precipitated with diethyl ether.  Peptides were purified by reverse phase 
HPLC with a mobile phase of water/0.05% TFA and eluted with acetonitrile/0.05% TFA.  
The masses were determined using a Bruker Ultraflex II MALDI-TOF mass 
spectrometer.   
2.2.5 Gel-Based Activity Assay 
A previously described gel-based assay was used to determine the steady state 
kinetic parameters of WT and PRMT1 mutants (Osborne et al. 2007).  Assays were 
performed in a reaction mixture of 50 mM HEPES pH 8.0, 1 mM EDTA, 50 mM NaCl, 
0.5 mM dithiothreitol, 15 μM [
14
C]-labeled SAM, and a varying concentration of AcH4-
21 (0-1000 μM final).  Reactions were pre-incubated at 37 °C for 10 min and WT 
PRMT1, or a PRMT1 mutant, was then added and the reaction was quenched after 15 
min.  For the assays varying SAM (0-39.7 μM final), the same reaction mixture was used 
except the concentration of AcH4-21 was held constant at 100 μM.  Each assay was done 





 20%.  The GraFit version 5.0.11 software (Leatherbarrow 2004) was used to fit the data 
to eq 1 or eq 2 if substrate inhibition was observed, 
υ  = Vmax[S]/(Km+[S])                                                       (1), 
                                       υ = Vmax[S]/[(Km+[S])(1+[S]/Ki)]                                              (2). 
2.2.6 MALDI-MS Based Activity Assay 
A previously described matrix assisted laser desorption/ionization (MALDI) MS 
based assay was used to determine the processivity of WT and select PRMT1 mutants 
(Osborne et al. 2007).  Briefly, assays were performed in a reaction mixture of 50 mM 
HEPES pH 8.0, 1 mM EDTA, 50 mM NaCl, 500 μM SAM, and 20 μM AcH4-21.  
Reactions were then pre-incubated at 37 °C for 10 min.  WT PRMT1 or a PRMT1 mutant 
was then added and the reaction was quenched with 3 μL of 50% TFA in ddH2O after the 
appropriate time period.  Spectra were acquired on a Bruker Ultraflex II MALDI-TOF 
MS or an Applied Biosystems 4800 Plus MALDI TOF/TOF MS and analyzed using Flex 
Analysis software.  The percent turnover was determined by dividing the intensity of the 
modified peptide by the sum of the intensities of the unmodified and modified substrates 
times 100%. 
2.2.7 Chemical Analysis of Methylation Products 
A reaction mixture of 10 μg of GST-GAR and 1.4 μM [
3
H]-SAM in 50 mM 
HEPES at pH 7.5 was incubated with 2 μg of WT PRMT1 or a PRMT1 mutant for 2 h at 
37 °C.  The products were then precipitated with an equal volume of 50% trichloroacetic 
acid, washed with acetone, and hydrolyzed for 20 h at 110 °C in 6 M HCl.  The 
hydrolysate was dried and mixed with standards of ADMA, SDMA, and w-MMA before 





2009). One-tenth of the fractions were used for ninhydrin analysis of the standards, and 
nine-tenths were counted. 
2.2.8 Partial Proteolysis 
Partial proteolysis assays were performed in a reaction mixture of 50 mM HEPES 
pH 8.0, 1 mM EDTA, 50 mM NaCl, 0.5 mM dithiothreitol, and in the absence or 
presence of 0.5 mM SAH and 0.75 μg/mL subtilisin on ice.  WT PRMT1, or a PRMT1 
mutant, was then added and the reaction was quenched after 60 min with 5 mM 
phenylmethylsulfonyl fluoride.  Protein fragments were separated by 12% SDS-PAGE 
and visualized with Coomassie Brilliant Blue. 
2.2.9 pH Profile 
The steady state kinetic parameters for the WT enzyme as well as the Y39F and 
H293A mutants were determined over a pH range of 6.0-9.25 using the gel-based activity 
assay described above.  Assays were performed in a reaction mixture of 50 mM Bis-Tris 
(6.0-7.0), 50 mM HEPES (7.0-8.5), 50 mM Tricine (8.5-9.0), or CHES (8.75-9.25), 1 
mM EDTA, 50 mM NaCl, and 0.5 mM dithiothreitol, with constant and varying 
concentrations of [
14
C]-SAM (0-41 μM final) and RGG3 (0-1000 μM final).  Each assay 
was done in duplicate and the standard deviation of the duplicate raw data values agreed 
within ≤20%.  Note that, in order to make certain that the variances in kinetic parameters 
were not the result of a buffer effect; an overlapping buffer method was utilized.  The 
kinetic parameters for the overlapping buffers were similar and thus the average was 
used.  In addition, time course assays were performed at each pH to demonstrate that 
activity was not lost over time.  The GraFit version 5.0.11 software (Leatherbarrow 2004) 





                                                                        (3), 














+1))           (4). 
For eq 3 and eq 4, Lim 1 corresponds to the activity measured at low pH, Lim2 
corresponds to the maximum activity measured at the optimum pH, and for eq 3, Lim3 is 
equal to the activity measured at high pH. 
2.2.10 Solvent Isotope Effect 
SIEs were investigated by determining the steady state kinetic parameters for the 
WT enzyme using the gel-based activity assay described above.  The reaction mixture 
consisted of 50 mM HEPES pH 8.0, 1 mM EDTA, 50 mM NaCl, 0.5 mM dithiothreitol, 
15 μM [
14
C]-labeled SAM, and a varying concentration of AcH4-21 (0-1000 μM final) in 
>92% D2O. The assay was done in duplicate and the standard deviation of the duplicate 
raw data values agreed within ≤20%.  The GraFit version 5.0.11 software (Leatherbarrow 
2004) was used to fit the data to eq 1. 
2.2.11 SAH Inhibition Studies  
The inhibition constants for SAH were determined for the WT and mutant 
enzymes using the gel-based activity assay described above.  The reaction mixture 
consisted of 50 mM HEPES pH 8.0, 1 mM EDTA, 50 mM NaCl, 0.5 mM dithiothreitol, 
15 μM [
14
C]-labeled SAM, 100 μM AcH4-21, and a varying concentration of SAH (0-
500 μM final). The assay was done in duplicate and the standard deviation of the 





(Leatherbarrow 2004) was used to fit the data to a Dixon plot of 1/υ versus SAH 
concentration.  The Ki was determined using eq 5, 
slope = Km/(Vmax*Ki*[S])                                        (5). 
2.2.12 pKa calculations 
 The structure of PRMT1 (PDB ID: 1ORI) was rebuilt using Amber topology 
parameters and hydrogen atoms added to the structure.  Atom partial charges and atomic 
radii were assigned based on Amber99 force-field using the program AMBER.  pKa value 
were computed taking into account desolvation effects and intra-protein interactions, 
including the proximity of neighboring functional groups.   
2.3 Results and Discussion 
To begin to investigate the catalytic mechanism of PRMT1, site directed 
mutagenesis was used to probe the roles of Y39, R54, E100, S102, E144, E153, M155, 
and H293.  The mutant enzymes were purified and characterized according to described 
procedures (Osborne et al. 2007).  AcH4-21, a 21 amino acid peptide based on the N-
terminus of histone H4, was used as a substrate for PRMT1 and mutants (Table 2.1).  The 
kinetic parameters of each mutant were determined for the AcH4-21 peptide as well as 
SAM (Table 2.2 & 2.3).  Note that similarly to other systems (Boehr et al. 2001 & 
Knuckley et al. 2007)
 2
, partial proteolysis studies were performed to ensure that the loss 
of activity associated with a particular mutation was not due to a gross structural 








Table 2.1 Peptide Sequences 
 
























 1.1 ± 0.5 ----- 4.6 x 10
-1
 ± 2 x 10
-2





 2.0 ± 0.7 1.8 4.2 x 10
-2
 ± 2 x 10
-3





 0.8 ± 0.6 0.7 1.09 x 10
-2
 ± 4 x 10
-4





 5 ± 1 4.5 6.0 x 10
-2
 ± 3 x 10
-3





 5 ± 1 4.5 3.6 x 10
-1
 ± 1 x 10
-2





 6 ± 2 5.5 2.5 x 10
-1
 ± 1 x 10
-2





 2.6 ± 0.9 2.4 1.85 x 10
-1
 ± 8 x 10
-3





 1.7 ± 0.4 1.5 2.2 x 10
-1
 ± 1 x 10
-2





 2.0 ± 0.6 1.8 1.3 x 10
-1
 ± 4 x 10
-3





 0.3 ± 0.2 0.3 9.5 x 10
-3
 ± 2 x 10
-4





 3.1 ± 0.5 2.8 2.65 x 10
-2
 ± 5 x 10
-4





 2.0 ± 0.8 1.8 7.7 x 10
-3
 ±  3 x 10
-4





 1.8 ± 0.6 1.6 3.8 x 10
-3
 ± 1 x 10
-4







3.0 ± 0.7 2.7 1.32 x 10
-1 
± 4 x 10
-3





 0.6 ± 0.4 0.5 1.73 x 10
-1
 ± 5 x 10
-3





 1.8 ± 0.5 1.6 4.6 x 10
-2
 ± 1 x 10
-3





 2 ± 2 1.8 7.6 x 10
-3
 ± 6 x 10
-4





 11.1 ± 0.6 10 1.81 x 10
-2
 ± 2 x 10
-4




[SAM] = 15 μM. 
b






2.3.1 Mutagenesis Studies of SAM Binding Mutants 
 
2.3.1.1 R54 Mutants 
R54 hydrogen bonds and/or forms an electrostatic interaction with E144, one of 
the two key glutamate residues, and presumably orients this residue for the productive 
recognition of the substrate guanidinium.  Additionally, both Nη1 and Nη2 of this residue 
interact with the carboxylate group on the methionine portion of SAM, which suggests 




















 6 ± 1 ----- 5.8 x 10
-1
 ± 3 x 10
-2 





 14 ± 3 2.3 7.0 x 10
-2
 ± 5 x 10
-3





 14 ± 1 2.3 3.3 x 10
-2
 ± 1 x 10
-3





 10 ± 1 1.7 9.5 x 10
-2
 ± 4 x 10
-3





 6 ± 2 1.0 4.8 x 10
-1 
± 5 x 10
-2





 7 ± 2 1.2 2.8 x 10
-1 
± 2 x 10
-2





 5 ± 2 0.8 1.6 x 10
-1 
± 2 x 10
-2





 4.0 ± 0.9 0.7 2.7 x 10
-1
 ± 2 x 10
-2 





 8.3 ± 0.9 1.4 1.60 x 10
-1
 ± 7 x 10
-3 





 3.1 ± 0.6 0.5 1.05 x 10
-2
 ± 4 x 10
-4





 5 ± 1 0.8 2.8 x 10
-2
 ± 2 x 10
3





 17 ± 4 2.8 1.9 x 10
-2
 ± 2 x 10
-3 





 9 ± 3 1.5 4.1 x 10
-3
 ± 4 x 10
-4 







10 ± 2 1.7 1.06 x 10
-1 
± 6 x 10
-3 





 10 ± 2 1.7 1.00 x 10
-1
 ± 8 x 10
-3 





 110 ± 21 18 2.9 x 10
-1
 ± 4 x 10
-2 





 17 ± 6 2.8 1.4 x 10
-2
 ± 2 x 10
-3 





 37 ± 2 6.2 5.6 x 10
-2
 ± 1 x 10
-3 









that this residue could play a key role in SAM binding (Figure 2.2).  Consistent with this 
prediction is the 42-fold decrease in the kcat/Km value observed for SAM with the R54K 
mutant.  However, the effect on kcat/Km is primarily driven by a decrease in kcat and not 
Km, suggesting that the lack of a more dramatic effect on the SAM Km reflects the multi-
step nature of the reaction, where Kd is not equal to Km; kcat/Km represents all steps up to 
and including the first irreversible step of the reaction.  To evaluate whether this was 
indeed the case, we determined the dissociation constants, i.e., Ki, for SAH binding to 
both the WT and R54A enzymes; SAH was used for these experiments as a proxy for 
SAM to more accurately gauge the effects of a particular mutation on SAM binding.  The 
results of these studies confirm that R54 is not critical for SAM binding, as evidenced by 






With respect to the peptide substrate, large changes in both kcat(app) (42- and 7.7-
fold) and kcat/Km (32- and 32-fold) were observed for both the R54K and R54A mutants, 
respectively.  Although these effects are at least partially related to our inability to 
completely saturate the enzyme with SAM in our radioactive methyltransferase assay, 
which is why the term kcat(app) is used, their magnitude, particularly on kcat(app), is 
consistent with a role for this residue in orienting the substrate guanidinium via E144 for 
nucleophilic attack on the methyl group of SAM.  Consistent with this notion is the fact 
Table 2.4: SAH Inhibition Studies 
 
Enzyme Ki (μM) 
WT 1.28 ± 0.06 
Y39F 26 ± 1 
R54A 1.8 ± 0.2 
E100A 1.9 ± 0.1 





that the kcat values obtained with SAM, where the peptide substrate is saturating, are 
decreased by a similar order of magnitude.         
2.3.1.2 E100 Mutants 
E100 hydrogen bonds to the ribose moiety of SAM and thus would be expected to 
play an important role in SAM binding.  Three mutants, i.e., the E100D, E100Q, and 
E100A mutants, were made to confirm this hypothesis.  With respect to the kinetic 
parameters determined for SAM, there is only a very small effect on kcat/Km.  For 
example, the complete removal of the E100 carboxylate, as occurs in the E100A mutant, 
decreases kcat/Km by only 3.2-fold.  The Ki for SAH with this mutant is similarly 
unaffected, quite clearly demonstrating that this residue is not important for SAM binding 
or catalysis. This result is especially surprising when one considers that the distances 
between the ribose hydroxyls and the α-carboxylate of E100 in the PRMT1●SAH 
complex are only 2.6-2.7 Å, which are distances typically associated with relatively 
strong hydrogen bonds.  Although the observed interactions may be an artifact of the 
crystallization conditions (the enzyme was crystallized at pH ~4.7, which would favor 
protonation of E100 and potentially promote hydrogen bond formation), similar distances 
and orientations are observed in the crystal structures of the PRMT3●SAH and 
CARM1●SAH complexes which were crystallized at pH 6.3 and pH 7, respectively 
(Zhang et al. 2000, Troffer-Charlier et al. 2007).  Thus, such an explanation is 
intellectually unsatisfying.  Nevertheless, these results are at least partially consistent 






With respect to the kinetic parameters determined for the AcH4-21 peptide, the 
effects, while still small, are significantly larger than those observed with SAM.  For 
example, the fold decrease in kcat(app)/Km for the E100D, E100Q, and E100A mutants are 
5.4-fold, 9.1-fold, and 5.7-fold, respectively.  As the effects are largely driven by an 
increase in Km, these results suggest that an interplay exists between the binding of both 
substrates, or alternatively, a change in the kinetic mechanism.  
2.3.1.3 M155 Mutants 
To probe the importance of M155, the M155L and M155A mutants were 
generated.  With respect to the peptide substrate, the kinetic parameters for the M155L 
mutant were similar to those obtained for the WT enzyme; the kcat(app) and kcat(app)/Km 
values were only decreased by 2.7-fold and 1.4-fold, respectively.  In contrast to these 
relatively minor effects, 5.8- and 10-fold decreases in kcat and kcat/Km were observed when 
SAM was tested as the varied substrate.  These effects either represent an inability to 
properly position the S-methyl group of SAM or, alternatively, an effect on SAM 
binding.  Given that M155 forms the bottom of the adenine portion of the SAM binding 
pocket, these results are most consistent with the latter possibility because the structural 
differences between a leucine and a methionine would be expected to alter SAM binding.  
Similar effects on SAM binding are observed with the M155A mutant.  For example, the 
Km and kcat/Km values of the M155A mutant for SAM are increased by 18- and 36-fold, 
respectively.  Confirming that this residue is important for SAM binding is the fact that 
the Ki for SAH is increased by 27-fold relative to WT.  The large changes in Ki, Km and 
kcat/Km likely reflect a loss of steric constraint within the SAM binding pocket, which 





respect to the peptide substrate, 10- and 16-fold reductions in kcat(app) and kcat(app)/Km were 
observed.  These effects are most likely due to our inability to completely saturate the 
enzyme with SAM in our radioactive methyltransferase assay. 
2.3.1.4 Role of M155 in ADMA Formation 
Given the postulated role of M155 in directing the formation of ADMA, as opposed 
to SDMA (Zhang et al. 2000 & Branscombe et al. 2001), we also investigated, in 
collaboration with Cecilia Zurita-Lopez and Steve Clarke (UCLA), the contribution of 
this residue to the regiospecific dimethylation of a substrate arginine residue.  For these 
studies, the M155A mutant was utilized because we hypothesized that this mutation 
would relieve the steric constraint imposed by the methionine and thereby open up the 
pocket and allow for SDMA formation.  To investigate this possibility, the M155A 
mutation, along with the WT control, was used to catalyze the 
3
H-SAM dependent 
methylation of GST-GAR, a fusion protein that links GST to the N-terminus of human 
fibrilarin (Figure 2.3).  Subsequently, the reaction was hydrolyzed in 6 M HCl at 110°C, 
and the extent of w-MMA, SDMA, and ADMA formed was quantified by high resolution 
cation exchange chromatography.  The results of these experiments indicate that the 
M155A mutant catalyzes the exclusive formation of w-MMA and ADMA.  Thus, despite 
the fact that this mutation relieves the steric constraint thought to prevent SDMA 
formation, our results indicate M155 is not responsible for the formation of ADMA over 
SDMA.   
Nevertheless, given that the mutation of this residue strongly impacts the kinetics of 
the PRMT1 catalyzed reaction, particularly with respect to the Km for SAM, we reasoned 





possibility, a previously established MALDI-MS assay (Osborne et al. 2007) was 
utilized.  Consistent with previous results with the WT enzyme, w-MMA and ADMA
 
Figure 2.3 Amino acid analysis of PRMT1-depedent methylation products.  
(A) WT PRMT1 produces a mixture of w-MMA and ADMA as products of 
methylation. (B) The M155A mutant also produces a mixture of w-MMA and 
ADMA as products of methylation.   In each case, the position of the 
standards was determined by ninhydrin assay (dotted lines); the position of the 
[
3
H]-radiolabeled derivatives by counting (solid lines).  The slightly earlier 




H]-w-MMA products compared to 
the standards is due to the mass and pKa differences of amino acids with 
tritium versus hydrogen-containing methyl groups (Fisk et al. 2009). 
 
containing peptides were initially produced in equimolar amounts, followed by a decrease 
in levels of w-MMA (Figure 2.4A).  As described previously, these results are 






Figure 2.4 Processivity of WT PRMT1 and M155 mutants. (A) WT PRMT1 
uses a partially processive mechanism to catalyze the formation of ADMA.  (B) 
The M155L mutant uses a partially processive mechanism, however, formation 
of ADMA is slower than with WT PRMT1. (C) The M155A mutant uses a 
distributive mechanism to catalyze the formation of ADMA. The large percent 
turnover of w-MMA suggests that w-MMA is released prior to the rebinding in 
preparation for the second round of methylation.  
 
ADMA before the first methylation product, w-MMA, is released (Osborne et al. 2007).  
Because ADMA formation is not obligatory, we have suggested that PRMT1 displays 
partial processivity.  With respect to the M155L mutant, similar results were obtained, 
however, the level of ADMA formed is significantly lower at the early time points 
(Figure 2.4B).  This result indicates that the M155L mutant is significantly less 
processive than the WT enzyme.  For the M155A mutant, little to no ADMA is formed 
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until the 20 min time point (Figure 2.4C), which suggests that w-MMA is released prior 
to the rebinding of SAM and that this mutant utilizes a distributive mechanism.  Note that 
the concentration of SAM used in these assays was 500 µM; thus the loss of processivity 
is not due to a failure to saturate the enzyme with SAM.  In total, these results are 
consistent with M155 playing a key role in SAM binding, as reduced affinity for SAM, as 
occurs with both the M155L and M155A mutants, would be expected to decrease the 
processivity of the enzyme because, for these mutants, the off rate for the 
monomethylated peptide is larger than the rate constant for SAM binding. 
2.3.2 Mutagenesis Studies of Catalytic Mutants 
2.3.2.1 E144 Mutants 
E144 appears to orient Nη2 of the substrate guanidinium group to facilitate 
nucleophilic attack on the S-methyl group of SAM.  In order to investigate this role, the 
E144D, E144Q, and E144A mutants were generated.  The kcat/Km values for the E144D 
mutant were decreased by 3.2-fold and 1.5-fold for AcH4-21 and SAM, respectively.  
The ability of aspartate to substitute for the glutamate indicates flexibility within the 
active site and reveals that positioning of this residue is not critical for catalysis.  For the 
E144Q mutant, the effects on kcat/Km are slightly larger, with these values down 6.1-fold 
and 5.3-fold for AcH4-21 and SAM, respectively.  These data suggest that the charge of 
this residue is significantly less important than its ability to hydrogen bond with both the 
substrate guanidinium and R54, as opposed to modulating the nucleophilicity of that 
group.  Note that the calculated pKa of the E144 carboxylate is ~2.7; thus this residue is 
likely deprotonated in the PRMT1 active site.  Nevertheless, this residue is important for 





AcH4-21 and SAM for the E144A mutant.  Note the effects on kcat/Km are dominated by a 
decreased kcat, suggesting that this residue is relatively unimportant for substrate binding.  
These results are consistent with previous findings from mutagenesis studies that only 
measured relative rates (Zhang et al. 2003).  In total, the data suggest that the hydrogen 
bonding characteristics, and to a lesser extent, the charge of E144, are important for 
orienting the substrate guanidinium for nucleophilic attack on the S-methyl group of 
SAM.   
2.3.2.2 E153 Mutants 
The carboxylate group of E153 is thought to play a crucial role in catalysis 
through its electrostatic and hydrogen bonding interactions with Nη1 and Nδ of the 
substrate guanidinium.  To investigate the importance of both the size and charge of this 
residue the E153D, E153Q, and E153A mutants were made and the kinetic parameters 
determined.  The results are consistent with this residue playing a key role in catalysis.  
For example, the kcat values for the E153D, E153Q, and E153A mutants are decreased by 
21-, 31-, and 140-fold, respectively.  Given that the effects on kcat/Km mirror the effects 
on kcat, these data indicate that both the charge and the position of E153 are more 
important for catalysis than substrate binding.  These results are also consistent with 
previous findings from mutagenesis studies that only measured relative rates (Zhang et al. 
2003).  The fact that mutating E153 has a more dramatic effect than mutating E144 is 
consistent with the notion that this residue plays an important role in redistributing 
electron density within the guanidinium group to enhance its nucleophilicity.    
2.3.3.3 E144A/E153A Mutant 





that the E144A/E153A double mutant would likely yield negligible, if any, activity.  
However, this was not the case, as kcat is decreased by only 5.5-fold and the kcat/Km values 
are only decreased by 9.3- and 9.1-fold for AcH4-21 and SAM, respectively.  The more 
significant effect on the single mutants is most easily explained by the formation of a 
strong salt bridge to the remaining glutamate.  Such an interaction would be expected to 
decrease activity by altering both the nucleophilicity of the guanidinium and its position 
such that methyl transfer is suboptimal.  The fact that the double mutant retains 
considerable activity is more difficult to rationalize.  However, it is possible that the 
removal of the two glutamate residues increases the hydrophobicity of the active site, 
which would be expected to depress the pKa of the guanidinium, and thereby increase its 
nucleophilicity.  Although we cannot rule out such a possibility, the active site possesses 
a number of other hydrophilic residues in close proximity (e.g., Y39, R54, and H293) that 
should minimize any change in hydrophobicity.  An alternative explanation that is 
equally supported by the data involves the PRMT1 catalyzed reaction being primarily 
driven by bringing the substrate guanidinium into close proximity to the S-methyl group 
of SAM. 
2.3.3.4 H293 Mutants 
H293 has been thought to play the role of a general base by accepting a proton 
from Nη2, however, this residue is >6 Å from the approximate position of the substrate 
guanidinium, a distance that is too far to directly remove the proton.  Although a water-
mediated proton transfer mechanism is possible, the high basicity of the substrate 
guanidinium makes this mechanism intellectually unsatisfying and we have suggested 





transfer, and that H293 may not act as a general base.  In order to probe this hypothesis, 
the H293Q and H293A mutants were generated. For the H293Q mutant, the kcat is 
decreased by 41-fold, whereas negligible changes in the Km values were observed, 
indicating that the 110- and 125-fold decreases in the kcat/Km values for AcH4-21 and 
SAM are driven by kcat.  For the H293A mutant, the effects on kcat/Km are similar in 
magnitude, with the kcat/Km values for AcH4-21 and SAM decreased by 256- and 50-fold, 
respectively.  Although these results indicate that H293 plays a critical role in catalysis, 
and could be interpreted as being consistent with a role for H293 as the general base, 
alternative explanations are also possible.  For example, in the structure of the 
PRMT1●SAH complex, H293 appears to form a salt bridge with D51, a conserved 
residue that is present on αY.  Given the short distance between the side chains of H293 
and D51 (i.e., 2.6 Å), this interaction likely plays a critical role in forming the two helix 
boundary that separates the SAM and peptide binding portions of the active site (Figure 
2.5).  As such, one would expect that disruption of this interaction would lead to 
decreased activity via the inability to properly form the substrate and cofactor binding 
pockets.  This is especially likely when one considers that Y39, H45, M48, and R54 are 
present on helix αY and αZ and likely play key roles in both PRMT1 catalysis (e.g., Y39 
and R54) and forming the active site cleft (e.g., H45 and M48).  Consistent with this 
possible role for H293 is the fact that similar effects on kcat/Km are observed for both 
SAM and the AcH4-21 peptide.  This is the case because either the alanine or glutamine 
mutations would not be expected to affect SAM binding, only kcat.  Given that R54 is also 
present on helix αY some of the effects of mutating this residue may also be due to the 






Figure 2.5 D51 and H293 interaction.  The kinetic 
effects of the H293 mutations can be explained by 
the fact that a salt bridge likely forms between D51 
and H293, which are only separated by 2.6 Å.  A 
disruption of this interaction could possibly prevent 
the proper formation of the binding pockets.  This 
figure was prepared with UCSF Chimera using the 
coordinates for PRMT1 (PDB 1ORI).  
 
2.3.3.5 Y39 Mutant 
 
In CARM1, Y154 appears to be important for both cofactor binding and orienting 
E267 (Y154 and E267 correspond to Y39 and E153 in PRMT1) (Yue et al. 2007, Troffer-
Charlier et al. 2007, Feng et al. 2009).  Although the Y154F mutant appears to abolish 
CARM1 activity, this was a single point assay and only relative rates were measured 
(Feng et al. 2009).  Thus, to establish the role of the corresponding residue in PRMT1, 
the Y39F mutant was generated and the kinetic parameters determined.  Although this 
mutation has only small, ~2-fold effects on the Km values for AcH4-21 and SAM, the Ki 
for SAH is increased by ~20-fold (Table 2.4), thereby confirming that this residue is 
important for cofactor binding; the lack of a more dramatic effect on the SAM Km reflects 









residue was further illustrated by the 20-fold decrease in the kcat/Km value observed for 
AcH4-21 and the 20-fold decrease seen with SAM.  The position of this residue within 
the PRMT1 active site and the fact that kcat is also decreased by 8.3 fold suggest that this 
residue also plays an important role in rate enhancement; the specific role of this residue 
in catalysis is described below (see pH studies).     
2.4 pH Studies 
In order to further increase our understanding of PRMT1 catalysis, pH rate 
profiles were generated for the WT enzyme by determining kcat and kcat/Km values for both 
SAM and the RGG3 peptide over a pH range of 6.0-9.25.  The RGG3 peptide (Table 2.1) 
was used in place of the AcH4-21 peptide to simplify the interpretation of the pH rate 
profiles.  This is the case because this peptide has comparable kinetic parameters to the 
AcH4-21 peptide and, more importantly, because, with the exception of the N-terminus 
(pKa ~ 8.0), this peptide lacks residues that typically ionize within the pH range under 
study.  Note that at all pH values enzyme activity was linear with respect to time, 
indicating that the loss of activity at the pH extremes was not due to a non-specific effect 
on enzyme structure.  Also note that kcat/Km is the apparent second order rate constant for 
the reaction of free substrate and free enzyme (or when one substrate (A) is saturating, 
the EA complex), and therefore the pH-dependence of kcat/Km monitors the ionization 
state of these entities.  In contrast, effects on kcat are interpreted as being due to the 
presence of important ionizable groups in the enzyme•substrate complex.  
 With SAM as the varied substrate, the plot of log kcat/Km versus pH is bell-shaped 
and is consistent with the presence of two ionizable groups that are important for 





and descending limbs, respectively (Figure 2.6A).  With respect to kcat, the rate of the 
reaction increases with increasing pH until a limiting value is reached (Figure 2.6B).
Fitting the data to eq 4 yields a pKa value of 5.1 ± 0.8.  Although it is difficult to 
definitively assign an observed pKa to a particular residue, or functional group on a 
substrate, the structures of PRMT1, SAM, and the RGG3 peptide suggest several possible 
residues/functional groups whose ionization could alter substrate capture or kcat. With 
respect to the ascending limb, protonation of the SAM carboxylate (pKa ~ 2 in solution), 
D51, E100, E144, and E153 could explain the loss in activity as the pH decreases.  
However, most of these groups are readily ruled out. For example, the pKa of the SAM 
carboxylate is significantly lower than the pKa for the ascending limb of the kcat/Km versus 
pH-rate profile.  Consistent with this notion is the fact that the R54A mutation does not 
affect the Ki for SAM.  Although protonation of D51, which is the residue that interacts 
with H293, could also explain the loss of activity at low pH, the fact that the pH rate 
profiles obtained for the H293A mutant show a similar loss of activity at low pH (vide 
infra) argues against this possibility.  Protonation of E100 could also potentially explain 
the loss of activity at low pH.  However, the fact that little to no effect on the kinetic 
parameters were observed when this residue was mutated to alanine makes this 
suggestion unlikely.  Of the remaining two residues, i.e., E144 and E153, the residue 
most likely responsible for the loss of activity at low pH is E153.  We surmise that this is 
the case because the E144Q mutant retains considerable activity; thus, the ionization of 
this residue would also be expected to minimally impact the reaction rate.  In contrast, the 
activity of the E153Q mutant is significantly decreased and similar to that obtained for 






Figure 2.6. pH profiles of WT PRMT1 with SAM. (A) The log kcat/Km versus 
pH plot is used to determine the pKa of ionizable groups on the enzyme or 
substrate.  (B) The log kcat versus pH plot is used to determine the pKa of 




































have a profound negative impact on rate acceleration.  Also consistent with the ionization 
of this residue corresponding to the ascending limb is the fact that the pKa of a glutamate 
residue in solution is typically in the range of 4-5.  In total, these data suggest that E153 
must be deprotonated for optimal PRMT1 activity.   
With respect to the descending limb, deprotonation of the amino group on SAM 
(pKa ~ 9.5 in solution), the N-terminal amino group on the RGG3 peptide (pKa ~ 8 in 
solution), Y39, and H293 could explain the loss in activity as the pH increases.  Given 
the similarities in the pKa values of these functional groups, it is more difficult to 
definitively assign the pKa of the descending limb.  Nevertheless, the fact that the pKa of 
the N-terminal amine on the RGG3 peptide is significantly lower than the pKa of the 
descending limb argues against the notion that the ionization of this group is responsible 
for the decreased activity at high pH.  Note also that the pKa of an arginine residue is 12.5 
and is significantly higher than the pKa observed for the descending limb, arguing against 
the idea that ionization of these residues in the RGG3 peptide is responsible for the loss 
in activity.  The fact that the concentration of the RGG3 peptide is fixed in these 
experiments further argues against these possibilities because, here, kcat/Km is the second 
order rate constant for the reaction of SAM with the E•RGG3 complex, and thus, kcat/Km 
monitors the ionization state of these entities and not the RGG3 peptide.  The fact that the 
calculated pKa of H293 (7.9) is significantly lower than the pKa observed for the 
descending limb suggests that this residue is also not responsible for the loss in activity at 
high pH.  Of the two remaining functional groups/residues, i.e., the amino group on SAM 





activity at high pH, as the pKa values of these groups (i.e., 9.5 and 10.5, respectively) are 
similar to that obtained for the descending limb.   
When the RGG3 peptide is used as the varied substrate, the plot of log kcat/Km 
versus pH is also bell-shaped with an ascending limb pKa of 5.2 ± 0.2 and a descending 
limb pKa of 10.0 ± 0.3 (Figure 2.7A).  For the same reasons described above, these pKa 
values likely correspond to the protonation states of E153 and Y39, respectively.  Note 
that the assignment of the descending limb to the amino group on SAM can be at least 
partially ruled out because the concentration of SAM is fixed in these experiments; thus, 
kcat/Km is the second order rate constant for the reaction of the RGG3 peptide with the 
E•SAM complex, and, as such kcat/Km monitors the ionization state of these entities, and 
not SAM.  Interestingly, and in contrast to the data presented for SAM, the plot of the log 
kcat values versus pH is relatively flat, thereby indicating that when the peptide is the 
varied substrate the turnover number is not influenced by pH (Figure 2.7B).  This 
difference most likely reflects a change in the rate determining step for the reaction.  
Given that PRMT1 methylates its substrates in a partially processive fashion, this data is 
most consistent with product release being rate limiting when the peptide is the varied 
substrate, as opposed to the case when the concentration of SAM is varied and chemistry, 
a conformational change, or SAM binding is potentially rate-limiting.   
pH-rate profiles were also generated for the H293A and Y39F mutants using the 
RGG3 peptide as the varied substrate (Figure 2.7).  Note that we focused on these 
mutants because of their putative roles as the general base and because the tyrosine 
residue possesses an ionizable group that potentially corresponds to the basic limb of the 






Figure 2.7. pH profiles of WT PRMT1 and mutants with the RGG3 
peptide. (A) The log kcat/Km versus pH plot is used to determine the pKa 
of ionizable groups on the enzyme or substrate.  (B) The log kcat versus 







































because we envisioned that this data would provide greater insights into the factors that 
are important for promoting methyl transfer to the peptide substrate.  For the H293A and 
Y39F mutants, the plots of log kcat versus pH are sigmoidal, with the rates increasing as a 
function of pH to a limiting value (Figure 2.7B).  Fitting the data to eq 4 identified pKa 
values of 4.8 ± 0.4 and 5.1 ± 0.8 for the H293A and Y39F mutants, respectively.  
Interestingly, these data differ substantially from that obtained with the WT enzyme, 
where changes in pH did not affect kcat.  This difference likely reflects a change in the 
rate limiting step.  Consistent with this possibility is the fact that the mutation of either 
residue decreases kcat by ≥11-fold; thus, chemistry is potentially rate limiting for both the 
H293A and Y39F mutants.  In total, these data indicate that both residues play an 
important role in rate enhancement.  
With respect to kcat/Km, the plots of log kcat/Km versus pH for both the WT and 
H293A are similarly bell-shaped, and the pKa values obtained with the H293A mutant 
(i.e., 5.2 ± 1.6 and 10.1 ± 0.9) are nearly identical to those obtained for the WT enzyme 
(Figure 2.7A).  Conversely, only the ascending limb is evident in the Y39F kcat/Km versus 
pH plot, which suggests that the phenolic side chain of this residue corresponds to the 
descending limb of the kcat/Km versus pH rate profile.  These results suggest that Y39 
must be protonated for optimal activity and that deprotonation of the phenol leads to a 
decrease in activity either by the loss of a key hydrogen bond between Y39 and E153 or 
electrostatic repulsion between these two residues that leads to a decrease in enzyme 
activity.  In contrast, it is interesting to note that the lack of an effect of mutating H293 on 





residue are not important for rate enhancement.  As such, these data suggest that H293 
does not act as the general base that deprotonates the substrate guanidinium.    
2.4 Solvent Isotope Effects 
To further probe the catalytic mechanism of PRMT1, we also determined the 
steady state kinetic parameters for the PRMT1 catalyzed reaction in D2O, using the 
AcH4-21 peptide as the varied substrate.  For these experiments, the rates of the reaction 
were measured in ≥92% D2O and compared to those obtained in H2O at the 
corresponding pL.  For the WT enzyme, a small inverse SIE (0.9) is apparent on kcat/Km 
when the peptide is the varied substrate (Table 2.5).  Although this result could be












WT 1.0 0.7 0.9 0.9 
E144A/E153A 0.8 0.7 0.4 0.6 
Y39F 0.4 0.4 0.3 1.8 
R54A 1.2 1.3 0.6 1.7 
H293A 0.1 1.2 0.1 1.6 
 
interpreted as being consistent with general base catalysis being unimportant for rate 
enhancement (a normal SIE would be expected if general base catalysis plays a 
prominent role in rate enhancement), the fact that chemistry is unlikely to be rate limiting 
for the peptide substrate with the wild type enzyme (see above), could suggest that the 
lack of an effect is due to the fact that product release is insensitive to the identity of the 
solvent.  Given this possibility, we also determined SIEs for the Y39F, R54A, 
E144A/E153A, and H293A mutants, because the large decreases in kcat (~5- to 20-fold) 







Figure 2.8 Processivity of WT PRMT1 and mutants.  (A) WT PRMT1 uses a partially 
processive mechanism to catalyze the formation of ADMA.  (B-D) TheY39F, R54A, 
and H293A mutants uses a distributive mechanism to catalyze the formation of 
ADMA in which ω-MMA is released prior to rebinding in preparation for the second 
round of methylation. (E) The E144A/E153A mutant uses a partially processive 
mechanism, however, the formation of ADMA is slower than WT.   
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possibility, we examined the processivity of the above described mutant enzymes.  The 
results of these studies (Figure 2.8) indicated that the Y39F, R54A, E144A/E153A, and 
H293A mutants do not methylate the AcH4-21 peptide in a partially processive fashion, 
further suggesting that chemistry is rate-limiting for at least a subset of these mutant 





kcat/Km ~ 0.6 to 0.9) were observed on both kcat and kcat/Km (Table 2.5).  
The two exceptions are the cases of the R54A and H293A mutants.  For the R54A 
mutant, the 
SIE
kcat is small and normal (
SIE
kcat = 1.2), whereas for the H293A mutant the 




 kcat/Km = 0.1).  Note that 
these experiments were performed in parallel and that representative data from one of at 
least two independent experiments is reported in Table 2.5.  
Inverse SIEs are often attributed to medium effects, the dissociation of a metal 
chelated water, viscosity effects, or effects on thiol ionization (Karsten et al. 1995).  
Although medium effects are difficult to exclude, they are typically small and normally 
ignored (Karsten et al. 1995).  Additionally, the lack of a requirement for metal ions or 
the presence of a thiol within the active site of PRMT1 suggests that the observed inverse 
SIE is not due to either of these possibilities.  To control for the effect of the increased 
viscosity of D2O, the kinetic parameters were determined in the presence of 10% 
glycerol, a concentration of glycerol that closely mimics the viscosity of D2O (Table 2.5).  
The results of these solvent viscosity experiments (SVEs) indicate that, with the 
exception of the R54A and H293A mutants, the kcat values for the WT and mutant 
enzymes were accelerated in the presence of 10% glycerol, suggesting that for these 





kcat/Km, inverse SVEs were detected for only the WT and E144A/E153A double mutant, 
suggesting again that for these mutants the inverse SIE on kcat/Km can be attributed to a 
viscosity effect.  However, normal SVEs were observed for the Y39F, R54A, and H293A 
mutants, indicating that the inverse SIEs are due to a direct effect of D2O on the PRMT1 
catalyzed reaction.  Although it is difficult to speculate on the molecular basis for the 
inverse SIEs, there are at least two possible explanations.  First, given that deuterium 
atoms are known to form stronger hydrogen bonds, D2O may stabilize the structure of 
PRMT1 and thereby enhance the rate of the reaction.  This may be particularly true for 
the H293A mutant, where a very large, and likely unprecedented, inverse SIE was 
observed (SIE = 0.1).  As mentioned previously, the disruption of the salt bridge between 
H293 and D51, which would be caused by the alanine mutation, likely prevents the 
proper formation of the substrate and cofactor binding pockets. However, when the 
H293A mutant is assayed in D2O, this solvent stabilizes the structure of PRMT1 and 
compensates for the loss of the interaction between H293 and D51.  As kcat/Km reports on 
all steps up to including the first irreversible step of the reaction, which for PRMT1 is 
likely methyl transfer, the observed inverse SIEs for the mutant enzymes may, 
alternatively, be reporting on the formation of the dication intermediate because 




 would be expected to yield an inverse 
isotope effect.  Regardless of the nature of the inverse SIE, the lack of a normal SIE for 
WT PRMT1, and all of the catalytically impaired mutants, suggests that general base 
catalysis is unimportant for the PRMT1 catalyzed reaction, and, more specifically, 







PRMT1 activity impacts a number of important cell signaling pathways (e.g.,
gene transcription), and is dysregulated in a number of human diseases including heart 
disease and cancer.  Given its role in these diseases, PRMT1 represents a novel 
therapeutic target, and, as such, we have been focused on developing inhibitors targeting 
this isozyme (Osborne et al. 2007, Osborne et al. 2008, Obianyo et al. 2010, Bicker et al. 
2010).  In order to gain insights that could guide the design of inhibitors with increased 
potency and selectivity, we used a combination of site directed mutagenesis, pH rate 
profiles, and SIEs to begin to characterize the catalytic mechanism of PRMT1.  For the 
mutagenesis studies, we focused our efforts on examining the contribution of eight 
residues lining the active site pocket of PRMT1, including Y39, R54, E100, S102, E144, 
E153, M155, and H293, which, based on structures of PRMT family members, have been 
hypothesized to be important for SAM binding (i.e., Y39, R54, E100), the regiospecific 
generation of ADMA (i.e., M155), the regulation of CARM1 (i.e., S102 and Y39), 
general base catalysis (i.e., H293), and modulating the nucleophilicity of the substrate 
guanidinium (i.e., E144 and E153).   
The results of the mutagenesis studies indicate that while R54 and E100 form 
hydrogen bonds and electrostatic interactions with the SAM carboxylate and the ribose 
moiety, respectively, neither residue is important for SAM binding.  However, the fact 
that the R54 mutations negatively impact the kinetic parameters obtained for the peptide 
substrate, helps to confirm that the observed hydrogen bond or electrostatic interaction 
between the R54 guanidinium and the E144 carboxylate is important for rate 





for nucleophilic attack on the S-methyl group of SAM.  In contrast to R54 and E100, 
M155 is important for SAM binding, as evidenced by the 26-fold increase in the Ki for 
SAH when this residue is mutated to alanine.  The kcat/Km obtained for SAM is similarly 
affected.  As M155 forms the bottom of the adenine portion of the SAM binding pocket, 
the loss of hydrophobic interactions between M155 and the adenine ring, as occurs both 
the M155L and M155A mutants, likely results in both a loss of affinity and an inability to 
properly position the cofactor for methyl transfer.  M155 is also important for the 
processivity, but not the regiospecificity of the PRMT1 catalyzed reaction, i.e., this 
residue does not direct the formation of ADMA over SDMA, as has previously been 
suggested.   
 E144 and E153 have previously been suggested to orient the substrate 
guanidinium and modulate its nucleophilicity to promote methyl transfer (Zhang et al. 
2000).  Consistent with previous mutagenesis studies that only measured relative rates 
(Zhang et al. 2000), our results indicate that both residues are important for PRMT1 
catalysis.  Interestingly, however, the charge and position of E144 appear to be relatively 
unimportant for rate enhancement as both the E144D and E144Q mutants retain 
considerable activity.  These results suggest that the hydrogen bond between E144 and 
the substrate guanidinium is most important, and that this interaction likely orients Nη2 
for nucleophilic attack on the S-methyl group of SAM.  In contrast, both the charge and 
position of E153 are important for rate enhancement, and the results are consistent with 
the previous suggestion that this residue modulates the nucleophilicity of the guanidinium 





With respect to Y39, in addition to being important for SAM binding (due to its 
position at the top of the SAM binding pocket), this residue appears to be important for 
rate enhancement.  This is apparent from the 20-fold decrease in kcat/Km when the peptide 
is the varied substrate.  This result indicates that the phenolic hydroxyl group enhances 
the rate of catalysis.  Based on structures of PRMT1 family members, this residue likely 
hydrogen bonds to E153, and this interaction is important for positioning the E153 
carboxylate such that it can modulate the nucleophilicity of the substrate guanidinium.  
This hypothesis is supported by the fact that PRMT1 loses activity at high pH, where the 
deprotonated form of Y39 would be expected to predominate and the resultant 
electrostatic repulsions between this residue and the E153 carboxylate would lead to a 
loss in activity.  This latter observation is further supported by the loss of the high pKa 
when this residue is mutated to phenylalanine.   
The results obtained for the H293A mutant are particularly interesting.  Although 
this residue has been suggested to act as general base to deprotonate the substrate 
guanidinium and thereby enhance the nucleophilicity of this group, our results do not 
support such a hypothesis despite the fact that mutation of this residue decreases kcat/Km 
by ≥ 50-fold.  This is the case because effects are observed on both the kinetic parameters 
determined for SAM and the peptide substrate.  Additionally, the pH rate profiles 
obtained for the H293A mutant are similar to those obtained for the WT enzyme, which 
indicates that the ionization of this residue does not contribute to either the rate limiting 
step of the reaction or substrate capture.  Although the contribution of this residue to rate 
enhancement may not be apparent in the pH rate profiles, because this residue is 





possibility unlikely and suggest that the decreased activity observed when this residue is 
mutated is due to the loss of a critical salt bridge between this residue and D51.  The loss 
of this salt bridge would be expected to destabilize the two N-terminal helices and impact 
cofactor and peptide binding, both of which occur when this residue is mutated.  The SIE 
data also do not support a role for this residue as a general base, as a large and inverse 
SIE was observed for the H293A mutant.  Further support for the idea that H293 is not a 
general base comes from the structure of PRMT1, which shows that this residue is ≥6 Å 
distal from the approximate site of the substrate guanidinium, a distance that is too great 
for this residue to play such a role.    
In total, the data described above support a mechanism in which SAM and a 
protein, or peptide, substrate bind to the enzyme in a random fashion to form a ternary 
complex (Figure 2.2).  E153 then likely redistributes the electron density towards either 
Nη1 or Nδ, or even both, which enhances the nucleophilicity of Nη2.  The methyl group of 
SAM is then transferred to the protonated guanidinium of the substrate arginine to form a 
dication intermediate.  Although such an intermediate is to our knowledge 
unprecedented, dianionic carboxylate intermediates have been proposed for several 
enzymes.  Rehybridization of the guanidinium destabilizes the dication intermediate, 
thereby facilitating the loss of the extra proton to water or an unknown general base.  
While E144 could serve such a role, this seems unlikely when one considers that the 
effect of mutating this residue to glutamine has only a small impact on kcat/Km.  Further 
support for the notion that methyl transfer precedes proton transfer comes from the lack 
of a normal SIE on both the wild type enzyme as well as several catalytically impaired 





that Hedstrom and colleagues (Guillen Schlippe et al. 2005) have noted that in several 
enzymes arginine residues can act as general bases and that the pKa of those residues is 
potentially modulated by slight structural perturbations to the normally planar 
guanidinium, we cannot completely rule out the possibility that E144 and E153 depress 
the pKa of the substrate arginine and thereby enhance its nucleophilicity, via such a 
mechanism.  However, it is difficult to rationalize such a mechanism with our findings 
that the E144A/E153A double mutant possesses considerably more activity than either of 
the single mutations alone.  Thus, we favor the mechanism proposed above where the 
methyl group is transferred to the protonated guanidinium.  In summary, our results 
suggest that the PRMT1-catalyzed reaction is primarily driven by bringing the substrate 
and cofactor into the proximity of each other and that the prior deprotonation of the 






Regulation of PRMT1 by Post-translational Modifications 
3.1 Introduction 
Post-translational modifications play a pivotal role in the cell by adding an 
additional level of functional regulation.  For example, the methylation of arginine 
residues within proteins, which is catalyzed by the PRMT family of enzymes, has been 
found to affect gene transcription, RNA splicing, signal transduction, and cell 
proliferation (Bedford et al. 2005, Bedford et al. 2007, Bedford et al. 2009, Wolf et al. 
2009, and Di Lorenzo et al. 2011).  Due to its numerous and various roles in cellular 
processes, it is only logical that arginine methylation itself would be regulated.  One such 
method of regulation of the PRMT family is that of PTMs.  
In fact, the activity of both CARM1 and PRMT5 has been found to be regulated 
by phosphorylation.  In CARM1, three different serine residues, i.e., S217, S228, and 
S448, have been demonstrated to be phosphorylated in vivo (Feng et al. 2009, 
Higashimoto et al. 2007, Carascossa et al. 2010).  S217 was identified by mass 
spectrometry on immunoprecipitated CARM1 from MCF-7 cells and this residue is 
conserved amongst Type I PRMTs.  Phosphorylation of this residue diminishes the 
methyltransferase activity of the enzyme in vitro and abrogates its coactivator function in 





cytoplasm.  Based on the structure of CARM1, this change in activity is presumably due 
to the addition of a phosphate group to the side chain hydroxyl of S217, disrupting the 
hydrogen bond to the backbone carbonyl of Y154 (Feng et al. 2009).  As a result, the 
enzyme cannot bind SAM.  Additionally, this PTM could affect the position of Y154 
(Y39 in PRMT1) (Feng et al. 2009), which has been suggested to interact with the ribose 
and sulfur atom of SAM, as well as with E267, a residue important for catalysis (Yue et 
al. 2007, Troffer-Charlier et al. 2007, & Rust et al. 2011).  S228, which is conserved 
among different species (but not among different PRMT family members), was also 
identified by mass spectrometry on immunoprecipitated CARM1 from HELA and MCF-
7 cells.  Mutation of S228 to glutamate inhibited methyltransferase activity in vitro and 
abrogated its coactivator function in vivo.  These results are likely due to the disruption of 
dimer formation (Higashimoto et al. 2007).  Finally, S448 was identified from MCF-7 
cells using an antibody against a PKA substrate consensus motif and verified by site-
directed mutagenesis.  Interestingly, unlike the previous two sites that were involved in 
regulating methyltransferase acitivty, phosphorylation of this residue mediates the 
interaction between CARM1 and apo-ERα and plays a role in ligand independent 
activation of the receptor by cAMP (Carascossa et al. 2010).   
PRMT5 is also phosphorylated in vivo at three tyrosine residues (i.e., Y297, 
Y304, and Y307) that are conserved amongst species.  Phosphorylation greatly decreases 
the methyltransferase activity of the enzyme in vitro against histones H2A and H4 and 
inhibits its association in vivo with MEP50, a known interacting partner that is critical for 





kinase 2 (JAK2), i.e., JAK2V617F and JAKK539L, and the phosphorylation of PRMT5 
by these mutants likely promotes myeloproliferative neoplasms (Liu et al. 2011).    
 In addition to phosphorylation, automethylation has been detected in select PRMT 
family members (i.e., CARM1 (Kuhn et al. 2011), PRMT6 (Frankel et al. 2002), and 
PRMT8 (Sayegh et al. 2007)).  Although the in vitro methyltransferase activity of 
CARM1 is not affected by automethylation of R551 in its C-terminal domain (CTD), as 
determined using an arginine to lysine mutant, this modification appears to down regulate 
its roles in mRNA splicing and transcriptional activation (Kuhn et al. 2011).  PRMT8 is 
monomethylated at R58 and dimethylated at R73 of its N-terminal tail. Interestingly, full 
length PRMT8 has very limited activity; however, a truncation mutant lacking the first 60 
residues is significantly more active.  The effect of automethylation on this isozyme 
remains to be determined, but it is speculated that it might alter substrate recognition 
(Sayegh et al. 2007).  Finally, the effect of automethylation on PRMT6 is unknown at this 
time (Frankel et al. 2002). 
As mentioned previously, our research is concentrated on PRMT1 because it is 
the dominant Type I PRMT and plays a role in a variety of diseases (e.g., cancer, heart 
disease, and ALS).  We have been focused thus far on the kinetic and catalytic 
mechanisms of the enzyme, as well as the development of potent inhibitors, while other 
groups have mainly focused on determining the functional roles of PRMT1.  The 
mechanisms (i.e., PTMs and protein-protein interactions) by which this otherwise 
constitutively active enzyme is regulated, however, have yet to be fully investigated.  In 
fact, knowledge of the regulation of PRMT1 by post-translational modifications is 





curated source for experimentally determined PTMs, lists phosphorylation, 
ubiquitylation, and acetylation as observed modifications to a variety of PRMT1 residues  
(Table 3.1).  Interestingly, the data for most, if not all, of the discovered PTMs arose 
from cancer cell lines such as K-562, AMO-1, and KMS-27 (Hornbeck et al. 2012), 
which would argue for a role for PRMT1 in disease.  These results, however, are only 
based on high throughput mass spectrometry data, with no site specific methods such as 
the use of site-directed mutagenesis or specific antibodies, to verity the existence and/or 
importance of this modification. 




# of records Modification Residue Sequence 
1 Phosphorylation Y34 EDMTSKDyyFDSYAH 
1 Phosphorylation Y35 EDMTSKDyyFDSYAH 
22 Ubiquitination K113 DYAVKIVkANkLDHV 
10 Ubiquitination K116 DYAVKIVkANkLDHV 
1 Ubiquitination K125 DHVVTIIkGKVEEVE 
1 Ubiquitination K165 TVLYARDkWLAPDGL 
12 Ubiquitination K215 CIKDVAIkEPLVDVV 
1 Ubiquitination K225 LDVVDPkQlVTNAC 
3 Phosphorylation S289 GFSTSPEsPyTHWkQ 
127 Phosphorylation Y291 STSPEsPytHWkQtV 
5 Phosphorylation T292 TSPEsPytHWkQtVF 
1 Acetylation K295 EsPytHWkQtVFYME 
6 Ubiquitination K295 EsPytHWkQtVFYME 
1 Phosphorylation T297 PytHWkQtVFYMEDY 
29 Ubiquitination K324 IGMRPNAkNNRDLDF 
a






Figure 3.1 Structural comparisons between the PRMTs and contrast between amino acid 
side chains.  (A) The hydroxyl of S217 of CARM1 hydrogen bonds to the backbone 
carbonyl of Y154 and is critical for activity. (B) The hydroxyl of S102 of PRMT1 (white) 
potentially hydrogen bonds to the backbone carbonyl of Y39.  Note that because Y39 is 
not visible in the crystal structure of PRMT1, an overlay of PRMT3 (tan) was used to 
demonstrate its approximate location. (C) S102 was mutated to a glutamate and alanine 
residue to probe its function.  This figure was prepared with UCSF Chimera using the 
coordinates from CARM1 (PDBID 3B3F), PRMT1 (PDBID 1ORI), and PRMT3 
(PDBID 1F3L). 
 
To address this issue in PRMT1, we set out to investigate the effect of 
phosphorylating S102 and Y291 on PRMT1 activity.  As described above, S217 of 
CARM1 (S102 in PRMT1 numbering) is conserved amongst the Type I PRMTs and 
phosphorylation of this residue abolishes the methyltransferase activity of CARM1.  
Examination of the crystal structures of CARM1 and PRMT1 (with PRMT3 overlay 
because the N-terminal tail residues are absent in the PRMT1 structure) revealed the 
possibility that phosphorylation of this residue may be a common regulatory mechanism 
between both enzymes due to their similar positions (Figure 3.1A-B).  In order to 
determine if phosphorylation of S102 in PRMT1 would yield the same effect as it does in 
CARM1, a S102E mutant was created, to mimic phosphorylation of the residue, and a 












Figure 3.2 Structure of PRMT1 and structural contrast of amino acid side chains.  (A) 
Results of previous studies involving mutation of H293 suggest that the addition of a 
phosphate to Y291 would likely negatively affect methyltransferase activity.  (B)  
Structural contrast of tyrosine and phosphorylated tyrosine clearly shows that the addition 
of a phosphate group adds both bulk and charge to the residue.  Mutation to a 
phenylalanine can reveal the importance of the hydroxyl group, whereas, a glutamate 
mutant is often used to determine the effect of the addition of a negative charge.  
However, due to the large difference in overall size between phosphotyrosine and 
glutamate, the incorporation of p-carboxymethyl L-phenylalanine is a better overall 
mimic.  This figure was prepared with UCSF Chimera using the coordinates from 
PRMT1 (PDBID 1ORI). 
 
Y291 was specifically chosen for this investigation because it has the largest 
number of curated mass spectrometry hits according to PhosphoSitePlus® (Hornbeck et 
al. 2012).  Based on the position of this residue in the structure of PRMT1, we 
hypothesized that phosphorylation would impact methyltransferase activity and/or 
protein-protein interactions (Figure 3.2A).  This prediction was based on previous studies 
that showed that H293 is important for catalysis, possibly due to the formation of a salt 
bridge with D51 (Rust et al. 2011).  Although hydrogen bond formation between Y291 





negatively charged phosphate group would likely cause repulsion and consequently open 
up the SAM binding pocket, as well as destabilize residues that are important for 
catalysis, similar to the case with H293.  Although glutamate mutations are often used as 
a mimic of phosphotyrosine, comparison of the two structures clearly demonstrates that 
there is a difference in both size and electronics.  In order to overcome this problem, p-
carboxymethyl-L-phenylalanine (pCMF) (Figure 3.2), a previously reported stable mimic 
of phoshotyrosine (Xie et al. 2007), was installed at this position using an established 
method of unnatural amino acid (UAA) incorporation that utilizes an orthogonal amber 
suppressor tRNA/aminoacyl-tRNA synthetase pair developed by the Schultz lab (Young 
et al. 2010 and Xie et al. 2007).  In addition to the above mutagenesis studies, PRMT1 
was profiled against thirty-three kinase targets in order to determine possible kinases 
responsible for phosphorylation.  These experiments were done in collaboration with 
Kinexus Bioinformatics Corporation.  
 Herein, we describe our efforts to decipher the means of regulation of PRMT1 
activity.  Site-directed mutagenesis and UAA incorporation was used to investigate the 
consequence of phosphorylation on S102 and Y291.  In addition, PRMT1 was profiled 
against a variety of kinases to determine if the protein could be phosphorylated.   
3.2 Materials and Methods 
3.2.1 Chemicals  
Iscove’s Modified Dulbecco’s Medium (IMDM) was purchased from (ATCC). 
Acrylamide, ammonium persulfate, beta-mercaptoethanol, sodium dodecyl sulfate (SDS), 
tetramethylethylenediamine (TEMED), and tris(hydroxymethyl)aminomethane (TRIS) 





acid (EDTA), dimethylformamide (DMF), Fmoc-protected amino acids, methanol, 
phenylmethylsulfonyl fluoride (PMSF), trifluoroacetic acid (TFA), and Wang resin were 
purchased from EMD (Gibbstown, NJ).  Dichloromethane, diethyl ether, sodium 
chloride, triisopropylsilane were purchased from Fisher Scientific (Pittsburgh, PA).  
Mutagenic primers were purchased from IDT Inc. (Coralville, IA).  Fetal bovine serum 
(FBS) was purchased from Mediatech Inc. (Manassas, VA).  Dithiothreitol (DTT), 4-(2-
Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), isopropyl β-D-1-
thiogalactopyranoside (IPTG), and tricine were purchased from RPI (Mt. Prospect, IL).  
4-(bromomethyl)phenylacetic acid, trimethylsilyl-diazomethane (TMSCH2N2), 
(diphenylmethylene) glycine ethyl ester, benzyl trimethylammonium hydroxide, dimethyl 
sulfoxide (DMSO), and piperidine were purchased from Sigma-Aldrich (St. Louis, MO).  
14
C-labeled SAM and γ-
33
P-labeled ATP were purchased from Perkin-Elmer and 
14
C-
labeled BSA from Sigma-Aldrich.  Triton X-100 and sodium acetate were purchased 
from VWR (West Chester, PA).  Site-directed mutagenesis, the purification of PRMT1, 
peptide synthesis, and the gel-based methylation assay were performed according to the 
procedures outlined in Chapter 2. 
3.2.1 Cell Culture Maintenance & Whole Cell Extract Preparation 
K562 cells were grown in Iscove’s Modified Dulbecco’s Medium (IMDM) 
supplemented with 10% fetal bovine serum and 1% antibiotic/antimycotic solution 
(Mediatech Inc) at 37 °C and 5% CO2.  For immunoprecipitation experiments, cells were 
grown to confluency and either 10 µM MG132, 10 µM MG132 (Cayman Chemical-
10012628) plus 1 mM orthovanadate (NEB-P0758S), or DMSO as a control was added to 





and centrifuged for 5 min at 225 x g and 4 °C.  After three washes with PBS, cells were 
lysed by a 30 min incubation at 4 °C in modified RIPA buffer (50 mM Tris pH 8, 150 
mM sodium chloride, 1 mM EDTA, 1% NP-40) in the presence of complete protease 
inhibitor cocktail (Roche-4693132), phosphatase inhibitor cocktail II (Sigma-P8465), and 
1 mM orthovanadate.  Lysed cells were centrifuged for 5 min at 3824 x g at 4 °C and the 
supernatant was removed as the whole cell extract.  Protein concentration was determined 
by a DC™ Protein Assay (Bio-Rad).  
3.2.2 Immunoprecipitation 
 K562 cell extracts were diluted to 4 µg/µL (1 mg total protein) in modified RIPA 
buffer (50 mM Tris pH 8, 150 mM sodium chloride, 1 mM EDTA, 1% NP-40) in the 
presence of cOmplete protease inhibitor cocktail (Roche), phosphatase inhibitor cocktail 
II (Sigma), and 1 mM orthovanadate (NEB).  Extracts and antibody control (dilution 
buffer only) were incubated with 5 µL of 1 µg/µL anti-PRMT1 antibody (Bethyl – A300-
722A) for 2 h with rotation at 4 °C.  A 50 µL slurry of Protein G Sepharose 4 Fast Flow 
Beads (GE) in cell extract dilution buffer was added to each sample and incubated ON 
with rotation at 4 °C.  Beads were washed three times with 200 µL of modified RIPA 
buffer.  Proteins were eluted with 60 µL of SDS-loading dye and heated for 10 min at 95 
°C.  Samples and controls were separated by 12% SDS-PAGE.  Proteins were transferred 
to a nitrocellulose membrane and probed with anti-PRMT1 (Abcam – ab7027) or 4G10® 
Platinum anti-phosphotyrosine antibodies followed by incubation with goat anti-mouse 
HRP conjugate (Millipore – 12-349).  Proteins were visualized using Pierce ECL western 






3.2.5 Synthesis of p-carboxymethyl-L-phenylalanine (pCMF) 
 pCMF was synthesized by modification of an already established protocol (Xie et 
al. 2007).  A solution of 4 g (17 mmol) of 4-(bromomethyl)phenylacetic acid in 78.4 mL 
of THF and 39.2 mL of methanol was cooled to 0 °C followed by the slow addition of 17 
mL (34 mmol) of  trimethylsilyl-diazomethane (TMSCH2N2).  The reaction was stirred 
for 25 min at 0 °C, then the solvent was evaporated in vacuo and the mass of the product 
was verified by LCMS: expected = m/z 242.99 (M + H
+
), observed = m/z 243.0 (M + H
+
). 
A solution of the product (17 mmol), 266 mg (1.6 mmol) of potassium iodide (KI), and 
4.54 g (17 mmol) of (diphenylmethylene) glycine ethyl ester in 77.5 mL of dioxane was 
cooled to 0 °C followed by the slow addition of 6.5 mL of benzyl trimethylammonium 
hydroxide (40% in water).  The reaction was stirred at rt for 1 h and then extracted with 
dichloromethane (CH2Cl2) and washed with brine.  Solvent was evaporated in vacuo and 
the mass of the product was verified by LCMS: expected = m/z 430.19 (M + H
+
), 
observed = m/z 430.2 (M + H
+
). Aqueous HCl (1N, 40 mL) was added to the product and 
stirred for 1 h at rt.  The pH was then adjusted 8 with solid NaHCO3 and the product was 
extracted with dichlormethane (CH2Cl2) and washed with brine.  Solvent was evaporated 
in vacuo and the mass of the product was verified by LCMS: expected = m/z 266.13 (M + 
H
+
), observed = m/z 266.1 (M + H
+
).  The compound was then dissolved in 30 mL of 
NaOH and 15 mL of THF and stirred overnight at rt. Solvent was evaporated in vacuo 
and product was partitioned in ether and water.  The aqueous portions were collected and 
lyophilized to yield a sodium salt of the final product and the mass was verified by 
LCMS: expected = m/z 224.08 (M + H
+
), observed = m/z 224.1 (M + H
+
).  The 





3.2.6 Incorporation of pCMF into PRMT1 
 Incorporation of pCMF was performed using methods adapted from previously 
reported protocols (Xie et al. 2007 & Young et al. 2010).  Y291 of PRMT1 was mutated 
to a TAG stop codon using the site directed mutagenesis methods described in Chapter 1.  
The pEVOL-pCMF plasmid, a generous gift from Peter Schultz, was co-transformed into 
E. coli BL21(DE3) cells with the Y291TAG mutant.  One colony was used to inoculate 5 
mL of 2YT media containing 50 μg/mL kanamycin and 25 μg/mL chloramphenicol.  
Two liters of 2YT media were inoculated with 20 mL of overnight culture containing 50 
μg/mL kanamycin and and 25 μg/mL chloramphenicol and grown at 37 °C and 250 rpm 
until OD600 = 0.8.  The cells were supplemented with 1 mM pCMF before being induced 
with 0.2% arabinose and 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG).  The cells 
were then incubated with shaking at 30 °C overnight and the mutant protein was purified 
according to the established protocol for WT PRMT1 (see Chapter 2). 
3.2.7 In-Gel Digest 
The Y291pCMF mutant (5 µg) was separated by 12% SDS-PAGE.  Coomassie 
stained gel bands corresponding to labeled PRMT1 were excised and the resultant gel 
pieces were washed and dehydrated two times.  Existing disulfide bonds were reduced 
with 10 mM DTT and the resulting thiols were alkylated with 54 mM N-ethylmaleimide.  
Proteins were digested with trypsin (Promega – V5113), at a 1:10 (w:w)(trypsin:protein) 
ratio, overnight at 37 °C.  The enzymatic reaction was quenched with 1% TFA and the 
resulting peptides were desalted and concentrated using C18 ZipTips (Millipore).  Dried 
peptides were reconstituted in 0.1 % formic acid. All samples were analyzed by liquid 





LTQ linear ion trap mass spectrometer (Thermo-Finnigan, San Jose, CA). Briefly, 
peptides were concentrated and desalted on an RP trapping column (0.31 x 20 mm, 
ReproSil-Pur C18-AQ, ThermoScientific) and eluted on-line with an analytical RP 
column (0.075 x 100 mm, ReproSil-Pur C18-AQ, ThermoScientific), operating at 300 
nl/min and using a 40-min gradient from 0% to 40% solvent B [solvent A: 0.1% formic 
acid (v/v), solvent B: 0.1% formic acid (v/v), and 80% acetonitrile (v/v)].  The LTQ was 
programmed in the ‘selected MS/MS ion monitoring’ (SMIM) mode. The m/z 400-1600 
survey scan was first performed in order to check for the presence of digested peptides as 
well as peptide separation along the gradient. This survey scan is followed by dependent 
MS/MS scans that fragment the six most intense ions to confirm the presence of the 
protein of interest.  Next, MS/MS spectra were programmed, focusing on m/z 641.64, 
which corresponds to the triply-charged precursor ion of the modified 
RTGFSTSPESPY*THWK peptide, and on m/z 883.90, corresponding to the doubly-
charged precursor ion of the modified TGFSTSPESPY*THWK peptide.  Note that the 
quadruple charge stems from a possible charge on the fragmented C21 peptide and that 
the MS/MS scans were repeated twice.        
3.2.8 Protein Kinase Assays 
 Protein kinase assays with PRMT1 as the substrate were performed by Kinexus 
Bioinformatics Corporation (Vancouver, B.C. Canada).  Briefly, 5 µL of γ-
33
P-labeled 
ATP (50 M, 0.8 Ci final) was added to a mixture of 10 µL of kinase assay buffer, 5 µL of 
an active protein kinase (~10-50 nM final), and 5 µL of PRMT1 or control substrate (1-5 
g) to start the reaction.  Samples were incubated at ambient temperature for 20-40 





reaction mixture onto a Multiscreen phosphocellulose P81 plate, which was then washed 
3 times for approximately 15 minutes each in a 1% phosphoric acid solution.  The 
radioactivity on the P81 plate was counted in the presence of scintillation fluid in a Trilux 
scintillation counter.  A control assay for each kinase target included all assay 
components except the appropriate substrate (replaced with equal volume of assay 
dilution buffer).  Both the sample and control assays were done in duplicate and the 
corrected activity for each kinase target was determined by subtracting the blank control 
value.        
3.3 Results and Discussion 
3.3.1 Effect of Phosphorylation of S102 
Disruption of the interaction between the hydroxyl group of S102, a conserved
residue amongst the type I PRMTs, and the back backbone carbonyl of Y39, also a 
conserved residue, by phosphorylation has been demonstrated to negatively regulate 
CARM1 (Feng et al. 2009).  To investigate whether phosphorylation of this residue may 
be a mechanism of regulation for PRMT1, we generated the S102A mutant to determine 
the importance of the hydroxyl group, and a S102E mutant to mimic phosphorylation.  As 
seen in Tables 3.2 and 3.3, the results show that neither mutant affects the kinetic 
parameters of PRMT1 to the degree that was observed with CARM1, where mutations 
appear to abolish activity.  However, we did observe a ~ 4.5- and ~ 5.5-fold increase in 
the Km values for AcH4-21 with the S102E and S102A mutant; there was essentially no 
effect on kcat, and the kinetic parameters for SAM are identical to WT.  These small but 
significant increases can likely be attributed to the destabilization of the N-terminal helix, 





results show that it is highly unlikely that PRMT1 activity is regulated by 
phosphorylation at S102, however, modification of this residue cannot be ruled out as 




3.3.2 Probing for Phosphotyrosine in PRMT1 
 As mentioned above, PhosphoSitePlus® (www.phosphosite.org) lists tyrosine 
phosphorylation as an observed modification to a variety of PRMT1 residues; this list is 
compiled from curated mass spectrometry data (Hornbeck et al. 2012).  In an attempt to 
confirm these mass spectrometry results and determine a phenotype for the modification, 
we immunoprecipitated PRMT1 from K562 cells, a cell line from which a subset of 




















 1.1 ± 0.5 ----- 4.6 x 10
-1
 ± 2 x 10
-2





 5 ± 1 4.5 5.7 x 10
-1
 ± 2 x 10
-2





 6 ± 1 5.5 6.3 x 10
-1
 ± 2 x 10
-2




[SAM] = 15 μM.   
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 5.6 ± 0.6 0.9 5.2 x 10
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PhosphoSitePlus® data is derived.  To aid in the enrichment of the phosphorylated 
enzyme, the cells were incubated with either DMSO as a control, MG132, a proteasome 
inhibitor, or MG132 and orthovanadate, a phosphatase inhibitor.  MG132 was added 
because phosphorylation can often be an upstream signal for degradation.  Orthovanadate 
was added to prevent the removal of the phosphate group and possibly lead to an 
accumulation of the modified protein.  The enzyme was immunoprecipitated with an anti-
PRMT1 antibody and the blots were probed with either an anti-PRMT1 or an anti-
phosphotyrosine antibody (Figure 3.3).  Unfortunately, phosphorylated PRMT1 was not 
detected under any of the conditions tested.  Immunoprecipitations were also performed 
with the anti-phosphotyrosine antibody, however, the results were the same.      
 
 
Figure 3.3 Immunoprecipitation of PRMT1.  K562 cells were treated prior to 
lysis with DMSO, MG132, or a combination of MG132 and orthovanadate, and 
immunoprecipitation on cell extracts was performed with anti-PRMT1.  The 
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3.3.3 Effect of Phosphorylation of Y291 
 
Although tyrosine phosphorylation was not detected in cell extracts, we sought to 
determine the effect that phosphorylation of Y291 could have on PRMT1 activity.  We 
generated the Y291F mutant to determine the importance of the hydroxyl group, and the 
Y291E mutant to mimic phosphorylation.  However, because of the size and electronic 
difference between glutamate and phosphotyrosine (Figure 3.2), we decided to generate a 
 
Figure 3.4 Synthesis of pCMF
 
better mimic.  To do this, the Y291 position on PRMT1 was mutated to a TAG stop 
codon and pCMF, a known stable mimic of phosphorylated tyrosine (Xie et al. 2007), 
was synthesized according to the scheme outlined in Figure 3.4.  pCMF was incorporated 
into the protein using an orthogonal amber suppressor tRNA/aminoacyl-tRNA synthetase 
pair.  Figure 3.51 shows a comparison between the expression of WT PRMT1 and the 
Y291pCMF mutant under the same conditions from a test expression in E. coli. 
BL21(DE3) cells.  The expression was then scaled up (Figure 3.6A) and the Y291pCMF 
mutant was purified according to the WT PRMT1 protocol (Figure 3.6B).  Note that the 
Y291TAG truncation mutant did not co-purify with the Y291pCMF mutant, likely due to 
the inability to fold properly.  The presence of pCMF at this position was confirmed by 






Figure 3.5 Incorporation of pCMF into 
PRMT1.  Test expressions were performed 
with the WT enzyme and the Y291TAG 
mutant in the presence of pCMF in E. coli.   
 
 
Figure 3.6 Expression and purification of PRMT1(Y291pCMF).  (A) Expression 
conditions were scaled up to 2 L and incorporation of pCMF was consistent with the 
test expressions.  (B) The mutant was purified according to the WT PRMT1 protocol 
and yielded only the full length enzyme.  
 
The kinetic parameters for the Y291 mutants can be found in Tables 3.4 and 3.5.  
In regards to AcH4-21, the Y291F and Y291E mutants yielded a ~ 2.0-fold and ~ 1.4-
fold decrease in kcat/Km, respectively, compared to the WT enzyme, and these observed 
decreases were solely based on small increases in Km.  The Y291pCMF mutant, however, 
yielded a more significant decrease (~ 5.1-fold) in kcat/Km that was caused by an ~ 7.3-
fold increase in Km.  These results suggest that the Y291 plays a small role in substrate 





















Figure 3.7 MS/MS Analysis of PRMT1(Y291pCMF). 
 
 




















 1.1 ± 0.5 ----- 4.6 x 10
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 ± 2 x 10
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 5 ± 1.8 4.6 1.03 ± 6 x 10
-2





 4.4 ± 0.6 4.0 1.32 ± 3 x 10
-2
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[SAM] = 15 μM.  




















 6 ± 1.0 ----- 5.8 x 10
-1
 ± 3 x 10
-2
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 7 ± 1.5 1.2 1.6 ± 1 x 10
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 6 ± 1.1 1.0 5.5 x 10
-1
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[AcH4-21] = 100 μM. 


















































































































Surprisingly, the kinetic parameters for all three mutants matched those of the WT 
enzyme.  This was puzzling because, based on the crystal structure of PRMT1 and 
previous studies with H293 (Figure 3.2A), we hypothesized that disruption of the N-
terminal α-helix would greatly impact SAM binding.  However, these results demonstrate 
that the Y291 residue does not play a role in SAM binding and therefore phosphorylation 
of this residue would like not affect SAM binding or catalysis.  
3.3.4 Profiling of PRMT1 Against Select Kinases 
 
 Because we were unable to detect phosphorylated PRMT1 in vivo, we decided to 
take a different approach by profiling PRMT1 against select kinases to determine if 
PRMT1 can be phosphorylated in vitro.  Radioactive kinase assays were performed by 
Kinexus Bioinformatics Corporation with our PRMT1 enzyme.  Thirty-three kinases 
were assayed in total and the twenty-five kinases with the most activity towards PRMT1 
can be found in Table 3.6.  There are two different methods for comparing activity.  The 
first method is to examine the percent change from control (% CFC) with percentages > 
5% being significant.  This method suggests that PRMT1 is a likely substrate for cKIT, 
KDR, ERK1, ERK5, JNK1, JNK2, JNK3, FLT1, and AXL.  This method can be 
misleading, however, because the control substrates are often optimized for the particular 
kinase and/or used in high concentrations.  The second method only examines the CPM 
counts for PRMT1 that pertain to each kinase, with counts >8000 being significant.  Note 
that the kinases displayed in Table 3.6 were chosen based on the second method.  This 
method suggests that PRMT1 is a likely substrate for AXL, KDR, FGR, FYN A, SRC, 
YES1, FER, and LYN A, which are all tyrosine kinases.  These results are promising in 




























Tab3. Table 3.6 Percent activity of select protein kinases with PRMT1 
 
Kinase Substrate CPM PRMT1 CPM % CFC 
AXL 303327 27780 9 
KDR 142513 14876 10 
FGR 332996 13096 4 
FYN A 341735 13058 4 
SRC 305044 11629 4 
YES1 389767 11474 3 
FER 454478 8759 2 
LYN A 347599 8751 3 
FES 210964 7214 3 
HCK 398546 6962 2 
FLT1 111562 6032 5 
LCK 146117 5646 4 
FLT3 134185 5310 4 
FGFR3 344175 5298 2 
ERK5 43006 4934 11 
JNK1 47712 4165 9 
ERK1 78080 4047 5 
MET 245282 3886 2 
FRFR1 (FLT2) 215787 2841 1 
JNK2 27479 2529 9 
FGFR4 136640 2495 2 
ITK 96295 2435 3 
FGFR2 263187 2024 1 
c-KIT 25199 1838 7 
JNK3 25072 1653 7 






 Post-translational modification of PRMT1 has yet to be characterized; therefore 
we set out to investigate the regulation of the enzyme by PTMs, specifically 
phosphorylation.  Our research efforts focused on two residues, S102 and Y291.  S102 is 
conserved in Type I PRMTs and phosphorylation of this residue is a means of regulation 
for CARM1.  Two mutants, S102A and S102E, were made in PRMT1 and the kinetic 
analysis of these mutants demonstrated that this residue is not important for substrate or 
cofactor binding, or catalysis, and thus it is highly unlikely that PRMT1 is regulated by a 
mechanism similar to CARM1.   
The Y291 residue was chosen for investigation based on curated mass 
spectrometry data from PhosphoSitePlus® (Hornbeck et al. 2012).  Y291F and Y291E 
mutants were generated, as well as the incorporation of pCMF into the protein, in an 
attempt to properly mimic phosphotyrosine.  The results showed that, in general, this 
residue likely plays a minor role in substrate binding and that phosphorylation at this 
position would likely disrupt substrate binding.  However, to our surprise, no affect was 
observed in regards to SAM, which was quite puzzling based on structural observations 
and previous studies with H293.  These results suggest that the interaction between H293 
and D51 is likely enough to hold the main portion of the α-helix in place, despite the 
addition of a phosphate group at Y291.  Interestingly, based on structure analysis, the 
interaction between histidine and aspartate appears to be conserved amongst Type I 
PRMTs, and thus it is likely that this is a critical interaction for PRMT catalysis.  In 
addition, as mentioned in Chapter 1, PRMT1 has a variety of splice variants and these 





2007).  Therefore, it is possible that phosphorylation of Y291 could modulate substrate 
specificity by affecting the position of the N-terminal tail.  Note that the pCMF residue is 
still lacking a negative charge compared to phosphotyrosine so it is possible that the 
modification may have an even greater effect in vivo.   
In collaboration with Kinexus Bioinformatics Company, we have profiled 
PRMT1 against thirty-three different protein kinases to determine if the enzyme can be 
phosphorylated in vitro.  The results show that several tyrosine kinases (i.e., AXL, KDR, 
FGR, FYN A, SRC, YES1, FER, and LYN A) are active against PRMT1.  Future 
experiments will include in vitro assays with the top purified kinases to attempt to 
determine potential sites of modification.  In vivo experiments will also be performed in 
which stimuli will be added in order to activate signaling pathways that are particular for 









Regulation of PRMT1 by Protein-Protein Interactions 
4.1 Introduction 
As discussed in Chapter 3, it is highly likely that the PRMTs are regulated by a 
variety of mechanisms (i.e., the activation or repression of gene expression, PTMs, and/or 
protein-protein interactions).  The role of PTMs in regards to PRMT1 activity was 
discussed in Chapter 3, but we also were interested in determining how protein-protein 
interactions regulate the activity of this enzyme because preliminary data indicates that 
the PRMTs are regulated via this mechanism.  For example, there is evidence that the 
tumor suppressor protein DAL-1/4.1B enhances PRMT3-dependent methylation of MCF-
7 cell lysates (Singh et al. 2004), however, it both enhances and inhibits PRMT5 
dependent methylation in a substrate specific manner (Jiang et al. 2005).  In another 
example, the substrate specificity of CARM1 is altered by BRG1, a component of the 
nucleosomal methylation activator complex (NUMAC), which shifts CARM1-dependent 
methylation towards nucleosomal histone H3 as opposed to the free histone (Xu et al. 
2004).  In addition, PRMT5 is regulated by its binding partner MEP50, as there is a 
substantial difference in methyltransferase activity between the enzyme alone and the 
enzyme in a complex with MEP50.  PRMT5 is also active as part of a variety of multi-
protein complexes, that include the 20S methylosome and the Swi/Snf complex, with 





Although still not fully understood, there is evidence that PRMT1 activity is 
regulated by protein-protein interactions.  The isozyme was originally identified due to its 
interaction with the anti-proliferative proteins BTG1 and BTG2 (Lin et al. 1996) and 
subsequent experiments suggested that these two proteins are capable of enhancing 
PRMT1 activity (Lin et al. 1996 & Berthet et al. 2002).  More recently, the deadenylase 
CCR4 Associated Factor 1 (CAF1) was found to modulate enzyme activity in a substrate 
specific manner by decreasing methylation of SAM68 and histone H4 but not affecting 
hnRNPA1 methylation in vitro.  These observations were validated in vivo using siRNA 
knockouts of CAF1 in MCF-7 cells and probing for asymmetric dimethylation of SAM68 
and histone H4.  The authors also showed that in vitro, BTG1 increases PRMT1-
dependent methylation of Histone H4 while decreasing methylation of SAM68.  In 
addition, the authors were able to pull down CAF1 and BTG1 with GST-PRMT1 and 
show that PRMT1 and CAF1 colocalize in the cell (Robin-Lespinasse et al. 2007).  
Interestingly, BTG1 and CAF1 are binding partners (Rouault et al. 1998 and Bogdan et 
al. 1998), thus providing further evidence for a likely regulatory mechanism involving all 
three proteins.   
Because the initial studies examining the effect of BTG1 and CAF1 on PRMT1 
activity only looked at relative rates, we set out to perform a more in depth 
characterization and thereby provide a molecular basis for the regulation afforded by 
these interacting proteins.  Using the PRMT1 catalyzed asymmetrical dimethylation of 
histone H4 at R3 as a model (Figure 4.1A), at least two possible scenarios exist for the 
regulation of PRMT1 by its interacting partners (Figure 4.1B).  In both cases, the 





case of CAF1, binding would prohibit methylation, however, in the case of BTG1, 
binding would recruit PRMT1 to the target arginine, in this case on histone H4.  The role 
that both CAF1 and BTG1 play together in the regulation of PRMT1 has yet to be 
determined.  To probe the illustrated scenarios, PRMT1 activity assays were performed at 
increasing concentrations of CAF1 and BTG1, individually and together, with low and 
high concentrations of histone H4 and AcH4-21, a minimal peptide substrate of histone 
H4.  The results suggest that CAF1 can bind histone H4 and prevent methylation and/or it 
can bind PRMT1 and target it to histone H4.  In addition, it is likely that BTG1 binds to 
both proteins as well; however, it appears to have less affinity for histone H4 compared to 
CAF1. 
 
Figure 4.1 Enzyme regulation scenarios of PRMT1 by CAF1 and BTG1.  (A) PRMT1 
asymmetrically dimethylates histone H4 at R3. (B)  CAF1 and BTG1 can exhibit their 







4.2 Materials and Methods 
4.2.1 Chemicals  
Acrylamide, ammonium persulfate, beta-mercaptoethanol, sodium dodecyl sulfate 
(SDS), tetramethylethylenediamine (TEMED), and tris(hydroxymethyl)aminomethane 
(TRIS) were purchased from Bio-Rad (Hercules, CA).  Acetonitrile, 
(ethylenedinitrilo)tetraacetic acid (EDTA), dimethylformamide (DMF), Fmoc-amino 
acids, methanol, phenylmethylsulfonyl fluoride (PMSF), trifluoroacetic acid (TFA), and 
Wang resin were purchased from EMD (Gibbstown, NJ).  Dichloromethane, diethyl 
ether, glutathione (reduced), imidazole, potassium phosphate monobasic, potassium 
phosphate dibasic, sodium chloride, triisopropylsilane (TIS), and urea were purchased 
from Fisher Scientific (Pittsburgh, PA).  Dithiothreitol (DTT), 4-(2-Hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), isopropyl β-D-1-thiogalactopyranoside (IPTG), 
and tricine were purchased from RPI (Mt. Prospect, IL).  Guanidinium hydrochloride, 
and piperidine were purchased from Sigma-Aldrich (St. Louis, MO).  
14
C-labeled SAM 
was purchased from Perkin-Elmer and 
14
C-labeled BSA from Sigma-Aldrich.  Triton X-
100 and sodium acetate were purchased from VWR (West Chester, PA).  The purification 
of PRMT1 and the synthesis of the AcH4-21 peptide are outlined in Chapter 2. 
 4.2.2 Purification of Histone H4 
Recombinant histone H4 was purified with slight modification to an established 
protocol (Thompson et al. 2001).  A plasmid encoding histone H4 was transformed into 
E. coli BL21(DE3) cells and starter cultures, prepared from single colonies in the 
presence of 100 µg/mL ampicillin, were incubated overnight at 37 °C with rotation.  





(32 g tryptone, 20 g yeast, 10 g NaCl, 100 µg/mL ampicillin) and the culture was grown 
at 37 °C with shaking to an OD600 of 0.4.  Protein expression was induced with 0.4 mM 
IPTG for 1.5 h.  Cells were harvested by centrifugation at 4400 x g for 10 min and the 
pellet was resuspended in Wash Buffer (50 mM Tris pH 7.5, 100 mM NaCl, 1 mM 
EDTA, 1 mM PMSF) followed by flash freezing in liquid nitrogen.  The cell suspension 
was thawed at 42 °C for 30 min and cells were lysed by 8 cycles of sonification (8 sec 
pulse with 1 min rest at 100% amplitude).  Lysed cells were centrifuged for 20 min at 
23,000 RPM and the resulting pellet was washed with 50 mL of Wash Buffer plus 1% 
Triton X-100.  The washed pellet was centrifuged for 10 min at 14,000 x g, the 
supernatant was discarded, and a second round of washing and centrifugation was 
performed.  The final pellet was minced in 1 mL of DMSO and incubated at RT for 30 
min followed by the addition of 10 mL of unfolding buffer (7 M guanidinium HCl, 20 
mM Tris pH 7.5, 10 mM DTT).  The resuspension was incubated for 1 h at RT with 
stirring then centrifuged for 10 min at 13,000 x g and the supernatant was removed and 
saved.  The pellet was resuspended in 5 mL of unfolding buffer, incubated for another 10 
min at RT with stirring, and centrifuged for 10 min at 13,000 x g.  The second 
supernatant was combined with the first and dialyzed overnight against 4 L of ddH2O and 
1 mM β-mercaptoethanol at 4 °C.  The solution was lyophilized the following day and 
the dried white powder was resuspended in 20 mM sodium acetate pH 5.2, 5 mM β-
mercaptoethanol, 1 mM EDTA, 7 M deionized urea and further purified using a CM 
Sepharose
TM
 Fast Flow (GE Healthcare) column on the FPLC, with a stationary phase of 
20 mM sodium acetate pH 5.2, 5 mM β-mercaptoethanol, 1 mM EDTA, and 5 mM 





mM β-mercaptoethanol, 1 mM EDTA, 5 mM deionized urea, and 2 M sodium chloride.  
Fractions were checked by SDS-PAGE and pure fractions were dialyzed against 4 L of 
ddH2O and 1 mM β-mercaptoethanol at 4 °C and subsequently lyophilized the next day.  
The dried protein was dissolved in unfolding buffer to a concentration of 2 mg/mL and 
incubated for 15 min at RT followed by a two-fold dilution in unfolding buffer and 
incubation for 1 h at RT.  Histone H4 was then dialyzed overnight against 10 mM Tris 
pH 7.5, 250 mM sodium chloride, 1 mM EDTA, and 5 mM β-mercaptoethanol at 4 °C.    
4.2.3 Purification of mCAF1, hBTG1, and Glutathione S-transferase 
The mCAF1 and hBTG1 plasmids were a generous gift from Dr. Muriel Le 
Romancer and were subcloned from their original pGEX-ET E. coli expression vectors 
into pGEX-6P-1 (BamHI and SmaI restriction sites) and pGEX-6P-2 (EcoRI restriction 
sites) E. coli expression vectors, respectively.  The plasmids were separately transformed 
into E. coli Rosetta cells and single colonies were used to inoculate starter cultures, in the 
presence of 80 µg/mL ampicillin and 25 µg/mL chloramphenicol, that were grown 
overnight at 37 °C.  Starter cultures, in addition to 50 µg/mL ampicillin and 17.5 µg/mL 
chloramphenicol, were added to 2 x 1 L of TB media (12 g tryptone, 24 g yeast, 0.4% 
glycerol, 0.17 M KH2PO4, and 0.72 M K2HPO4 ) and grown at 37 °C with shaking until 
an OD600 of 0.8-1.0 was achieved.  Protein expression was induced with 0.3 mM 
isopropyl β-D-1-thiogalactopyranoside and cultures were incubated at 16 °C overnight.  
Cells were harvested by centrifugation at 4,400 x g for 10 min at 4 °C.  The pellet was 
resuspended in 26 mL of lysis buffer (20 mM Tris pH 8, 5 mM EDTA, 20% glycerol, 400 
mM sodium chloride, and 5 mM DTT) and 4 mL of protease inhibitor cocktail solution 





3200 µL of ddH2O).  The resuspended pellet was mixed slowly for 30 min at 4 °C 
followed by 12 cycles of sonication (15 sec pulse with 1 min rest at 100% amplitude).  
Lysed cells were centrifuged at 23,000 x g for 30 min at 4 °C.  The supernatant was 
applied to a Glutathione Sepharose® 4B (GE Healthcare) column followed by a low salt 
wash (20  mM Tris pH 8, 1 mM EDTA, 20% glycerol, 200 mM sodium chloride, and 1 
mM DTT) and a high salt wash (20  mM Tris pH 8, 1 mM EDTA, 20% glycerol, 500 mM 
sodium chloride, and 1 mM DTT).  The proteins were then eluted with glutathione buffer 
(10 mM reduced glutathione, 50 mM Tris-HCl pH 8 and 1 mM DTT).  Washes and 
elution fractions were checked by SDS-PAGE and PreScission Protease (GE Healthcare) 
was added to the fractions containing protein prior to overnight dialysis against 20 mM 
Tris pH 8, 20 mM EDTA, 1 mM DTT, and 500 mM sodium chloride 4 °C.  Dialyzed 
protein was applied to a regenerated Glutathione Sepharose® 4B column and the flow 
through was collected and dialyzed for 3 h against 20 mM Tris pH 8, 1 mM EDTA, and 1 
mM DTT 4 °C.  The protein was further purified using a HiTrap
TM
 Q Fast Flow (GE 
Healthcare) column on the FPLC, with a stationary phase of 20 mM Tris pH 8.5 and 2 
mM DTT and a linear gradient mobile phase of 10 mM Tris pH 8.5, 2 mM DTT, and 1 
mM sodium chloride.  Fractions were checked by SDS-PAGEe and pure fractions were 
dialyzed against 20 mM Hepes pH 8, 1 mM EDTA, 1 mM DTT, 10% glyercol, and 5 
mM sodium chloride at 4 °C.   
Glutathione S-transferase (GST) was purified using a modified mCAF1 and 
hBTG1 protocol.  The empty pGEX-6P-1 vector was used to express GST and the pure 
protein was collected in the glutathione buffer fraction (10 mM reduced glutathione, 50 





Healthcare) column.  The protein was then dialyzed against 20 mM HEPES pH 8, 1 mM 
EDTA, 1 mM DTT, 10% glyercol, and 5 mM sodium chloride at 4 °C.   
4.2.4 Gel-Based Methylation Assay 
The gel-based PRMT1 methylation assay has been previously described (Osborne 
et al. 2007).  For percent activity experiments in which the enzyme was preincubated 
with the interacting proteins, reaction mixtures of 50 mM HEPES pH 8.0, 1 mM EDTA, 
50 mM sodium chloride, 0.5 mM dithiothreitol, 15 μM [
14
C]-labeled SAM, 0.2 μM 
PRMT1 or 0.8 μM PRMT1, and varying concentrations of GST, mCAF1, hBTG1, or 
mCAF1/hBTG1 (0-30 μM) were preincubated at 37 °C for 10 min.  The reaction was 
initiated with 25 μM AcH4-21, 3 μM histone H4, or 25 μM histone H4 and was quenched 
after 15 min or 90 min.  For percent activity experiments in which the substrate was 
preincubated with the interacting proteins, the same reaction mixture was preincubated 
with either 15 μM AcH4-21 or 3 μM histone H4 at 37 °C for 10 min.  The reaction was 
initiated with 0.8 μM PRMT1 and was quenched after 90 min.  The samples were run on 
tris-tricine gels and incorporated radioactivity was quantified using Image Quant 
(Molecular Dynamics).  The assays were done in duplicate and the standard deviation of 
the raw data values agreed within ≤ 20%.  Percent activity was determined by dividing 
the rates at each particular interacting protein concentration by the acquired rate at 0 μM 
interacting protein.   
4.3 Results and Discussion 
 Previous studies have qualitatively determined that PRMT1 activity is affected by 
CAF1 and BTG in a substrate specific manner (Lin et al. 1996, Berthet et al. 2002, 






Figure 4.2 Effect of interacting proteins on PRMT1 activity at high concentrations of 
substrate.  Enzyme was preincubated with the interacting protein(s) followed by 
initiation of the methylation reaction with (A) histone H4 (25 µM) or (B) AcH4-21 
(25 µM).  
 
determine the possible mechanism of regulation (Figure 4.1), we performed in vitro 
activity assays with PRMT1 in the presence of CAF1, BTG1, and a combination of the 
two.  These assays were done at low and high concentrations of both histone H4 and the 
AcH4-21 peptide.  Because the original studies demonstrated that CAF1 and BTG1 co-
immunoprecipitate with PRMT1, the first assays that were performed involved 
preincubating PRMT1 with the interacting protein(s) followed by initiation of the 
methylation reaction with a high concentration of substrate (Figure 4.2).  The results 
show a general increase in activity in the presence of the interacting proteins, individually 
and together, as well as for the GST control, for both histone H4 and the AcH4-21 
peptide.  These results were confusing as they do not agree with previously published 
results, which show that CAF1 inhibits and BTG1 enhances methylation of histone H4.  
Therefore, the assay was repeated in the same manner but with a lower concentration of 
[Interacting Protein] (µM)




























































histone H4, similar to that of the original study, to determine if substrate concentration 
was a factor (Figure 4.3).  Here, an increase in activity in the presence of CAF1, BTG1, 
and a combination of both was observed, followed by a decrease starting at 10 µM, while 
the GST control remained constant.  Although inhibition was observed, these results were 
still not consistent with previous findings and thus unsatisfying.   
 
Figure 4.3 Effect of interacting proteins on 
PRMT1 activity at low concentrations of 
substrate.  Enzyme was preincubated with the 
interacting protein(s) followed by initiation of 
the methylation reaction with histone H4 (3 
µM). 
 
To determine if the two proteins affect PRMT activity by binding to the substrate 
instead (Figure 4.1), assays were repeated except with preincubation of the interacting 
proteins and the substrates followed by initiation of the reaction with PRMT1 (Figure 
4.4).  The results observed with histone H4 were more like the results that we expected, 
with a decrease in activity in the presence of CAF1 and a slight increase with BTG1.  
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Quite surprisingly, however, there was generally no inhibition or activation with AcH4-
21 as the substrate.  This observation suggests that the interacting proteins likely bind to 
the core of histone H4, which is absent from the peptide.  In addition, the presence of 
both CAF1 and BTG1 decreased PRMT1 activity, almost to the extent of CAF1.  
Conclusions cannot yet be made from this observation however, as more experiments 
will need to be done to probe this interaction. 
 
Figure 4.4 Effect of interacting proteins on PRMT1 activity at low concentrations of 
substrate. (A) Histone H4 (3 µM) or (B) AcH4-21 (15 µM) was preincubated with the 
interacting protein(s) followed by initiation of the methylation reaction with PRMT1. 
 
A summary of the individual results with CAF1 and BTG1 can be found in Figure 
4.5.  It is obvious from these graphs that the preincubation conditions play a role in the 
effect of CAF1 on PRMT1 activity, i.e., inhibition when preincubated with histone H4 
and activation when preincubated with PRMT1.  This further demonstrates the likelihood 
that CAF1 can bind PRMT1, but may also be a histone binding protein, which has not 
been previously observed.  The preincubation conditions only yield a very small 
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difference in regards to BTG1, which suggests that if BTG1 binds to histone H4 it is 
likely not a strong interaction.  
 
Figure 4.5 Summary of the effects of CAF1 and BTG1 on PRMT1 activity.  The red bars 
show results for the preincubation with histone H4 (3 µM) and the blue bars show for 




  Studies have shown that CAF1 and BTG1 are capable of inhibiting or enhancing 
PRMT1 activity in a substrate dependent manner, although the exact mechanism of this 
regulation is unknown (vide supra).  Therefore, efforts were made to quantify these 
effects and possibly determine the mechanism of inhibition or activation of PRMT1.  
Activity assays were performed with low and high concentrations of histone H4 and 
AcH4-21 and with varying concentrations of interacting proteins.  The results show that 
preincubation of PRMT1 with the interacting protein(s) followed by initiation with a high 
concentration of substrate only enhances activity.  The same assay repeated at lower 
concentrations of substrate showed some inhibition but not to the degree described by 
other groups.  However, when histone H4 was preincubated with the interacting proteins, 
the results were similar to the previously reported results with inhibition caused by CAF1 
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and activation by BTG1.  Surprisingly, there was no effect on activity when AcH4-21 
was preincubated with the proteins, which suggests that the proteins likely bind to the 
core of histone H4.   
 Looking at the possible scenarios for protein-protein interactions (Figure 4.1), the 
results allude to a possible scenario where CAF1 can bind PRMT1 and target it to histone 
H4, but can also bind histone H4 and prevent methylation.  In the case of BTG1, it 
appears as though it can bind both proteins but has a lower affinity for histone H4 
compared to CAF1.  The lack of an effect with AcH4-21 further demonstrates the 
likelihood that both of these proteins bind histone H4. 
 Overall, initial efforts have been made to characterize the regulation of PRMT1 
by its interacting partners.  There is still a lot of work that needs to be done to determine 
their exact role in vivo.  The fact that the effects on PRMT1 appear to be substrate 
dependent (Robin-Lespinasse et al. 2007) suggests that interaction with the substrates is 
critical for these observations.  Therefore, studies with other substrates (e.g. SAM68) and 
co-immunoprecipitation experiments may shed light on whether the observed effects are 
mainly due to interactions with the substrate or with PRMT1.  It would also be interesting 








Development of PRMT1 Inhibitors 
5.1 Introduction 
 As described in detail in Chapter 1, dysregulation of PRMT1 likely plays a role in 
breast cancer (Le Romancer et al. 2008 & Baldwin et al. 2012), leukemia (Cheung et al. 
2007 & Shia et al. 2012), heart disease (Vallance et al. 2004), and ALS (Tradewell et al. 
2012), thus suggesting that it may be a viable drug target.  In addition, the precise roles 
that PRMT1 plays in normal cells have yet to be fully characterized, further 
demonstrating the usefulness of a specific inhibitor.  The structural similarities between 
the PRMT family members as well as between the PRMTs and protein lysine 
methyltransferases (PKMTs),  however, presents a difficult challenge when attempting to 
develop a potent and selective inhibitor or inactivator for PRMT1, as there are currently 
no cell permeable selective inhibitors to date.  However, this shortcoming should not 
overshadow the efforts that have been made by various groups in the last decade to solve 
this predicament. 
Arginine methyltransferase inhibitor 1, more commonly known as AMI-1, was 
the first PRMT selective inhibitor to be described.  This compound, along with several 
less potent and/or selective compounds, was identified by screening a small molecule 





found to reversibly inhibit all of the PRMTs tested, but not the PKMTs, and shown to be 
cell permeable (Cheng et al. 2004).  The lack of an effect on SAM binding in UV 
 
Figure 5.1 Structures of selected PRMT inhibitors discovered from 
library screenings. 
 
crosslinking experiments suggested that AMI-1 likely binds in the arginine binding 
pocket (Cheng et al.2004) and this hypothesis was confirmed by inhibition studies using a 
fluorescence based assay (Feng et al. 2009).  However, others have suggested that, 
according to molecular models, it binds partially in the SAM binding pocket and partially 
in the arginine binding pocket (Ragno et al. 2007).  Centering on AMI-1 and several 
other compounds identified in the original library screen (i.e., AMI-5, AMI-6, and AMI-
9) various groups have attempted to modify these structures in order to improve their 





et al. 2010, Castellano et al. 2010).  These analogues include substitutions of carboxylic 
groups for the sulfonic groups (e.g., 1b) (Castellano et al. 2010), substituted 1,5-diphenyl-
1,4-pentadien-3-ones (e.g., 8) (Mai et al. 2007), as well as combining parts of AMI-1, 
AMI-6, and AMI-9 into one molecule (e.g., 4) (Bonham et al. 2010) (Figure 5.1).  
Although some of these compounds were found to be more potent than the original 
compounds, specificity was still lacking.  
 
Figure 5.2 Structures of selected PRMT inhibitors discovered from virtual 
screenings. 
 
A second and more targeted approach has also been undertaken by way of virtual 
screening using the structures of PRMT1, PRMT3, and CARM1 as guides (Spannhoff et 
al. 2007, Spannhoff et al. 2007, Heinke et al. 2009).  These screens have produced 
compounds such as stilbamidine (Spannhoff et al. 2007), allantodapsone (Spannhoff et al. 





subsequent analogs of these original compounds such as 2e (Bissinger et al. 2011) 
(Figure 5.2).  In addition, a series of compounds, which possess the AMI-1 core, (e.g., 3) 
were found that target the substrates of PRMT1 as opposed to the enzyme itself (Feng et 
al. 2010) (Figure 5.2); this later finding raises questions regarding the inhibition 
mechanism of the aforementioned sulfonylureas.  In spite of the fact that the 
aforementioned compounds are suitable inhibitors, and in some cases are cell permeable, 
their specificity amongst the members of the PRMT family has not been fully 
investigated.  
 
 Figure 5.3 Structures of SAM analogues and selected bisubstrate PRMT inhibitors. 
 
Although, library and virtual screenings are popular techniques for the discovery 
of small molecule inhibitors, other groups have taken a more logical approach by 
modifying SAM and/or peptide versions of PRMT substrates for use as inhibitors.  In 





PRMT-dependent methylation, and sinefungin, a SAM analog, are potent inhibitors of the 
PRMTs, with specific IC50’s for PRMT1 at 19.8 ± 5.57 µM and 1.44 µM ± 0.41 µM, 
respectively (Osborne et al. 2007) (Figure 5.3).  Several bisubstrate analogs that 
incorporate both the SAM moiety and the target arginine residue have been characterized 
(e.g., 17 (Dowden et al. 2010) and 19 (Dowden et al. 2011)), with both showing 
specificity for the PRMTs over the PKTs and the latter showing specificity for PRMT1 
over CARM1 (Figure 5.3).  Another group has used a peptide based on the methylation 
site of fibrilarin as scaffolding for inhibitor design (e.g., R1-4) (Figure 5.3).  In this case, 
substitutions were made at the Nη of the guanidinium group and the results show that 
these inhibitors are selective for PRMT1 and PRMT6 over CARM1 with IC50 values less 
than 80 µM (Lakowski et al. 2010).       
 
Figure 5.4 Mechanism of PRMT1 inhibition by AAI. 
 
Our lab has also been focused on developing inhibitors for the PRMTs, 
specifically for PRMT1.  The first inhibitor developed in our lab was 5’-
(diaminobutyric acid)-N-iodoethyl-5’-deoxyadenosine ammonium hydrochloride 
(AAI) (Figure 5.4), with an IC50 of 18.5 ± 4.2 µM in comparison to 350 ± 36 µM for 
AMI-1 (Osborne et al. 2008).  Note that the large difference in the IC50 values 





in experimental conditions, (e.g., substrate identity and concentration), thus 
demonstrating the error in comparing IC50 values stemming from different conditions.  
Although more laborious and time consuming, the best method for comparing 
inhibition potency is Ki or, in the case of irreversible inhibitors, kinact/KI.  
 
 











 Target based inhibitor design in our lab has not been limited to the PRMTs.  
In fact, our lab previously described two potent inactivators, Cl-amidine and F-
amidine, for the PADs, a family of enzymes that convert arginine to citrulline in 













PRMT1 1.8 ± 0.1 225 ± 10 94 ± 17 >500 
PRMT3 >500 >500 109 ± 28 >500 
CARM1 >500 >500 >500 >500 
PRMT6 8.8 ± 0.5 >500 >250 >500 
PAD4 145 ± 20 5.9 ± 0.3 117 ± 14 21.6 ± 2.1 
a





proteins (Figure 5.5) (Luo et al. 2006a and Luo et al. 2006b).  Because the PADs and 
the PRMTs both modify arginine residues, it was thought that these two compounds 
might also inhibit the PRMTs.  The IC50 values for the compounds with PRMT1 were 
high (Table 5.1) (Obianyo et al. 2010), however, based on previous studies in our lab 
that demonstrated that positively charged residues distal to the site of modification are
critical for substrate recognition (Osborne et al. 2007), it was likely that the lack of 
substrate recognition elements was the cause of this high value as opposed to the 
warhead.  To test this hypothesis, the Cl- and F-acetamidine moieties were 
incorporated at the arginine 3 position of AcH4-21, a peptide substrate of PRMT1 
that is based on the N-terminus of histone H4 (Figure 5.5) (Osborne et al. 2007).  
Indeed, the potency of the peptide based inhibitors, termed C21 and F21, was greatly 
increased and C21 was found to be selective for PRMT1 and PRMT6 over PRMT3 
and CARM1 (Table 5.1).  Interestingly, C21 was ~ 52-fold more potent than F21, and 
subsequent dialysis experiments demonstrated that C21 is an irreversible inactivator, 
however, F21 is a competitive reversible inhibitor. (Obianyo et al. 2010).    
 






Possible mechanisms of inactivation of the PRMTs with the haloacetamidine-
based inhibitors are illustrated in Figure 5.6.  Further kinetic studies with C21 and 
PRMT1 revealed that inactivation for this isozyme is a two-step mechanism with Ki, 
kinact, and kinact/Ki values of ≤ 0.8 ± 0.4 µM, 3.1 ± 0.4 min
-1







respectively, thus making this the most potent PRMT1 inhibitor at this time (Obianyo 
et al. 2010).  Studies with C21 also demonstrated inhibition of PRMT1 in cellulo 
(Obianyo et al. 2010), and the addition of a fluorescein or biotin tag, F-C21 and B-
C21 respectively, transforms the inactivator into an activity-based probe that can 
selectively label or pull down PRMT1 from cell extracts (Obianyo et al. 2011).     
 Although C21 has been characterized extensively, the site of modification has 
remained a mystery.  Substrate protection experiments, however, have suggested that it is 
likely an active site residue because the enzyme is protected from inactivation at higher 
substrate concentrations (Obianyo et al. 2010).  Cl-amidine and F-amidine modify an 
active site cysteine residue in the PADs (Luo et al. 2006a and Luo et al. 2006b), however, 
the residue modified in PRMT1 is unknown; although a cysteine residue (C101) is 
present in the active site of PRMT1.  Herein, we describe our efforts to determine the 
residue in PRMT1 that is modified by both Cl-amidine and C-21.  We also describe our 
efforts to develop more potent and selective inhibitors for PRMT1 based on the site of 
modification.  The results of these studies have opened new doors for the rational design 
of selective SAM-based inactivators of the PRMTs.  
5.2 Materials and Methods 
5.2.1 Chemicals  





 (SDS), tetramethylethylenediamine (TEMED), and tris(hydroxymethyl)aminomethane 
(TRIS) were purchased from Bio-Rad (Hercules, CA).  Acetonitrile, 
(ethylenedinitrilo)tetraacetic acid (EDTA), dimethylformamide (DMF), Fmoc-protected 
amino acids, methanol, phenylmethylsulfonyl fluoride (PMSF), trifluoroacetic acid 
(TFA), and Wang resin were purchased from EMD (Gibbstown, NJ).  6-chloropurine 
riboside, dichloromethane, diethyl ether, N-ethylmaleimide, imidazole, sodium chloride, 
and triisopropylsilane (TIS) were purchased from Fisher Scientific (Pittsburgh, PA).  
Dithiothreitol (DTT), 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 
isopropyl β-D-1-thiogalactopyranoside (IPTG), and tricine were purchased from RPI (Mt. 
Prospect, IL).  Piperidine was purchased from Sigma-Aldrich (St. Louis, MO).  
14
C-
labeled SAM was purchased from Perkin-Elmer and 
14
C-labeled BSA from Sigma-
Aldrich.  The purification of PRMT1, site-directed mutagenesis, the synthesis of the 
AcH4-21 peptide, and the gel-based activity assay are outlined in Chapter 2.  The 
synthesis of Cl-amidine (Luo et al. 2006a) and C-21 (Obianyo et al. 2010) have been 
previously described. 
5.2.2 Labeling Reactions 
 For labeling of PRMT1 with Cl-amidine, a reaction mixture of 50 mM HEPES pH 
8.0, 1 mM EDTA, 50 mM NaCl, 0.5 mM dithiothreitol, and 5 mM Cl-amidine was pre-
incubated at 37 °C for 10 min.  The reaction was initiated with 4.17 µM (5 µg) of 
PRMT1 and the reaction was quenched after 15 min with 4x SDS-loading dye.  The 
entire reaction (5 µg of PRMT1) was separated by SDS-PAGE.  For labeling of PRMT1 
with C21, a reaction mixture of 50 mM HEPES pH 8.0, 1 mM EDTA, 50 mM NaCl, 0.5 





reaction was initiated with 8.33 µM (10 µg) of PRMT1 and the reaction was quenched 
after 15 min with SDS-loading dye.  Half of the reaction (5 µg of PRMT1) was separated 
by SDS-PAGE. 
5.2.3 In-Gel Digestion 
 Coomassie stained gel bands corresponding to labeled PRMT1 were excised and 
the resultant gel pieces were washed and dehydrated two times.  Existing disulfide bonds 
were reduced with 10 mM DTT and the resulting thiols were alkylated with 54 mM N-
ethylmaleimide.  Proteins were digested with trypsin (Promega – V5113), at a 1:10 
(w:w)(trypsin:protein) ratio, overnight at 37 °C.  The enzymatic reaction was quenched 
with 1% TFA and the resulting peptides were desalted and concentrated using C18 
ZipTips (Millipore).  Dried peptides were reconstituted in 0.1 % formic acid. All samples 
were analyzed by liquid chromatography-tandem MS (LC-MS/MS) using an EASY-nLC 
II system coupled to an LTQ linear ion trap mass spectrometer (Thermo-Finnigan, San 
Jose, CA). Briefly, peptides were concentrated and desalted on an RP trapping column 
(0.31 x 20 mm, ReproSil-Pur C18-AQ, ThermoScientific) and eluted on-line with an 
analytical RP column (0.075 x 100 mm, ReproSil-Pur C18-AQ, ThermoScientific), 
operating at 300 nl/min and using a 40-min gradient from 0% to 40% solvent B [solvent 
A: 0.1% formic acid (v/v), solvent B: 0.1% formic acid (v/v), and 80% acetonitrile (v/v)].  
For analysis of PRMT1 labeled with Cl-amidine, a m/z 400-1600 survey scan was 
performed followed by the fragmentation of the ten most intense ions. A database search 
with the MS/MS results was performed using the SEQUEST algorithm to identify the 
modified cysteine residue(s) (m/z 377.15).  For analysis of PRMT1 labeled with C21, the 





400-1600 survey scan was first performed in order to check for the presence of digested 
peptides as well as peptide separation along the gradient. This survey scan is followed by 
dependent MS/MS scans that fragment the six most intense ions to confirm the presence 
of the protein of interest.  Next, MS/MS spectra were programmed, focusing on m/z 
564.55, which corresponds to the quadruply-charged precursor ion of the modified 
KVIGIEC*SSISDYAVK peptide, and on m/z 752.40, corresponding to the same 
modified peptide but in its triply-charged state.  Note that the quadruple charge stems 
from a possible charge on the fragmented C21 peptide and that the MS/MS scans were 
repeated twice.             
5.2.4 IC50 Assay 
IC50 values were determined using a gel-based radioactive assay with a reaction 
mixture of 50 mM HEPES pH 8.0, 1 mM EDTA, 50 mM NaCl, 0.5 mM dithiothreitol, 25 
µM AcH4-21, 0.2 µM PRMT1, and varying concentrations of inhibitor.  Samples were 
pre-incubated for 10 min at 37 °C and the reaction was then initiated with 15 μM [
14
C]-
labeled SAM.  The reaction was quenched with tris-tricine gel loading dye after 15 min 
and the samples were run on tris-tricine gels.  Incorporated radioactivity was measured by 
phosphorimage analysis (Molecular Dynamics).  Each assay was done in duplicate and 
the standard deviation of the duplicate raw data values agreed within ≤ 20%.  The GraFit 
version 5.0.11 software (Leatherbarrow 2004) was used to fit the data to eq. 1,  
                               Fractional activity of PRMT1 = 1/(1 + ([I]/IC50))                             (1), 
in which the concentration of inhibitor equals [I] and the concentration of inhibitor that 
yields half-maximal activity equals the IC50. 





For C21, a reaction mixture of 50 mM HEPES pH 8.0, 1 mM EDTA, 50 mM 
NaCl, 0.5 mM dithiothreitol, 125 µM C21, and 10 µM enzyme (WT PRMT1 or C101A 
mutant) in a final volume of 150 µL was incubated for 1 h at 37 °C.  Note that a control 
reaction was also performed without C21.  Samples were then dialyzed for 24 h at 4°C 
against 100 mM HEPES, 200 mM NaCl, 1 mM DTT, 2 mM EDTA, and 10% glycerol in 
a total volume of 2 L.   An aliquot was removed from all samples, before dialysis, and 
activity was measured using the gel-based assay described in Chapter 2, with 15 µM 
14
C-
SAM, 25 µM AcH4-21, 125 µM C21, and 0.2 µM enzyme or enzyme-inhibitor complex 
for 15 min at 37 °C, followed by quenching with tris-tricine gel loading dye.  After 
dialysis, protein concentration in each sample was determined by Bradford assay and 
activity was measured with 15 µM 
14
C-SAM, 25 µM AcH4-21, and 0.2 µM enzyme or 
enzyme-inhibitor complex for 15 min at 37 °C, followed by quenching with tris-tricine 
gel loading dye.  Samples were separated by tris-tricine gels and radioactivity was 
measured using phosphorimage analysis (Molecular Dynamics).  The product formed by 
the control reactions was set to 100% and the percent activity of the other samples was 
determined based on this number.  The same procedure was repeated for Cl-acetamidino-
N-ethyl-aminoadenosine, except the concentration of inhibitor was 1 mM and only the 
WT enzyme was assayed. 
5.2.6 Synthesis of N-ethyl-aminoadenosine 
A solution of 100 mg (0.35 mmol) of 6-chloropurine riboside and 70 µL (1.1 
mmol) of ethylene diamine in 3 mL of IPA was refluxed for 1 h at 83 °C.  Ether was then 
added to the reaction and the compound was purified by trituration.  The ether was then 





verified by LC-MS: expected = m/z 311.14 (M + H
+
), observed = m/z 311.1 (M + H
+
).  
N-ethyl-aminoadenosine was used in subsequent experiments without further 
purification. 
5.2.7 Synthesis of Cl-acetamidino-N-ethyl-aminoadenosine 
 A solution of 39 mg (0.126 mmol) of the N-ethyl-aminoadenosine, 30 mg (0.189 
mmol) of ethylchloroacetimidate hydrochloride, and 71.7 µL (0.377 mmol) of potassium 
carbonate in 5 mL of methanol was then rocked overnight at rt.  The solvents were 
evaporated in vacuo and the product was purified by RP-HPLC with a linear gradient of 
water (0.05% TFA)/acetonitrile (0.05% TFA). The mass of the product was verified by 
LC-MS: expected = m/z 386.13 (M + H
+
), observed = m/z 386.1 (M + H
+
).   
5.3 Results and Discussion 
5.3.1 Identifying the Site of Modification of Haloacetamidine-Based Inactivators 
 Our lab previously described two irreversible inactivators of PRMT1, i.e., Cl-
amidine and C21, with the latter of the two being the most potent PRMT1 inhibitor 
described to date (Obianyo et al. 2010).  Cl-amidine was originally described as a potent 
PAD inhibitor (Luo et al. 2006a and Luo et al. 2006b) and because both families of 
enzymes modify arginine residues, it was thought that it might inhibit the PRMTs as well, 
which proved to be true.  The site of modification of the PADs is an active site cysteine 
residue that is critical for activity (Luo et al. 2006a and Luo et al. 2006b); however, it has 
been unclear as to the identity of the site of modification for PRMT1, as a cysteine 
residue is not important for catalysis.  Discovery of the site of modification would aid in 
the development of more potent and selective inhibitors by allowing for modification of 








Figure 5.7 MS/MS of the site of modification of PRMT1 with (A) Cl-amidine and (B) 
C21.  For both inactivators, KVIGIECSSISDYAVK was identified as the modified 
peptide, with C101 as the modified residue. 





































































































































































Because C21 is peptide based, which can complicate the MS/MS analysis, 
PRMT1 was first labeled with Cl-amidine and then an in-gel trypsin digest was 
performed followed by MS/MS analysis.  The results show that C101, an active site 
cysteine residue, is the site of modification (Figure 5.7A).  The experiment was then 
repeated with C21 and the results revealed that C101 is the site of modification for this 
inactivator as well (Figure 5.7B).   
5.3.2 Characterization of the C101A Mutant 
To characterize the role of C101 in PRMT1 catalysis, an alanine mutant was made 
and the kinetic parameters were determined (Tables 5.2 and 5.3).  Unlike the modified
 
 
cysteine in the PADs, mutation of this cysteine residue confirmed previous observations 
(Zhang et al. 2003) that it does not play a role in substrate binding or catalysis, as 
demonstrated by the similar Km, kcat, and kcat/Km values.  In fact, based on kcat/Km, it is a 
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slightly better enzyme.  We then hypothesized that the C101A mutant would likely not be 
inhibited by C21, due to the fact that the enzyme can no longer be covalently
modified.  The results show, however, that the C101A mutant is still inhibited by C21, 
but the IC50 value is increased by ~ 18-fold (Table 5.4).  These results suggest that C21 
may be a reversible inhibitor for C101A, while an irreversible inactivator of the WT 







Figure 5.8 Dialysis experiments of WT PRMT1 and the 
C101A mutant with C21.  The WT enzyme remains 
inactivated after dialysis, thus demonstrating that C21 is an 
irreversible inactivator towards the enzyme.  The C101A 
mutant regains activity after dialysis, thus showing that C21 
is only a reversible inhibitor for the mutant enzyme. 
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showed that the C101A mutant regained activity after dialysis (Figure 5.8).  The WT 
enzyme, however, remained inactivated, thus suggesting that C21, is a reversible 
inhibitor for C101A.  These results also confirm that C101 is the relevant site of 
modification.    
5.3.3 Design of SAM Analogues as PRMT1 Inactivators 
 The fact that PRMT1 is modified at C101 by C21 would suggest that the residue 
is located in the substrate binding pocket.  Surprisingly however, examination of the 
crystal structure shows that C101 faces the SAM binding pocket instead and is only 3.9 Å 
from the adenine rings and 4.1 Å from the ribose of SAH (Figure 5.9).  Based on these 
 
Figure 5.9 Structure of PRMT1 showing the 
position of the C101 residue in relation to SAH.  
This figure was prepared with UCSF Chimera 
using the coordinates from PRMT1 (PDBID 
1ORI). 
 
structural observations, as well as the fact that SAM analogues (i.e. SAH and sinefungin) 










more potent inactivators for PRMT1 by designing analogues of SAH that contain 
warheads that react with cysteine (i.e., chloroacetamidine, fluoromethylketone, and 
acrylamide).  As a starting point for inhibitor development, only the adenosine portion of 
SAH was used for the first SAM analogue, i.e., Cl-acetamidino-N-ethyl-aminoadenosine.   
The synthetic scheme for this compound can be found in Figure 5.10.  Briefly, ethylene 
diamine was coupled to 6-chloropurine riboside followed by coupling of 
ethylchloroacetamidate to yield the final product.  
 
Figure 5.10 Synthesis of N-ethyl-aminoadenosine and Cl-acetamidino-N-ethyl-
aminoadenosine.  
 
 IC50 values were determined for adenosine, N-ethyl-aminoadenosine, and Cl-
acetamidino-N-ethyl-aminoadenosine and can be shown in comparison to C21 in Table 
5.5.  The results show that the chloroacetamidine warhead is critical for inhibition, as 
demonstrated by the large IC50 values, i.e., >2000 µM, for adenosine and N-ethylamino-
adenosine; in comparison, the IC50 of Cl-acetamidino-N-ethyl-aminoadenosine is 200 ± 
109 µM.  The high value for the C101A mutant, >1000 µM, further suggests that 
covalent modification of this residue by Cl-acetamidino-N-ethyl-aminoadenosine is 
critical for inhibition.  To confirm that this SAM analogue is an irreversible inhibitor, 





C21 (Figure 5.8), activity is not regained after dialysis and therefore it too is an 
irreversible inhibitor (Figure 5.11). 
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Figure 5.11 Dialysis experiments of WT 
PRMT1 with Cl-acetamidino-N-ethyl-
aminoadenosine.  The WT enzyme remains 
inactivated after dialysis, thus demonstrating 
that Cl-acetamidino-N-ethyl-aminoadenosine 




 The development of potent, selective, and cell permeable inhibitors of the PRMTs 
has been a challenge due to the structural similarities between the family members.  Our 
lab has previously described the most potent inactivator to date, C21 (Obianyo et al. 
2010), however, the site of modification was a mystery.  To identify the site of 
modification, PRMT1 was first labeled with Cl-amidine, a potent inhibitor for the PADs, 
and the MS/MS analysis revealed that C101 was modified.  The same experiment was 
performed with C21 and C101 was once again identified as the modified residue.  A 
C101A mutant was created to determine if this residue is important for catalysis, and the 
kinetic parameters demonstrated that it is not.  Although the C101A mutant is still 
inhibited by C21, dialysis experiments determined that the inhibitor was reversible 
compared to its irreversibility with the WT enzyme.  Interestingly, this residue has 
Dialysis

























previously been described as a hyper-reactive cysteine residue (Weerapana et al. 2010), 
thus making it a good target for covalent modification.  In fact, examination of the 
structure of PRMT1 revealed that C101 is in the SAM binding pocket.  Therefore, we 
hypothesized that SAM analogues containing warheads that react with cysteine would be 
potent inhibitors of PRMT1.  To test our hypothesis, a SAM analogue, i.e., Cl-
acetamidino-N-ethyl-aminoadenosine, was synthesized.  IC50 values were determined for 
not only the inhibitor, but for its precursors, adenosine, and N-ethyl-aminoadenosine, and 
the results show that the warhead is critical for inhibition.  Comparison of the values for 
the WT enzyme and the C101A mutant suggests that C101 is the site of modification and 
important for inhibition with the analogue.  In addition, dialysis experiments confirmed 
that Cl-acetamidino-N-ethyl-aminoadenosine is an irreversible inhibitor of the WT 
enzyme. 
Interestingly, a cysteine residue as this position is only found in PRMT1 and 
PRMT8 (Figure 5.9A).  This observation may explain why C21 is selective for PRMT1 
over PRMT3 and CARM1, who each contain a cysteine residue that is buried away from 
the active site (Figure 5.9B-C).  It is thus surprising that C21 is also quite potent for 
PRMT6, even though an active site cysteine residue is not present in the crystal structure.  
However, a cysteine residue is located on the N-terminal tail of this isozyme, which looks 
as though it may be in a position to react with C21 after it is bound, based on the crystal 
structures of other PRMTs.   
Of most interest is a cysteine residue in the active site of PRMT5 that is opposite 
the position of C101 in PRMT1 (Figure 5.9D).  Although the reactivity of this cysteine 





 analogues that are individually selective for PRMT1 and PRMT5 by varying the position 
of the warhead. 
 
Figure 5.12 Structural representation of PRMT cysteine 
residues around the active site for (A) PRMT1, (B) PRMT3, 
(C) CARM1, and (D) PRMT5.  Note that the transparent 
spheres (B and C) are facing away from the active site. This 
figure was prepared with UCSF Chimera using the coordinates 
from PRMT1 (PDBID 1ORI), PRMT3 (PDBID 3SMQ), 
CARM1 (PDBID 3B3F), and PRMT5 (PDBID 4GQB). 
 
 Overall, the results described in this chapter have opened up a new door for our 
efforts to develop potent and selective inhibitors and inactivators of not only PRMT1, but 
other isozymes as well.  Future studies will include the synthesis of SAM analogues with 
SAH as the backbone and a variety of different linkers and warheads.  We hypothesize 












 As mentioned in Chapter 1, the best characterized examples of crosstalk between 
two or more different post-translational modifications (PTMs) occur with respect to 
histones.  These examples demonstrate the critical roles that crosstalk plays in regulating 
cell signaling pathways.  Recently, however, non-histone crosstalk has been observed 
between serine/threonine phosphorylation and the modification of arginine residues 
within kinase consensus sequences.  We hypothesize that crosstalk between 
serine/threonine phosphorylation and arginine modifications (Figure 6.1) is a general 
mechanism to regulate eukaryotic cell signaling, given that these neighboring arginine 
residues are key substrate recognition elements for many protein kinases (Figure 6.2). 
 
Figure 6.1 Potential model for crosstalk between arginine 
methylation and phosphorylation. 
                                                 
3
 Adapted with permission from Rust, H.L.; Thompson, P.R., Kinase consensus sequences: a breeding 








Figure 6.2 Serine/Threonine Protein Kinase consensus sequences.  A number of 
serine/threonine protein kinases recognize protein sequences that contain positively 
charged arginine and lysine residues adjacent to the site of phosphorylation.  For 
example, Akt, prefers substrates that have two arginines (or lysines) at positions -3 and -5 
with respect to the modification site that are separated by a variant residue.  Each box 
represents one residue’s position and multiple single letter amino acid codes demonstrate 
variability within that position.  Adapted from (Kinexus 2011). 
 
6.1.1 Arginine Methylation Blocks Phosphorylation 
 
Four examples of direct, adjacent cis crosstalk (see Chapter 1) have emerged 
Kinase -5 -4 -3 -2 -1 0 1 2 3 4
Akt/PKB R R STA STA pSpT FL
AMPK ILMV HKR HKR HKR pSpT ILMV
CaMK1 FILMV R pSpT FILMV
CaMK2 FILVY R pSpT FILMVY DE
CaMK4 FILVY R pSpT
CDK1 KR pS P KR KR
CDK2 R P M pSpT P KR K
CDK4 P L pSpT P I P HKR
CDK5 P pSpT P K
CHK1 IMLV KR pSpT
CLK1 KR KR pSpT R
DCK1-b2 FILMV R R pSpT FILMV
DMPK-E KR K R R R pSpT LV
MAPKAPK2 ILV R L pT ILMV
MSK1/2 R pSpT
NIMA NR FLM KR KR pS IVMR IVMR FIMV FIM
PAK KR R pSpT
Phos. Kinase KR FILM pS FILMV FKR IL FIL
Pim1 KR KR R KR L pSpT
PKA KR KR KR RN pSpT FILVY I F D
PKCα RF R R KR G pSpT FL KR KRQ
PKCβ FL KR R KQ G pSpT FM K K
PKCγ R R R K KG pSpT F KR KR K
PKCδ R R K G pSpT F
PKCε K R KRQ G pSpT V R R
PKCζ F R pSpT FM FM
PKCη R KR R pSpT F R R
PKCμ VL ALV R M pSpT
RSK1 KR R R pSpT
SLK1 R R F G pS FILVY R R FILVY
ZIPK KR R R R pS
Site of
Phosphorylation 





involving arginine methylation and serine phosphorylation.  First, Yamagata et al. 
demonstrated that FOXO1 (forkhead box O1) is methylated in vitro and in vivo by 
PRMT1 (Protein Arginine Methyltransferase 1) (Yamagata et al. 2008).  FOXO1 is a 
member of the FOXO family of transcription factors, which play essential roles in cell 
cycle regulation, apoptosis, the oxidative stress response, and overall cell survival (Greer 
et al. 2005).  The sites of FOXO1 modification, R248 and R250, are conserved across 
family members and species.  Interestingly, the FOXO family members are 
phosphorylated by Akt at three conserved residues, one of which, i.e., S253 in FOXO1 
(Brunet et al. 1999), lies adjacent to R248 and R250 (mouse numbering).  The authors 
then demonstrated that methylation of these two arginine residues inhibited 
phosphorylation of S253, a clear example of cis crosstalk.  However, the converse was 
not observed – phosphorylation does not prevent methylation (Yamagata et al. 2008).    
 Functionally, methylation of R248 and R250 blocks the phosphorylation of S253, 
thereby preventing the phosphorylation dependent nuclear export of FOXO1 (Zhang et al. 
2002).  Additional experiments indicated that it is the lack of phosphorylation, and not 
the presence of methylated arginine residues, that is responsible for inhibiting FOXO1 
export (Yamagata et al. 2008).  Because the phosphorylation and nuclear export of 
FOXO1 is associated with its polyubiquitination and degradation by the proteasome 
(Matsuzaki et al. 2003 and Huang et al. 2005), the authors tested the effects of PRMT1 
knockdown on FOXO ubiquitination and stability.  The results indicated that PRMT1 
knockdown enhanced the polyubiquitination of FOXO1, which promoted its degradation 





 Since it is well established that FOXO family members control the response to 
oxidative stress (Greer et al. 2005), the authors further hypothesized that the methylation 
of FOXO1 would affect this pathway.  As expected, hydrogen peroxide led to an increase 
in the PRMT1-dependent methylation of FOXO1, which in turn blocked the 
phosphorylation of S253, and nuclear export.  As a result, the transcription of a number 
of FOXO1-dependent genes was increased including, BIM (BCL-2-interacting mediator), 
an apoptosis inducing protein (Yamagata et al. 2008).  Consistent with this model, when 
either PRMT1 or FOXO1 were knocked down by siRNA, no increase in BIM 
transcription was observed.  Although PRMT1 knockdown inhibited apoptosis in 
response to oxidative stress, inhibition of PI3K-Akt signaling has the reverse effect 
(Yamagata et al. 2008).  Taken together, these results demonstrate a functional crosstalk 
between the methylation of R248 and R250 and phosphorylation of S253 of FOXO1.  
This mechanism of crosstalk appears to be evolutionarily conserved because methylation 
of the FOXO1 orthologue in C. elegans, DAF-16, also inhibits its phosphorylation by 
Akt.  Interestingly, this activity in C. elegans appears to play a role in life span extension, 
as PRMT1 knockouts died significantly earlier than wild type worms, thereby suggesting 
that PRMT1 inhibition may exert pleiotropic off target effects (Takahashi et al. 2011). 
 Recently, Sakamaki et al. published a second example of cis crosstalk between 
PRMT1 and Akt.  Specifically, the authors investigated whether the phosphorylation of 
other proteins that contain an Akt consensus sequence (i.e., RXRXXS/T) are modulated 
by the methylation of adjacent arginine residues (Sakamaki et al. 2011).  Several known 
Akt substrates (i.e., BAD, PGC-1, eNOS, p27, GSK3, and MDM2) were tested as 





coactivator) (Yamagata et al. 2008) and BAD (BCL-2 antagonist of cell death) 
(Sakamaki et al. 2011), were shown to be methylated by PRMT1.  The fact that eNOS, 
p27, GSK3, and MDM2 were not methylated (Sakamaki et al. 2011) suggests that 
additional PRMT1 recognition elements are required for substrate methylation (vide 
infra).  In BAD, the sites of modification were identified as R94 and R96, and, as was the 
case with FOXO1 (Yamagata et al. 2008), arginine methylation prevented 
phosphorylation of an adjacent serine residue (i.e., S99), but prior phosphorylation did 
not affect BAD methylation by PRMT1 (Sakamaki et al. 2011).  
 Due to the functional role of a methylation/phosphorylation switch in regulating 
FOXO1 activity (Yamagata et al. 2008), it was probable that crosstalk would also affect 
the physiological activity of BAD.  BAD is a pro-apoptotic member of the BCL-2 protein 
family and plays a major role in regulating cellular apoptosis (Danial et al. 2008).  
Previous studies have demonstrated that several kinases and phosphatases are responsible 
for altering the phosphorylation state of BAD and thus dictating its location and activity 
(Danial et al. 2008, Yang et al. 1995, Datta et al. 1997, Harada et al. 1999, Bonni et al. 
1999, Datta et al. 2000, Tan et al. 2000, Virdee et al. 2000, Ayllon et al. 2000, Chiang et 
al. 2001, Wang et al. 1999).  For example, when BAD is dephosphorylated, it binds to the 
pro-survival proteins BCL-XL/BCL-2 and displaces the pro-apoptotic proteins BAK 
and/or BAX (from BCL-XL/BCL-2) to create activated homodimers that form a pore in 
the mitochondria, which ultimately leads to apoptosis (Danial et al. 2008, Yang et al. 
1995, Dewson et al. 2009).  However, in response to cellular stress, BAD is 
phosphorylated at S75, S99, and S118.  Once phosphorylated, BAD binds to a 14-3-3 





cytoplasm.  As a consequence, the pro-apoptotic function of BAD is muted (Datta et al. 
1997, Harada et al. 1999, Bonni et al. 1999, Datta et al. 2000, Tan et al. 2000, Virdee et 
al. 2000, Zha et al. 1996, del Peso et al. 1997).  Based on this model, one would expect 
that decreased methylation of BAD by PRMT1 would increase phospho-BAD levels, 
which would lead to enhanced 14-3-3 binding, sequesteration in the cytoplasm, decreased 
caspase activity, and consequently an increase in cell viability, all of which were 
observed when PRMT1 was knocked down by siRNA (Sakamaki et al. 2011).  In contrast 
to the situation with FOXO1, methylation of BAD was not triggered by oxidative stress 
or known BAD activators.  Thus it is unclear whether BAD methylation is constitutive or 
occurs in response to an unknown stimulant (Sakamaki et al. 2011).  In any case, these 
observations demonstrate that the methyltransferase activity of PRMT1 is critical for the 
pro-apoptotic function of BAD through its prevention of Akt mediated phosphorylation 
of S99 (Sakamaki et al. 2011).   
 The previous two examples involved PRMT1, a Type I PRMT that catalyzes the 
asymmetric dimethylation of arginine residues in proteins.  In the third example of direct 
adjacent cis crosstalk, PRMT5, a Type II PRMT that symmetrically dimethylates 
arginines, is the responsible enzyme.  Specifically, Guo et al. show that FEN1 (flap 
endonuclease 1) is methylated at R192 by PRMT5 and that methylation of this particular 
arginine inhibits the phosphorylation of S187 by Cdk2-cyclin E (cyclin dependent kinase-
2).  As with the previous examples, the reverse scenario was not observed, i.e., 
phosphorylation does not prevent methylation (Guo et al. 2010).  Since FEN1 
phosphorylation prevents its binding to PCNA (proliferating cell nuclear antigen) 





promotes the PCNA and FEN1 interaction.  However, methylation occurring after 
phosphorylation did not re-establish this protein complex, confirming that the inhibition 
of phosphorylation, and not methylation alone, is responsible for the observed effect 
(Guo et al. 2010).  The interaction between PCNA and FEN1 is responsible for localizing 
FEN1 to the site of replication.  This interaction is important because FEN1 is an exo- 
and endonuclease involved in essential DNA processes, such as replication and repair 
(Shen et al. 2005).  A R192K mutant, which cannot be methylated, abrogated both the 
PCNA/FEN1 interaction and the localization of FEN1 to the site of replication.  As a 
consequence, a buildup of DNA double-stranded breaks was detected, followed by 
slower progression through the cell cycle, and ultimately mitotic arrest (Guo et al. 2010).  
Because other studies have shown that PRMT1 plays a role in the oxidative stress 
response (Yamagata et al. 2008), the authors also investigated the effect of hydrogen 
peroxide on the methylation of FEN1.  The results showed that oxidative stress results in 
localization of methylated FEN1 to the nucleus.  FEN1 that lacked methylation resulted 
in a decrease in cell survival and an increase in mutations, thus demonstrating a 
correlation between arginine methylation and DNA repair (Guo et al. 2010).  These 
observations demonstrate that PRMT5 dependent methylation of the R192 residue of 
FEN1 plays a critical role in preventing Cdk2-cyclinE dependent phosphorylation of 
S187 and subsequently allows for proper DNA replication and repair.  With respect to 
human disease, these results suggest that PRMT5 inhibition would synergize with DNA 
damaging agents as a way to treat cancer.  
6.1.2 Phosphorylation Blocks Arginine Methylation 
 





serine phosphorylation by arginine methylation, but not the inverse.  More recently, Sims 
et al. uncovered such an example of direct adjacent cis crosstalk, where phosphorylation 
of RNA polymerase II (RNAPII) prevents its methylation at R1810 (Sims et al. 2011).  
The CTD (carboxy terminal domain) of RNAPII contains a series of heptad repeats 
whose consensus sequence is YSPTSPS (Egloff et al. 2008), however, several of these 
repeats contain arginine or lysine substitutions in the last position (i.e., YSPTSP[R/K]) 
(Sims et al. 2011).  It is known that S2 and S5 of these sequences can be phosphorylated 
by P-TEFb (positive transcription elongation factor  b) and CAK, (CDK activating 
kinase), respectively (Sims et al. 2011).  Phosphorylation of these residues activates 
RNAPII and aids in the recruitment of essential proteins (Fong et al. 2001 & Misteli et al. 
1999) that are important for gene transcription (Egloff et al. 2008).  Due to the unique 
nature of the arginine and lysine substitutions, the authors investigated whether they were 
specifically modified.  The only PTM to be identified was methylation of R1810 by 
CARM1 (co-activator-associated protein arginine methyltransferases 1) or PRMT4.  
Interestingly, phosphorylation of S2 and S5 prevented methylation of R1810 but 
methylation did not prevent phosphorylation.  Also, the presence of both methylation and 
phosphorylation was observed in vivo suggesting that methylation occurs before 
phosphorylation (Sims et al. 2011).  The functional consequence of a lack of methylation 
of R1810 is downregulated transcription of small nuclear RNA (snRNA) and small 
nucleolar RNA (snoRNA) (Sims et al. 2011).   
6.1.3 Distal Crosstalk Between Arginine Methylation and Phosphorylation 
Although the main focus of this chapter is direct adjacent cis crosstalk within 





non-histone crosstalk between arginine methylation and phosphorylation.  The first 
example involves an interesting interplay between the CARM1 dependent methylation of 
R3 in C/EBP (CCAAT/enhancer-binding protein ) (Kowenz-Leutz et al. 2010), a 
transcription factor, and the phosphorylation of T253 by MAPK (Nakajima et al. 1993).  
Here, phosphorylation of T253 abrogates the interaction between C/EBP and CARM1, 
which abolishes the methylation of R3 (Kowenz-Leutz et al. 2010).  Unmethylated 
C/EBP is then free to bind to the SWI/SNF nucleosome remodeling and the Mediator 
transcriptional co-activator complexes to facilitate the increased transcription of C/EBP-
dependent genes.  Thus, R3 methylation inhibits interactions between C/EBP, 
SWI/SNF, and Mediator, and as a consequence, down regulates the transcription of genes 
under the control of C/EBP.   
 A second example of distal crosstalk involves the members of the STAT (signal 
transducer and activator of transcription) family of proteins, which play important roles 
in cell differentiation, survival, and apoptosis (Calo et al. 2003).  Given that STAT1 is 
methylated by PRMT1 at R31, a conserved arginine residue (Mowen et al. 2001), Chen et 
al. investigated whether the corresponding arginine in STAT6, R27, was also modified, 
and found that this was the case.  However, the responsible methyltransferase was not 
identified (Chen et al. 2004).  Nevertheless, the authors did show that the lack of 
methylation prevented phosphorylation of a distal tyrosine residue (i.e., Y641) and 
consequently inhibited nuclear translocation, abrogated DNA binding, and decreased 
protein stability.  It was shown that this crosstalk was not due to the activation of tyrosine 
phosphatases.  Overall, the results demonstrated that arginine methylation of STAT6 is 





location of the protein, its DNA binding capabilities, and protein stability (Chen et al. 
2004).  
6.1.4 Structural Basis for Crosstalk  
 Protein kinases typically bind and phosphorylate serine, threonine, or tyrosine 
residues within a distinct consensus sequence.  Of these kinases, Akt is a perfect example 
of how PTMs within a consensus sequence can alter substrate binding.  For Akt, the 
consensus sequence (i.e., RXR[S/T/A][S/T/A][S/T][F/L]) contains two positively 
charged arginine residues at the -3 and -5 positions relative to the phosphorylation site
 
Figure 6.3 Structural basis for crosstalk.  A structure of Akt (white) 
bound to a GSK3 (cyan) derived peptide demonstrates that 
arginine residues in the -5 and -3 positions are critical for Akt 
substrate recognition. R-5 forms direct and indirect hydrogen 
bonds with several key residues (i.e. E279, Y316, E342), as well 
as, with T-2 on the peptide.  This residue is also capable of 
forming a salt bridge with E279.  R-3 forms both a hydrogen bond 
and salt bride with E236.  The methylation of both R-5 and R-3 
would disrupt these key interactions and thus result in the observed 
inhibition of serine phosphorylation, which is demonstrated in 
several examples presented in this review (i.e., FOXO1 (Yamagata 
et al. 2008) and BAD (Sakamaki et al. 2011).  This figure was 
prepared with UCSF Chimera using the coordinates for the 























(Figure 6.2).  Based on the structure of Akt bound to a peptide whose sequence is derived 
from GSK3Yang et al. 2002) (Figure 6.3), it is apparent that R-5 forms several direct 
and indirect hydrogen bonds with surrounding Akt residues, including E279, Y316, and 
E342, as well as T-2 on the peptide itself.  In addition, the positive charge of R-5 and the 
negative charge of E279 are likely capable of forming a salt bridge.  R-3 also forms a 
hydrogen bond and salt bridge with E236, and, although the distance between R-3 and 
D440 is too great for a hydrogen bond interaction, it is also possible that there are 
electrostatic attractions between these two residues.  In the examples described above, 
both R-3 and R-5 were methylated and this prevented the phosphorylation of the targeted 
serine residue (Yamagata et al. 2008 & Sakamaki et al. 2011).  The structural basis for 
this crosstalk is easily discerned.  For example, while the formation of an asymmetrically 
dimethylated arginine would not alter the charge of the residue, it would undoubtedly 
create steric bulk.  This added steric bulk would prevent the formation of key hydrogen 
bonds, with for example E279 and Y316 in the substrate binding cleft, which would 
result in an inability to properly bind the substrate and thereby inhibit phosphorylation.  
Similar effects would be expected for the methylation of R-3.  One could imagine that 
deimination of these two arginine residues by the PADs would likely yield the same 
result.  However, instead of adding steric bulk, abrogation of protein binding would be 
due to the neutralization of the positively charged arginine residue and the disruption of 
proper hydrogen bonding.  Although the conversion to citrulline would still allow for a 





hydrogen bond acceptor, thus terminating the bidentate interactions between R-3 and 
E236 and R-5 and E279.  
 Interestingly, phosphorylation does not block methylation by PRMT1 and 
PRMT5.  Based on the crystal structure of PRMT1 (Zhang et al. 2003), as well as work 
from our own lab (Osborne et al. 2007), this observation is easily rationalized.  For 
example, while the surface of PRMT1 is highly negatively charged (Zhang et al. 2003), 
which would suggest that the introduction of a phosphate group would lead to 
electrostatic repulsions, we have shown that the residues between the site of methylation 
and distal positively charged residues are relatively unimportant for substrate recognition 
(Osborne et al. 2007).  Although a similar explanation is likely for PRMT5, detailed 
substrate specificity studies have not been performed on this isozyme.  In contrast to the 
situation with PRMTs 1 and 5, phosphorylation of S2 and S5 in RNAPII blocked the 
methylation of R1810 by CARM1 (Sims et al. 2011).  Given that detailed substrate 
specificity studies have also not been performed for this enzyme and no structures of 
CARM1 bound to cognate peptide substrates are available, it is difficult to speculate on 
why phosphorylation blocks methylation.  Nevertheless, the addition of two phosphate 
groups adjacent to the site of methylation would likely not only cause a perturbation in 
the peptide structure itself, due to repulsion between the two phosphate groups, but would 
also likely disrupt key interactions within the substrate binding cleft. 
6.1.5 Role of Additional Modifications 
Although the discussion so far has focused mainly on arginine methylation, this 
residue is also subject to deamination and it is likely that this additional modification will 





group recently showed that Elk-1 (ETS like gene 1), a member of the ETS family of 
transcription factors, is deiminated by PAD4 and that this modification increases Elk-1 
phosphorylation by ERK2.  Although it has yet to be established that these two 
modifications occur in the same consensus sequence, it is known that phosphorylation 
facilitates a tight interaction between Elk-1 and p300 leading to increased histone 
acetylation and ultimately the activation of c-Fos (Zhang et al. 2011).   
One final layer of complexity is the role of antagonistic PTMs.  For example, we 
and others have shown that deimination/citrullination of an arginine residue can 
antagonize/prevent the methylation of that same arginine residue (Hidaka et al. 2005, 
Kearney et al. 2005, Thompson et al. 2006, Raijmakers et al. 2007, Cuthbert et al. 2004, 
Guo et al. 2011).  In addition, serine O-GlcNAcylation has been shown to antagonize 
phosphorylation of the same serine residue (Hart et al. 2010 & Wang et al. 2010).  
Overall, these individual observations suggest that crosstalk within kinase consensus 
sequences is potentially quite complex, has multiple levels, and that eukaryotic cell 
signaling is not well represented by the linear pathways often depicted in textbooks.  
6.1.6 Crosstalk and Disease 
Crosstalk between protein phosphorylation and modification of arginine residues 
within kinase consensus sequences potentially has significant relevance to human 
disease.  This is the case because the modification of these basic residues can potentially 
have either growth promoting or growth suppressing effects.  For example, in the two 
examples of Akt crosstalk, PRMT1 opposes the effects of Akt-mediated phosphorylation 
(Yamagata et al. 2008 & Sakamaki et al. 2011).  Given that PI3K-Akt signaling is 





further stimulate the growth promoting and cell survival effects of Akt signaling.  
Nevertheless, PRMT1 has been shown to be required for the growth promoting effects of 
estrogen signaling and siRNA knockdown of PRMT1 has been shown to suppress the 
growth of MCF7 cells (Le Romancer et al. 2008).  As such, it is unclear whether PRMT1 
represents a valid target for the development of an anticancer therapeutic, thereby 
highlighting the critical need for developing bioavailable PRMT1 inhibitors that can be 
used to specifically address this question.  Additionally, the putative role of arginine 
modifying enzymes in regulating kinase signaling highlight the possibility that the effects 
of inhibitors targeting these enzymes may be due not only to effects on gene transcription 
but also to effects on kinase signaling pathways.  Again, this highlights the need for 
additional research to examine the links between consensus crosstalk and human disease.  
Finally, the fact that the mutation of K303 to an arginine residue in ERα is present in one-
third of patients with premalignant hyperplasias (Fuqua et al. 2000) is highly interesting 
because it suggest that cancer associated mutations can impinge on crosstalk.  Given the 
numerous PRMTs, PADs, and kinases, research in this area is undoubtedly an untapped 
treasure waiting to be discovered.  
6.1.7 Predicting Crosstalk  
 Given that protein kinase substrates can be readily predicted based on the 
presence/absence of a particular consensus sequence, the most obvious question is 
whether it is possible to predict crosstalk.  The answer appears to be yes.  Below we 
predict potential crosstalk between Akt substrates and PRMT1-mediated methylation.  
Note that we focused on these two enzymes because of prior precedents with Akt (see 





Additionally, PRMT1 is responsible for 85% of all PRMT activity in vivo (Tang et al. 
2000 & Nicholson et al. 2009), thus it is likely that, if kinase consensus crosstalk is a 
global mechanism for cellular regulation, PRMT1 would be the principal isozyme 
involved.  Nevertheless, it should be recognized that the same approach could be taken to 
predict crosstalk between any given kinase with a known consensus sequence and a 
lysine or arginine modifying enzyme whose substrate specificity determinants are known.   
In contrast to kinases, the distinct substrate recognition sequences for PRMT1, 
and the PRMTs in general, are relatively unknown.  In an effort to determine a minimal 
peptide substrate, based on the N-terminus of histone H4, our lab discovered that 
positively charged residues distal to the site of methylation are important for substrate 
recognition and catalysis (Osborne et al. 2007).  This makes sense because the surface of 
PRMT1 is negatively charged and therefore electrostatic interactions between the protein 
and the substrate are likely present (Zhang et al. 2003 & Osborne et al. 2007).  With this 
knowledge, we investigated whether similarities are present between histone H4 and the 
recently discovered PRMT1 substrates described above.  As shown in Table 6.1, for 
histone H4, BAD, and the FOXO family members, two arginine residues, in close 
proximity to each other, are present distal to the site of methylation in addition to a 
number of other positively charged residues.  This observation coincides with our
previous findings (Osborne et al. 2007).  Closer examination of Akt substrates that failed 
to be methylated by the PRMTs, (e.g., eNOS, p27, and GSK3) (Sakamaki et al. 2011) 
shows that they lack distal positively charged residues throughout the intervening 
sequences (Table 6.1).  The one exception is MDM2.  However in this case, the presence  






charged residues.  In light of this analysis, we hypothesized that novel Akt/PRMT1 
substrates can be predicted based on the identity of residues downstream from the kinase 
consensus sequences (Table 6.2).  Note that we have stratified the Akt substrates into 
three groups, i.e., highly probable, likely, and unlikely PRMT1 substrates.  Highly 
probable substrates were selected based on the presence of at least two distal arginine 
residues separated by one or two variable residue(s), as these RXR and RXXR motifs are 
a common theme among the known PRMT substrates.  These predictions also include at 
least one other distal positively charged residue in addition to these motifs.  Likely 
substrates include those Akt substrates that possess a number of positively charged 
residues distal from the predicted sites of methylation, but do not possess the RXR or 
RXXR motifs, or do not contain an additional positively charged residue.  Note that 
further studies will need to be conducted to determine whether lysine can substitute for 
arginine in these positions or if the presence of several nonspecific positively charged 
residues alone is enough for efficient substrate recognition and catalysis.  The effect of 
Table 6.1.  Tested Substrates for PRMT1 and Akt 
 
Protein Sequence Function 
Histone H4
ab
      3-RGKGGKGLGKGGAKRHRKVLRD-24 transcriptional regulation 
BAD
a
   94-RGRSRSAPPNLWAAQRYGRELRRM-117 pro-apoptotic 
FOXO1
ac
  251-RRRAASMDNNSKFAKSRSRAAKKK-274 transcription (pro-apoptotic) 
PGC-1
ad
  566-RSRSRSFSRHRSCSRSPYSRSRSR-589 gluconeogenesis 
e-NOS
e 
 1172-RIRTQSFSLQERQLRGAVPWAFEP-1195 vasodilation, angiogenesis  
GSK3-
e
    4-RPRTTSFAESCKPVQQPSAFGSMK-27 cell cycle, apoptosis 
p27
e
  152-RKRPATDDSSTQNKRANRTEENVS-175 cell cycle 
MDM2
e
  161-RRRAISETEENSDELSGERQRKRH-184 proteolysis 
MDM2
e
  181-RKRHKSDSISLSFDESLALCVIRE-204 proteolysis 
a
Known PRMT1 substrate. 
b
Not known to be an Akt Substrate. 
c
Numbers correspond to human 
FOXO1. Mouse FOXO1 begins at 248. 
d
Sites of methylation have not been identified. 
e
Not a 
PRMT1 Substrate. The light blue represents sites of methylation
de
.  The red represents known sites 
of Akt phosphorylation.  The purple represents positively charged residues. The orange represents 





Table 6.2.  PRMT1 and Akt Crosstalk Predictions 
 
A. Known PRMT1 & Akt Substrates  
Protein Sequence Function 
Histone H4ab      3-RGKGGKGLGKGGA----KRHRKVLRD-24 transcriptional regulation 
BADa   94-RGRSRSAPPNLWAAQ----RYGRELRRM-117 pro-apoptotic 
FOXO1aa  251-RRRAASMDNNSKFA-----KSRSRAAKKK-274 transcription (pro-apoptotic) 
FOXO3aa  248-RRRAVSMDNSNKYT-----KSRGRAAKKK-271 transcription (pro-apoptotic) 
FOXO4a  192-RRRAASMDSSSKLL-----RGRSKAPKKK-215 transcription (pro-apoptotic) 
PGC-1ac  566-RSRSRSFSRHRSCS-----RSPYSRSRSR-589 gluconeogenesis 
B. Highly Probable PRMT1 Substrates  
Protein Sequence Function 
Acinus 1175-RSRSRSRD-----------RRRKERAKSKEKKS-1198 apoptosis 
B-Raf  424-RERKSSSSSED--------RNRMKTLGRRDSD-447 Erk1/2 pathway 
Cot (Tpl2)    397-RCQSLDSALLE------RKRLLSREKEL-418 oncogene 
eIF4B  417-RSRTGSESSQTGTSTTSS-RNARRR-440 translation initiation 
EZH2   16-RKRVKSEYM----------RLRQLKRFRRADEVK-39 methyltransferases 
FOXG1  274-RRRSTTSRAKLAF------KRGARLTSTGL-107 transcription 
HMOX1  183-RSRMNSLEMTPAV------RQRVIEEAKTA-206 heme oxigenase 
PFKFB2  461-RMRRNSFTPLSSSNTI---RRPRNYSV-484 glycolysis 
TERT  222-RRRGGSASRSLPLP-----KRPRRGAAPE-245 telomerase reverse transcriptase 
Tuberin  934-RARSTSLNERPKSL-----RIARPPKQGL-957 tumor suppressor 
Tuberin 1457-RPRGYTISDSAPS------RRGKRVERDAL-1480 tumor suppressor 
C. Likely PRMT1 Substrates  
Protein Sequence Function 
Arfaptin  255-RGRLESAQATFQAH-----RDKYEKLRGD-278 cell survival 
Ataxin  771-RKRRWSAPES---------RKLEKSEDEPPLTL-794 neurodegeneration 
CK1-D  365-RERKVSM------------RLHRGAPVNISSSD-388 circadian clock 
GATA-1  305-RNRKASG------------KGKKKRGSSLGGTG-328 transcription factor 
GATA-2  396-RNRKMSN------------KSKKSKKGAECFEE-419 transcription factor 
p21  140-RKRRQTSMTDFYHS-----KRRLIFSKRK-163 cell cycle 
PDE3A  288-RRRRSSSVVSAEMSGCSS-KSHRRT-311 regulates cAMP and cGMP 
PRAS40  241-RPRLNTSDFQ---------KLKRKY-256 insulin signaling 
Skp2   67-RKRLKSKGSDKDFVIV---RRPKLNRE-90 E3 ubiquitin ligase 
TBC1D4  637-RRRAHTFSHPPSST-----KRKLNLQDGR-660 Glut4 trafficking 
Tuberin  976-RCRSISVSEHVV-------RSRIQTSLTSAS-999 tumor suppressor 
D. Unlikely PRMT1 Substrates  
Protein Sequence Function 
AR  208-RAREASGAPTSSKDYNLGGTSTIS-231 nuclear receptor 
AR  786-RMRHLSQEFGQLQITPQEFLCMKA-809 nuclear receptor 
BIM     84-RRSSLLSRSSSGYFSFDTDRSP-105 pro-apoptotic 
IRS-1   522-RKRTHSAGTSPTITHQKTPSQSSV-545 insulin receptor signaling 
mTOR 2443-RTRTDSYSAGQSVEILDGVELGEP-2466 cell growth 
Nur77  346-RGRLPSKPKQPPDASPANLLTSLV-369 nuclear receptor 
p300 1829-RRRMASMQRTGVVGQQQGLPSPTP-1852 transcriptional coactivator 
Rac1   66-RLRPLSYPQTDVFLICFSLVSPAS-89 Rho-GTPase 
a
Known PRMT1 substrate. 
b
Not known to be an Akt Substrate. 
c
Numbers correspond to human 
FOXO1. Mouse FOXO1 begins at 248. 
d
Sites of methylation have not been identified. 
e
Not a PRMT1 
Substrate. The light blue represents sites of methylation
de
.  The red represents known sites of Akt 
phosphorylation.  The purple represents positively charged residues. The orange represents negatively 
charged residues. 
 
the presence and position of negatively charged residues on substrate recognition also 





positively charged residues.  Validation of the predicted PRMT1 and Akt substrates 
would indicate that consensus crosstalk is a general mechanism to control eukaryotic cell 
signaling. 
6.1.8 Research Overview 
Herein we describe our initial efforts toward proving that crosstalk between 
arginine methylation and phosphorylation of serine/threonine residues exists and is 
possible to predict.  Although studies by other groups have already demonstrated 
crosstalk between PRMT1 and Akt in regards to FOXO1 (see Section 6.1.1), our results 
with this model will be used as a proof of concept before moving on to our predicted 
models (i.e., EZH22 & B-Raf).  The determination of a minimal peptide substrate for 
FOXO1, the effect of serine phosphorylation on substrate recognition by PRMT1, 
processivity experiments, as well as initial efforts to investigate crosstalk between 
phosphorylation and deminination will be described.       
6.2 Materials and Methods 
6.2.1 Chemicals 
Sodium dodecyl sulfate (SDS), tris(hydroxymethyl)aminomethane (TRIS), 
tetramethylethylenediamine, acrylamide, and ammonium persulfate were purchased from 
Bio-Rad (Hercules, CA).  4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 
Tricine, dithiothreitol (DTT) were purchased from RPI (Mt. Prospect, IL).  Acetonitrile 
and methanol were purchased from Fisher Scientific (Pittsburgh, PA).  Sodium chloride 
and dimethylformamide (DMF) were purchased from Alfa Aesar (Ward Hill, MA). 
Piperidine was purchased from Sigma-Aldrich (St. Louis, MO).  Fmoc-protected amino 





purchased from EMD (Gibbstown, NJ). 
14
C-labeled SAM was purchased from Perkin-
Elmer and 
14
C-labeled BSA from Sigma-Aldrich.  The purification of PRMT1 and the 
synthesis of the AcH4-21, FOXO1-21, FOXO1-22, and FOXO-30 peptides are outlined 
in Chapter 2. 
6.2.2 Purification of PAD4 
The purification of PAD4 has been described (Knuckley et al. 2007).  In brief, a 
pGEX-6P-1 construct (Nakashima et al. 1999) containing the PAD4 gene and an N-
terminal GST tag was transformed into E. coli Rosetta cells.  One colony was used to 
inoculate 5 mL starter cultures containing 50 μg/mL ampicillin and 20 μg/mL 
chloramphenicol and incubated overnight with shaking at 37 °C.  One liter of TB media 
was inoculated with 10 mL of overnight culture containing 50 μg/mL ampicillin and 20 
μg/mL chloramphenicol and grown at 37 °C and 250 rpm until OD600 = 0.8-1.0.  Protein 
expression was then induced with 0.3 mM isopropyl-β-D-thiogalactopyranoside and the 
cells were incubated with shaking at 16 °C overnight.  The next day the cells were 
harvested by centrifugation at 5000 rpm (4400 g) for 10 min.  The pellet was resuspended 
in 30 mL of Lysis Buffer (20 mM Tris-HCl pH 8, 1 mM EDTA, 1 mM DTT, 400 mM 
NaCl, 20% glycerol) plus 2 mL of protease inhibitor cocktail (Sigma-P8465).  Cells were 
mixed slowly for 30 min at 4 °C before being lysed by sonication (13 cycles of 15 sec 
burst with 1 min rest at output of 10 and a constant duty cycle).  The lysate was 
centrifuged at 14,000 rpm (21,808 g) for 30 min and the supernatant was applied to a 
Glutathione Sepharose 4B (GE Healthcare) column.  The column was washed with 50 
mL of a low salt buffer (20 mM Tris-HCl pH 8, 1 mM EDTA, 1 mM DTT, 250 mM 





EDTA, 1 mM DTT, 500 mM NaCl, and 10% glycerol), and eluted with two 25 mL 
washes of glutathione buffer (50 mM Tris-HCl pH 8.0, 1 mM DTT, and 10 mM reduced 
glutathione pH 8.0).  Fractions were screened on a 12% SDS-PAGE gel and 10 µL of 
Prescission Protease (GE Healthcare) was added to fractions containing protein followed 
by dialysis overnight in 20 mM Tris-HCl pH 7.6, 1 mM EDTA, 2 mM DTT, and 500 mM 
NaCl.  Dialysis buffer was exchanged 3x to remove excess glutathione.  The next day the 
protein was re-applied to the Glutathione Sepharose 4B column and collected followed 
by a 50 mL column wash of glutathione buffer (see above).  The flow through was 
dialyzed against 20 mM Tris-HCl pH 8.0, 1 mM EDTA, 50 mM NaCl, and 2 mM DTT 
for 3 h.  The dialyzed protein was additionally purified by FPLC using a HiTrap Q Fast 
Flow column (GE Healthcare) with 20 mM Tris-HCl pH 8.5 and 2 mM DTT as buffer A 
and a linear gradient from 0-100% of buffer B (20 mM Tris-HCl pH 8.5, 2 mM DTT, and 
1 M NaCl).  Fractions were screened on a 12% SDS-PAGE gel and by a COLDER 
activity assay.  Fractions containing pure and active protein were dialyzed overnight in 20 
mM Tris-HCl pH 8.0, 1 mM EDTA, 2 mM DTT, 500 mM NaCl, and 10% glycerol.  The 
next day the protein was concentrated using a 10 kDa Amicon Centriplus centrifugal 
filter and the concentration was determined using a Bradford assay.  The enzyme was 
flash frozen in liquid nitrogen and stored at -80 °C. 
6.2.3 Gel-Based Activity Assay 
A gel-based activity assay was used to acquire the steady state kinetic parameters 
of PRMT1 and has been previously described.  (Osborne et al. 2007).  Assays were 
performed in a reaction mixture of 50 mM HEPES pH 8.0, 1 mM EDTA, 50 mM NaCl, 
0.5 mM dithiothreitol, 15 μM [
14





(0-1000 μM final).  Reactions were pre-incubated at 37 °C for 10 min before the addition 
of PRMT1.  Assays with AcH4-21 were quenched after 15 min and assays with the 
FOXO1 peptides were quenched after 1 h.  Each assay was done in duplicate and the 
standard deviation of the duplicate raw data values agreed within ≤ 20%.  The GraFit 
version 5.0.11 software (Leatherbarrow 2004) was used to fit the data
to eq 1, 
υ  = Vmax[S]/(Km+[S])                                                       (1), 
6.2.4 COLDER Based Activity Assay 
 Reaction mixtures of 100 mM Tris-HCl pH 7.6, 10 mM CaCl2, 50 mM NaCl, 2 
mM dithiothreitol, and a varying concentrations of benzoyl arginine ethyl ester (BAEE) 
(0-10 mM) or peptide substrates (0-1mM final) were pre-incubated at 37 °C for 10 min.  
The reactions were initiated by the addition of PAD4 (0.2 µM final), giving a total 
volume of 60 µL.  Reactions were incubated for 6 min at 37 °C before being quenched by 
liquid nitrogen.  Color development was accomplished by the addition of 200 µL of 
COLDER Solution (2.25 M H3PO4, 4.5 M H2SO4, 1.5 mM NH4Fe(SO4), 20 mM diacetyl 
monoxime, and 1.5 mM thiosemicarbazide), followed by vortexing and incubation at 95 
°C for 30 min.  The absorbance for each reaction was measured at 540 nm and the 
amount of citrulline produced was determined using a citrulline standard curve.  Each 
assay was done in duplicate and the standard deviation of the duplicate raw data values 
agreed to within ≤ 20%.  The GraFit version 5.0.11 software (Leatherbarrow 2004) was 
used to fit the data to eq 1. 
6.2.7 MALDI-MS Based Activity Assay 





desorption/ionization (MALDI) MS based assay that was previously described (Osborne 
et al. 2007).  Assays were performed in a reaction mixture of 50 mM HEPES pH 8.0, 1 
mM EDTA, 50 mM NaCl, 500 μM SAM, and 20 μM AcH4-21 or FOXO1-22.  Reactions 
were then pre-incubated at 37 °C for 10 min followed by the addition of PRMT1 (500 
nM final).  The reaction was quenched with 3 μL of 50% TFA in ddH2O at the 
appropriate time point.  Spectra were acquired on an Applied Biosystems 4800 Plus 
MALDI TOF/TOF MS and analyzed using Data Explorer® software.  The percent 
turnover was determined by dividing the intensity of the modified peptide by the sum of 
the intensities of the unmodified and modified substrates times 100%. 
 For the PAD4 activity assay, a reaction mixture of 100 mM Tris-HCl pH 7.6, 10 
mM CaCl2, 50 mM NaCl, 2 mM dithiothreitol, and 1 mM FOXO1-22 were pre-incubated 
at 37 °C for 10 min.  The reactions were initiated by the addition of PAD4 (0.2 µM final), 
incubated for 0 min and 60 min at 37 °C, and then quenched by liquid nitrogen.  
Reactions were desalted using a C
18
 ZipTip and spectra were acquired using an Applied 
Biosystems 4800 Plus MALDI TOF/TOF MS.  The spectra were analyzed using Data 
Explorer® software. 
6.3 Results and Discussion 
6.3.1 Identifying a Minimal Peptide Substrate 
 FOXO1 is methylated by PRMT1 at R251 and R253 (human numbering) 
(Yamagata et al. 2008); the original numbers (R248 and R250) are for mouse FOXO1.  
Because we have previously demonstrated that peptides can be used in place of full 
proteins for kinetic studies (Osborne et al. 2007), we first sought to identify a minimal 





advantages, i.e., the ability to achieve higher concentrations for use in determining kinetic 
parameters, as well as the ability to easily mimic different post translational 
modifications.  The sequences of the peptides tested against PRMT1 can be found in 
Table 6.3.  Note that AcH4-21 is the minimal peptide substrate previously determined for 
Histone H4 and was used for kinetic comparison because it is an excellent substrate for 
PRMT1.  All three FOXO1 sequences contain the sites of methylation with variation at 
the N- and C-termini.  The kinetic parameters for these four peptides can be found in 
Table 6.4.  
Table 6.3 Peptide Sequences 
 
Peptide Sequence  














Based on the observed kinetic parameters, the results clearly show that positively 
charged residues distal to the site of methylation are important for substrate recognition.  


















AcH4-21a 1.1 ± 0.5 ----- 4.6 x 10
-1
 ± 2 x 10
-2
 ----- 4.1 x 10
5
 ----- 
FOXO1-21a 110 ± 20 100 4.3 x 10
-2
 ± 2 x 10
-3
 11 3.8 x 10
2
 1079 
FOXO1-22a 23 ± 8.5 20 1.46 x 10
-1
 ± 9 x 10
-3
 3.2 6.4 x 10
3
 64 
FOXO1-30a 20 ± 13 18 2.0 x 10
-1
 ± 2 x 10
-2









For example, there is a ~ 5-fold decrease in Km between FOXO1-21 and the two longer 
peptides, which each contain 2 or more additional positively charged residues at their C-
termini.  This observation is consistent with our hypothesis (see Section 6.1.7) that 
PRMT1 substrates can be predicted based on the sequence C-terminal to the site of 
methylation (Table 6.2). Note that while FOXO1-30 has the lowest fold decrease in 
kcat/Km (~ 48-fold) relative to AcH4-21, longer peptides tend to be more difficult to 
synthesize.  Additionally, the ~1.3-fold difference in the kcat/Km values for FOXO1-30 
and FOXO1-22 is not significant.  Therefore, FOXO1-22 was chosen as the minimal 
peptide substrate for use in future studies.  
6.3.2 Processivity of PRMT1 with FOXO1-22 
 Although previous studies utilized an antibody that was raised towards a FOXO1 
peptide that contained asymmetric dimethylarginine at R251 and R253 (Yamagata et al. 
2008), the total extent of methylation at these positions (i.e., ω-MMA, ADMA, or a 
mixture of both) has not been confirmed.  It is also uncertain as to whether PRMT1 uses a 
processive or distributive mechanism with this substrate, i.e., the production of ω-MMA 
and ADMA before substrate release versus substrate release after ω-MMA formation 
followed by rebinding of the substrate and SAM for the formation of ADMA.  Note that 
it was previously determined that with the AcH4-21 peptide, PRMT1 uses a partially 
processive mechanism (Osborne et al. 2007) (Figure 6.4A).  The presence of two 
potentially methylated arginine residues in FOXO1-22, compared to one in AcH4-21, 
adds an additional level of complexity, because processivity can result from the 
formation of ω-MMA and ADMA on a single residue or it can also describe whether both 






Figure 6.4 Processivity of PRMT1.  (A) With AcH4-21 as a substrate, PRMT1 
utilizes a partially processive mechanism in which a second molecule of SAM can 
rebind to form ADMA prior to release of ω-MMA, but ω-MMA can also be released 
prior to rebinding of SAM.  (B)  The FOXO1-22 peptide contains the addition of up 
to four methyl groups, however, the majority of methylated peptides contain only 2 
methyl groups. 
 
Nevertheless, as an initial effort to better characterize the mechanism of methylation of 
FOXO1, a MALDI-based mass spectrometry assay was used to assess the formation of 
the methylation products over time (Figure 6.4).  The results show up to four methylation 
events, which is consistent with two arginine residues being dimethylated.  However, 
methylation appears to be quite slow, with the majority of peptides only containing one 
or two methyl groups.  In order to determine the order of methylation, i.e., whether these 
two methylation events takes place on the same arginine residue or if ω-MMA is present 
on both R251 and R253, further analysis using MS/MS will need to be performed. 
6.3.3 Effect of Serine Phosphorylation on PRMT1-Dependent Methylation 
 FOXO1 is phosphorylated by Akt at S256 (human numbering).  As stated 
previously, studies have shown that methylation by PRMT1 prevents phosphorylation but 
the reverse is not observed (Yamagata et al. 2008).  To determine the effect of 
Time (min.)









































phosphorylation on methylation in our peptide model, S256 of FOXO1-22 was 
substituted with glutamate to mimic phosphoserine (FOXO1-22(S256E)).  The kinetic 
parameters of PRMT1 with this mutant can be seen in Table 6.5.  The results show a ~ 
3.1-fold increase in Km compared to the WT FOXO1-22 peptide and a ~ 4.9-fold decrease 
in kcat/Km, thus demonstrating that phosphorylation likely has a small but significant 
effect on methylation.  The discrepancy between our study and Yamagata et al. may lie in 
the fact that the authors only made a visual observation and thus the conclusion was only 
relative and not based on quantification.  It is also possible that other residues in FOXO1 
are critical for methylation, thus demonstrating the need for kinetic analysis with the full 
length protein to determine if our peptide model is relevant. 
 
6.3.4 FOXO1 as a PAD4 Substrate 
 As mentioned previously, because the PAD family of enzymes also modifies 
arginine residues, there is the possibility for crosstalk between deimination and 
phosphorylation.  To test whether FOXO1 is a potential substrate for PAD4, kinetic 
parameters were determined with the FOXO1 peptides.  Benzoyl arginine ethyl ester 
(BAEE), an excellent PAD4 substrate, is used for comparison (Table 6.6).  The data show 
that all three FOXO1 peptides are good substrates for PAD4.  Previous studies in our lab


















FOXO1-22a 23 ± 8.5 ----- 1.46 x 10
-1
 ± 9 x 10
-3





72 ± 13 3.1 9.8 x 10
-2
 ± 4 x 10
-3










with PAD4 have demonstrated that the enzyme is capable of deiminating multiple 
arginine residues on a single peptide, thus the slower kcat values for FOXO1-22 may be 
due to the lack of two additional arginine residues compared to the other peptides.  To 
determine the number of arginine residues that are converted to citrulline on FOXO1-22 
by PAD4, the enzyme was reacted with the peptide for 1 h before being analyzed by 
MALDI-MS (Figure 6.5).  A mass shift of 3 Da indicates that three arginine residues are
  
Figure 6.5 Mass spectrometric analysis of the deimination of FOXO1-22 by PAD4.  
A 3 Da shift is observed between (A) the control reaction minus PAD4 and (B) plus 





































































BAEE 0.4 ± 0.10 ----- 6.2 ± 3 x 10
-1
 ----- 1.6 x 10
4
 ----- 
FOXO1-21 0.2 ± 0.08 0.5 6.8 x 10
-1
 ± 9 x 10
-2
 9.1 3.3 x 10
3
 4.7 
FOXO1-22 0.2 ± 0.03 0.5 4.5 ± 3 x 10
-1
 1.3 2.3 x 10
4
 0.7 
FOXO1-30 0.4 ± 0.07 1 2.8 ± 2 x 10
-1







converted to citrulline, as this modification adds 1 Da to the residue mass.  Because all 
three peptides contain at least three arginine residues, it remains uncertain as to whether 
the slower catalysis observed with FOXO1-21 is due to a smaller number of arginine 
residues or a difference in substrate recognition elements.  
6.3.5 Effect of Serine Phosphorylation on PAD4-Dependent Deimination 
 Because FOXO1 is a potential substrate for PAD4 based on our peptide model, 
we next wanted to investigate the effect of phosphorylation on deimination.  As with 
PRMT1, the kinetic parameters were determined for PAD4 with the S256E mutant (Table 
6.7).  Interestingly, the results show that phosphorylation has a very similar effect on 
PAD4-dependent deimination as it did with PRMT1-dependent methylation with an ~
4.7-fold decrease in kcat/Km that can be attributed to an increase in Km.  These results 
suggest that the presence of a negatively charged residue or residues C-terminal to the 
potentially modified arginine residue(s) has a negative effect on substrate recognition for 
both PRMT1 and PAD4.   
 
6.4 Conclusions 
 There are currently several examples of crosstalk between arginine methylation 
and serine/threonine phosphorylation (vide supra).  Based on these examples and our 




















0.2 ± 0.03 ----- 4.5 ± 3 x 10
-1





0.87 ± 0.09 4.4 4.3 ± 4 x 10
-1









knowledge of PRMT1 catalysis, we have hypothesized that this form of crosstalk is a 
common mechanism of regulation in cell signaling pathways and that it can likely be 
predicted based on the sequence surrounding an Akt consensus motif (Table 6.2).  Before 
exploring our theory, we first wanted to better characterize an already known crosstalk 
model, specifically that of FOXO1, to use as a basis for subsequent studies. 
In vitro and in vivo studies have demonstrated that FOXO1 is methylated at R251 
and R253.  These sites of methylation have only been confirmed by mutation to lysine 
residues and the use of an antibody that was raised towards a peptide that contained 
asymmetric dimethylarginine at these positions (Yamagata et al. 2008).  Therefore, 
confirmation by mass spectrometry is still needed and is currently underway in our lab.  
To further characterize the mechanism of PRMT1-dependent methylation of FOXO1, 
initial studies were conducted to determine a minimal peptide substrate (because of the 
ease of working with peptides in comparison to full length proteins) and the fact that the 
peptide models have worked well for other PRMT1 substrates (i.e., histone H4).  
FOXO1-22 was determined to be a sufficient peptide substrate, although kinetic studies 
still need to be conducted with the full length protein to confirm that this model works for 
this particular substrate.  However, the observed results could aid in defining a possible 
consensus sequence for PRMT1-dependent methylation.     
Because the exact methylation products (i.e., ω-MMA, ADMA, or a mixture of 
both) at R251 and R253 have also not been confirmed by mass spectrometry, initial 
studies were done to further characterize methylation of these residues.  Although a 
degree of complication exists because there are two potentially methylated residues as 





to FOXO1-22.  The data show that up to four methyl groups are added to the peptide, 
however, the addition of only one or two methyl groups is predominant.  Further studies, 
such as MS/MS, will be needed to confirm the processivity of PRMT1 towards FOXO1. 
 FOXO1 is phosphorylated at S256 and this phosphorylation event is inhibited by 
arginine methylation of R251 and R253, however, phosphorylation did not affect 
methylation (Yamagata et al. 2008).  However, the latter conclusion was only based on 
relative amounts, therefore, we sought to confirm this observation using our peptide 
substrate.  The S256 residue of the FOXO1-22 peptide was exchanged for a glutamate to 
mimic phosphoserine.  Although small, the observed decrease in kcat/Km (~ 4.9-fold) is 
significant, suggesting that phosphorylation can subtly modulate PRMT1 activity. This 
result will need to be confirmed with the full length protein to determine if other residues 
surrounding the site of methylation compensate for the addition of a phosphate group.        
Since PAD4 also modifies arginine residues within proteins, we examined 
whether our FOXO-22 peptide was a substrate for PAD4.  The results show that all three 
of the FOXO1 peptides are substrates for the enzyme.  The PAD4-FOXO1 reaction was 
also analyzed by mass spectrometry, which showed that three arginine residues are 
deiminated on the FOXO1-22 peptide.  A similar effect was observed with PAD4 
compared to PRMT1 in regards to the FOXO1-22(S256E) peptide, thus suggesting a 
common link between the consensus sequences of arginine modifying enzymes.  Future 
studies will involve trying to confirm if FOXO1 is actually deiminated in vivo. 
Overall, the aforementioned studies are only our initial efforts towards proving 
our crosstalk hypothesis, as much more work needs to be done.  Future efforts will 





used to study the PRMT1-FOXO1 mechanism, and confirmation of the methylation sites 
by mass spectrometry.  Our PRMT1 inactivator, C21, will be used to to examine the 
crosstalk mechanism between methylation and phosphorylation of FOXO1 in vivo.  We 

























Conclusions & Future Directions 
Protein post-translational modifications (PTMs) play a variety of roles in the cell 
by affecting protein-protein interactions, the cellular location of proteins, and protein 
stability.  Due to their importance in normal cellular function, dysregulation of a variety 
of PTMs has been linked to a plethora of diseases (e.g., cancer and autoimmune 
diseases), therefore making them effective drug targets.  Our lab is focused on arginine 
modifying enzymes, more specifically the Protein Arginine Methyltransferases (PRMTs).  
This family of nine isozymes catalyzes the transfer of a methyl group from S-
adenosylmethionine (SAM) to the guanidinium moiety of arginine residues in proteins, 
generating an ω-monomethylarginine residue (ω-MMA), which can then be further 
methylated to produce either an asymmetrically dimethylated arginine residue (ADMA) 
or a symmetrically dimethylated arginine (SDMA) residue.  Of the nine family members, 
we are most interested in PRMT1 because it is thought to be responsible for the majority 
of asymmetrically dimethylated arginine residues in the cell (Tang et al. 2000 & Pawlak 
et al. 2000).  In addition, a variety of studies have suggested that the enzyme plays an 
important role in the onset of diseases such cancer, heart disease, and ALS. 
In order to begin to better understand the roles that PRMT1 plays in healthy and 
diseased cells, we first investigated the catalytic mechanism of the enzyme.  Using site-
directed mutagenesis, we confirmed the importance of several active site residues to 





also determined that H293 likely does not act as a general base in the mechanism.  
Finally, our results suggest that prior deprotonation of the guanidinium is not required 
and the reaction is simply catalyzed by bringing the cofactor and substrate into close 
proximity. 
We next set out to probe the means by which PRMT1 activity is regulated.  
Although several of the PRMT family members have been found to be regulated by 
PTMs, the regulation of PRMT1 by this method has yet to be revealed.  According to 
curated mass spectrometry data from PhosphoSitePlus® (www.phosphosite.org), PRMT1 
is potentially phosphorylated, ubiquitylated, and acetylated in the cell (Hornbeck et al. 
2012).  As a starting point, we investigated two possibly phosphorylated residues, i.e., 
S102 and Y291.  Using site-directed mutagenesis and the incorporation of pCMF, a 
stable phosphotyrosine mimic, we determined the effect that phosphorylation of these 
individual residues would have on activity.  The S102 residue, which is conserved 
amongst Type I PRMTs, is important for CARM1 activity and phosphorylation of this 
residue prevents SAM binding and abolishes activity.  The results show, however, that 
phosphorylation of S102 does not affect PRMT1 activity and thus modification of this 
residue is likely not a mechanism for regulating this enzyme.  The Y291 residue, which 
was chosen based on PhosphoSitePlus® (www.phosphosite.org) data, appears to play a 
role in substrate binding, as demonstrated by increases in the Km values for the Y291A, 
Y291E, and Y291pCMF mutants.  Although we hypothesized that phosphorylation of 
this residue would greatly affect overall activity, especially SAM binding, the results 
suggest that the interaction between H293 and D51 is enough to hold the N-terminal α-





mimic phosphotyrosine because it is lacking a negative charge and a greater effect on 
SAM binding would be observed in vivo.  However, based on studies showing that the N-
terminal splice variants of PRMT1 have different substrate specificities, we hypothesize 
that phosphorylation of this residue may destabilize the N-terminal tail and alter the 
substrate specificity.  Future studies will involve, not only further investigation into the 
effect of phosphorylation of Y291, but also the effect of other potentially phosphorylated 
PRMT1 residues, and a search for the responsible kinases. 
 PTMs are not the only means of enzyme regulation, as protein-protein interactions 
have also been found to affect the activity of the PRMTs.  PRMT1 has two known 
interacting proteins, CAF1 and BTG1, which appear to inhibit and/or enhance activity in 
a substrate specific manner (Lin et al. 1996, Berthet et al. 2002, Robin-Lespinasse et al. 
2007).  To characterize the effects of these two proteins from a mechanistic point of 
view, we performed assays in vitro with increasing concentrations of CAF1 or BTG1.  
The results suggest that CAF1 binds to histone H4 and inhibits methylation, but it can 
also bind PRMT1 and target it to the histone.  On the other hand, BTG1 appears to bind 
both PRMT1 and histone H4, but does not inhibit activity.  Future studies will involve 
examining the effects of these two proteins in regards to other histones, as well as, 
immunoprecipitation experiments to confirm that they can interact with PRMT 
substrates.   
 PRMT1 appears to be involved in a variety of diseases, and thus one of our main 
goals is to develop potent and selective inhibitors and inactivators for the enzyme.  We 
have previously described C21, the most potent PRMT1 inhibitor to date (Obianyo et al. 





used to identify an active site cysteine, C101, as the site of modification.  Although this 
residue is not important for catalysis, as demonstrated by the fact that the kinetic 
parameters are similar to the WT enzyme, other studies have shown that it is a hyper-
reactive cysteine (Weerapana et al. 2010).  Interestingly, only PRMT1 and PRMT8 have 
an active site cysteine residue as this position, as PRMT3 and CARM1 each have a 
cysteine residue that is buried away from the active site.  In an attempt to target C101 and 
potentially develop a new PRMT1 selective inhibitor, we coupled a chloroacetamidine 
warhead to the adenosine portion of SAM to create Cl-acetamidino-N-ethyl-
aminoadenosine.  Although it is not nearly as potent as C21, it is irreversible, and 
comparison of the IC50 for the compound with N-ethyl-aminoadenosine and adenosine 
show that the warhead is essential for inhibition.  As this is only a first generation 
inhibitor, future studies will involve designing and synthesizing SAM analogues based on 
SAH with a warhead attached.  In addition, PRMT5 has an active site cysteine residue 
that is in the SAM binding pocket but on the opposite side of C101.  We hypothesize that 
we will be able to create selective inhibitors for both of these enzymes by fine tuning the 
position of a warhead on SAH. 
 Finally, there are several examples that demonstrate crosstalk between arginine 
methylation and phosphorylation within kinase consensus sequences, more specifically 
between PRMT1 and Akt.  In the case of FOXO1, studies have shown that methylation of 
R251 and R253 prevents the phosphorylation of S256 by Akt, however, prior 
phosphorylation does not affect methylation (Yamagata et al. 2008).  Based on this 
example, and several others, and examination of the sequences of Akt substrates, we 





previously shown that positively charged residues C-terminal and distal to the site of 
methylation are important for substrate recognition (Osborne et al. 2007).  Therefore, the 
presence of positively charged residues C-terminal to arginine residues within kinase 
consensus sequences are likely an indicator that the substrate can be methylated by 
PRMT1 and that this methylation inhibits phosphorylation.  Before testing predicted 
substrates, we first set out to characterize crosstalk in regards to FOXO1.  Analysis of the 
kinetic parameters of PRMT1 with peptides based on the methylated sequence of FOXO1 
confirmed our suspicion that positively charged residues are critical.  The results also 
showed that prior phosphorylation does have a small effect on substrate binding.  In 
addition, the FOXO1 peptides were found to be good substrates for PAD4, an enzyme 
which converts arginine to citrulline in proteins.  Future studies will be focused on 
confirming the sites of methylation with the full length FOXO1 protein, examining 
crosstalk between methylation and phosphorylation of FOXO1 in vivo with C21, our 
PRMT1 inhibitor, attempting to identify deiminated FOXO1 in vivo.  We will also use 
these same methods to attempt to identify crosstalk within our predicted PRMT1 
substrates.    
In conclusion, the results presented in the previous chapters have given us further 
insight into the catalytic mechanism of PRMT1-dependent methylation and the regulation 
of enzyme activity by phosphorylation and protein-protein interactions.  They have also 
laid the groundwork for the development of more potent and selective inhibitors for 
PRMT1 and PRMT5, as well as, the prediction of crosstalk between arginine methylation 







Abramovich, C.; Yakobson, B.; Chebath, J.; Revel, M., A protein-arginine
methyltransferase binds to the intracytoplasmic domain of the IFNAR1 chain in 
the type I interferon receptor. The EMBO journal 1997, 16 (2), 260-6. 
 
Achan, V.; Broadhead, M.; Malaki, M.; Whitley, G.; Leiper, J.; MacAllister, R.; 
Vallance, P., Asymmetric dimethylarginine causes hypertension and cardiac 
dysfunction in humans and is actively metabolized by dimethylarginine 
dimethylaminohydrolase. Arteriosclerosis, thrombosis, and vascular biology 
2003, 23 (8), 1455-9. 
 
An, W.; Kim, J.; Roeder, R. G., Ordered cooperative functions of PRMT1, p300, and
CARM1 in transcriptional activation by p53. Cell 2004, 117 (6), 735-48. 
 
Antonysamy, S.; Bonday, Z.; Campbell, R. M.; Doyle, B.; Druzina, Z.; Gheyi, T.; Han, 
B.; Jungheim, L. N.; Qian, Y.; Rauch, C.; Russell, M.; Sauder, J. M.; Wasserman, 
S. R.; Weichert, K.; Willard, F. S.; Zhang, A.; Emtage, S., Crystal structure of the 
human PRMT5:MEP50 complex. Proceedings of the National Academy of 
Sciences of the United States of America 2012, 109 (44), 17960-5. 
 
Ayllon, V.; Martinez, A. C.; Garcia, A.; Cayla, X.; Rebollo, A., Protein phosphatase 
1alpha is a Ras-activated Bad phosphatase that regulates interleukin-2 
deprivation-induced apoptosis. The EMBO journal 2000, 19 (10), 2237-46. 
 
Baek, S. H., When signaling kinases meet histones and histone modifiers in the nucleus. 
Molecular cell 2011, 42 (3), 274-84. 
 
Baldwin, R. M.; Morettin, A.; Paris, G.; Goulet, I.; Cote, J., Alternatively spliced protein 
arginine methyltransferase 1 isoform PRMT1v2 promotes the survival and 
invasiveness of breast cancer cells. Cell Cycle 2012, 11 (24), 4597-612. 
 
Bannister, A. J.; Kouzarides, T., Regulation of chromatin by histone modifications. Cell 
research 2011, 21 (3), 381-95. 
 
Bedford, M. T., Arginine methylation at a glance. Journal of cell science 2007, 120 (Pt 
24), 4243-6. 
 
Bedford, M. T.; Clarke, S. G., Protein arginine methylation in mammals: who, what, and 






Bedford, M. T.; Richard, S., Arginine methylation an emerging regulator of protein 
function. Molecular cell 2005, 18 (3), 263-72. 
 
Berthet, C.; Guehenneux, F.; Revol, V.; Samarut, C.; Lukaszewicz, A.; Dehay, C.; 
Dumontet, C.; Magaud, J. P.; Rouault, J. P., Interaction of PRMT1 with 
BTG/TOB proteins in cell signalling: molecular analysis and functional aspects. 
Genes to cells : devoted to molecular & cellular mechanisms 2002, 7 (1), 29-39. 
 
Bicker, K. L.; Obianyo, O.; Rust, H. L.; Thompson, P. R., A combinatorial approach to 
characterize the substrate specificity of protein arginine methyltransferase 1. 
Molecular bioSystems 2011, 7 (1), 48-51. 
 
Bissinger, E. M.; Heinke, R.; Spannhoff, A.; Eberlin, A.; Metzger, E.; Cura, V.; 
Hassenboehler, P.; Cavarelli, J.; Schule, R.; Bedford, M. T.; Sippl, W.; Jung, M., 
Acyl derivatives of p-aminosulfonamides and dapsone as new inhibitors of the 
arginine methyltransferase hPRMT1. Bioorganic & medicinal chemistry 2011, 19 
(12), 3717-31. 
 
Blatch, G. L.; Lassle, M., The tetratricopeptide repeat: a structural motif mediating 
protein-protein interactions. BioEssays : news and reviews in molecular, cellular 
and developmental biology 1999, 21 (11), 932-9. 
 
Blythe, S. A.; Cha, S. W.; Tadjuidje, E.; Heasman, J.; Klein, P. S., beta-Catenin primes 
organizer gene expression by recruiting a histone H3 arginine 8 
methyltransferase, Prmt2. Developmental cell 2010, 19 (2), 220-31. 
 
Boehr, D. D.; Thompson, P. R.; Wright, G. D., Molecular mechanism of aminoglycoside 
antibiotic kinase APH(3')-IIIa: roles of conserved active site residues. The Journal 
of biological chemistry 2001, 276 (26), 23929-36. 
 
Bogdan, J. A.; Adams-Burton, C.; Pedicord, D. L.; Sukovich, D. A.; Benfield, P. A.; 
Corjay, M. H.; Stoltenborg, J. K.; Dicker, I. B., Human carbon catabolite 
repressor protein (CCR4)-associative factor 1: cloning, expression and 
characterization of its interaction with the B-cell translocation protein BTG1. The 
Biochemical journal 1998, 336 ( Pt 2), 471-81. 
 
Boisvert, F. M.; Dery, U.; Masson, J. Y.; Richard, S., Arginine methylation of MRE11 by 
PRMT1 is required for DNA damage checkpoint control. Genes & development 
2005, 19 (6), 671-6. 
 
Boisvert, F. M.; Rhie, A.; Richard, S.; Doherty, A. J., The GAR motif of 53BP1 is 
arginine methylated by PRMT1 and is necessary for 53BP1 DNA binding 
activity. Cell Cycle 2005, 4 (12), 1834-41. 
 





of a novel arginine methyltransferase inhibitor on T-helper cell cytokine 
production. The FEBS journal 2010, 277 (9), 2096-108. 
 
Bonni, A.; Brunet, A.; West, A. E.; Datta, S. R.; Takasu, M. A.; Greenberg, M. E., Cell 
survival promoted by the Ras-MAPK signaling pathway by transcription-
dependent and -independent mechanisms. Science 1999, 286 (5443), 1358-62. 
 
Bosco, D. A.; Lemay, N.; Ko, H. K.; Zhou, H.; Burke, C.; Kwiatkowski, T. J., Jr.; Sapp, 
P.; McKenna-Yasek, D.; Brown, R. H., Jr.; Hayward, L. J., Mutant FUS proteins 
that cause amyotrophic lateral sclerosis incorporate into stress granules. Human 
molecular genetics 2010, 19 (21), 4160-75. 
 
Boulanger, M. C.; Liang, C.; Russell, R. S.; Lin, R.; Bedford, M. T.; Wainberg, M. A.; 
Richard, S., Methylation of Tat by PRMT6 regulates human immunodeficiency 
virus type 1 gene expression. Journal of virology 2005, 79 (1), 124-31. 
 
Branscombe, T. L.; Frankel, A.; Lee, J. H.; Cook, J. R.; Yang, Z.; Pestka, S.; Clarke, S., 
PRMT5 (Janus kinase-binding protein 1) catalyzes the formation of symmetric 
dimethylarginine residues in proteins. The Journal of biological chemistry 2001, 
276 (35), 32971-6. 
 
Brunet, A.; Bonni, A.; Zigmond, M. J.; Lin, M. Z.; Juo, P.; Hu, L. S.; Anderson, M. J.; 
Arden, K. C.; Blenis, J.; Greenberg, M. E., Akt promotes cell survival by 
phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 96 (6), 
857-68. 
 
Buhr, N.; Carapito, C.; Schaeffer, C.; Kieffer, E.; Van Dorsselaer, A.; Viville, S., Nuclear 
proteome analysis of undifferentiated mouse embryonic stem and germ cells. 
Electrophoresis 2008, 29 (11), 2381-90. 
 
Calo, V.; Migliavacca, M.; Bazan, V.; Macaluso, M.; Buscemi, M.; Gebbia, N.; Russo, 
A., STAT proteins: from normal control of cellular events to tumorigenesis. J Cell 
Physiol 2003, 197 (2), 157-68. 
 
Canzio, D.; Chang, E. Y.; Shankar, S.; Kuchenbecker, K. M.; Simon, M. D.; Madhani, H. 
D.; Narlikar, G. J.; Al-Sady, B., Chromodomain-mediated oligomerization of HP1 
suggests a nucleosome-bridging mechanism for heterochromatin assembly. 
Molecular cell 2011, 41 (1), 67-81. 
 
Carascossa, S.; Dudek, P.; Cenni, B.; Briand, P. A.; Picard, D., CARM1 mediates the 
ligand-independent and tamoxifen-resistant activation of the estrogen receptor 
alpha by cAMP. Genes & development 2010, 24 (7), 708-19. 
 





Bauer, I.; Brosch, G.; Spannhoff, A.; Cheng, D.; Bedford, M. T.; Sbardella, G., 
Design, synthesis and biological evaluation of carboxy analogues of arginine 
methyltransferase inhibitor 1 (AMI-1). ChemMedChem 2010, 5 (3), 398-414. 
 
Cha, B.; Kim, W.; Kim, Y. K.; Hwang, B. N.; Park, S. Y.; Yoon, J. W.; Park, W. S.; Cho, 
J. W.; Bedford, M. T.; Jho, E. H., Methylation by protein arginine 
methyltransferase 1 increases stability of Axin, a negative regulator of Wnt 
signaling. Oncogene 2011, 30 (20), 2379-89. 
 
Chadee, D. N.; Hendzel, M. J.; Tylipski, C. P.; Allis, C. D.; Bazett-Jones, D. P.; Wright, 
J. A.; Davie, J. R., Increased Ser-10 phosphorylation of histone H3 in mitogen-
stimulated and oncogene-transformed mouse fibroblasts. The Journal of 
biological chemistry 1999, 274 (35), 24914-20. 
 
Chang, X.; Yamada, R.; Sawada, T.; Suzuki, A.; Kochi, Y.; Yamamoto, K., The 
inhibition of antithrombin by peptidylarginine deiminase 4 may contribute to 
pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 2005, 44 (3), 293-8. 
 
Chen, D.; Ma, H.; Hong, H.; Koh, S. S.; Huang, S. M.; Schurter, B. T.; Aswad, D. W.; 
Stallcup, M. R., Regulation of transcription by a protein methyltransferase. 
Science 1999, 284 (5423), 2174-7. 
 
Chen, W.; Daines, M. O.; Hershey, G. K., Methylation of STAT6 modulates STAT6 
phosphorylation, nuclear translocation, and DNA-binding activity. J Immunol 
2004, 172 (11), 6744-50. 
 
Chen, X.; Niroomand, F.; Liu, Z.; Zankl, A.; Katus, H. A.; Jahn, L.; Tiefenbacher, C. P., 
Expression of nitric oxide related enzymes in coronary heart disease. Basic 
research in cardiology 2006, 101 (4), 346-53. 
 
Cheng, D.; Cote, J.; Shaaban, S.; Bedford, M. T., The arginine methyltransferase 
CARM1 regulates the coupling of transcription and mRNA processing. Molecular 
cell 2007, 25 (1), 71-83. 
 
Cheng, D.; Yadav, N.; King, R. W.; Swanson, M. S.; Weinstein, E. J.; Bedford, M. T., 
Small molecule regulators of protein arginine methyltransferases. The Journal of 
biological chemistry 2004, 279 (23), 23892-9. 
 
Cheung, N.; Chan, L. C.; Thompson, A.; Cleary, M. L.; So, C. W., Protein arginine-
methyltransferase-dependent oncogenesis. Nature cell biology 2007, 9 (10), 1208-
15. 
 
Cheung, P.; Tanner, K. G.; Cheung, W. L.; Sassone-Corsi, P.; Denu, J. M.; Allis, C. D., 
Synergistic coupling of histone H3 phosphorylation and acetylation in response to 






Chevillard-Briet, M.; Trouche, D.; Vandel, L., Control of CBP co-activating activity by 
arginine methylation. The EMBO journal 2002, 21 (20), 5457-66. 
 
Chiang, C. W.; Harris, G.; Ellig, C.; Masters, S. C.; Subramanian, R.; Shenolikar, S.; 
Wadzinski, B. E.; Yang, E., Protein phosphatase 2A activates the proapoptotic 
function of BAD in interleukin- 3-dependent lymphoid cells by a mechanism 
requiring 14-3-3 dissociation. Blood 2001, 97 (5), 1289-97. 
Chiou, Y. Y.; Lin, W. J.; Fu, S. L.; Lin, C. H., Direct mass-spectrometric 
identification of Arg296 and Arg299 as the methylation sites of hnRNP K protein 
for methyltransferase PRMT1. The protein journal 2007, 26 (2), 87-93. 
 
Chumanevich, A. A.; Causey, C. P.; Knuckley, B. A.; Jones, J. E.; Poudyal, D.; 
Chumanevich, A. P.; Davis, T.; Matesic, L. E.; Thompson, P. R.; Hofseth, L. J., 
Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase 
inhibitor. American journal of physiology. Gastrointestinal and liver physiology 
2011, 300 (6), G929-38. 
 
Clayton, A. L.; Rose, S.; Barratt, M. J.; Mahadevan, L. C., Phosphoacetylation of histone 
H3 on c-fos- and c-jun-associated nucleosomes upon gene activation. The EMBO 
journal 2000, 19 (14), 3714-26. 
 
Cook, J. R.; Lee, J. H.; Yang, Z. H.; Krause, C. D.; Herth, N.; Hoffmann, R.; Pestka, S., 
FBXO11/PRMT9, a new protein arginine methyltransferase, symmetrically 
dimethylates arginine residues. Biochemical and biophysical research 
communications 2006, 342 (2), 472-81. 
 
Cote, J.; Boisvert, F. M.; Boulanger, M. C.; Bedford, M. T.; Richard, S., Sam68 RNA 
binding protein is an in vivo substrate for protein arginine N-methyltransferase 1. 
Molecular biology of the cell 2003, 14 (1), 274-87. 
 
Cozzio, A.; Passegue, E.; Ayton, P. M.; Karsunky, H.; Cleary, M. L.; Weissman, I. L., 
Similar MLL-associated leukemias arising from self-renewing stem cells and 
short-lived myeloid progenitors. Genes & development 2003, 17 (24), 3029-35. 
 
Cuthbert, G. L.; Daujat, S.; Snowden, A. W.; Erdjument-Bromage, H.; Hagiwara, T.; 
Yamada, M.; Schneider, R.; Gregory, P. D.; Tempst, P.; Bannister, A. J.; 
Kouzarides, T., Histone deimination antagonizes arginine methylation. Cell 2004, 
118 (5), 545-53. 
 
Dacwag, C. S.; Bedford, M. T.; Sif, S.; Imbalzano, A. N., Distinct protein arginine 
methyltransferases promote ATP-dependent chromatin remodeling function at 
different stages of skeletal muscle differentiation. Molecular and cellular biology 
2009, 29 (7), 1909-21. 
 





methyltransferase Prmt5 is required for myogenesis because it facilitates ATP-
dependent chromatin remodeling. Molecular and cellular biology 2007, 27 (1), 
384-94. 
 
Danial, N. N., BAD: undertaker by night, candyman by day. Oncogene 2008, 27 Suppl 1, 
S53-70. 
 
Daser, A.; Rabbitts, T. H., The versatile mixed lineage leukaemia gene MLL and its 
many associations in leukaemogenesis. Seminars in cancer biology 2005, 15 (3), 
175-88. 
 
Datta, S. R.; Dudek, H.; Tao, X.; Masters, S.; Fu, H.; Gotoh, Y.; Greenberg, M. E., Akt 
phosphorylation of BAD couples survival signals to the cell-intrinsic death 
machinery. Cell 1997, 91 (2), 231-41. 
 
Datta, S. R.; Katsov, A.; Hu, L.; Petros, A.; Fesik, S. W.; Yaffe, M. B.; Greenberg, M. E., 
14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain 
phosphorylation. Molecular cell 2000, 6 (1), 41-51. 
 
del Peso, L.; Gonzalez-Garcia, M.; Page, C.; Herrera, R.; Nunez, G., Interleukin-3-
induced phosphorylation of BAD through the protein kinase Akt. Science 1997, 
278 (5338), 687-9. 
 
Dery, U.; Coulombe, Y.; Rodrigue, A.; Stasiak, A.; Richard, S.; Masson, J. Y., A glycine-
arginine domain in control of the human MRE11 DNA repair protein. Molecular 
and cellular biology 2008, 28 (9), 3058-69. 
 
Dewson, G.; Kluck, R. M., Mechanisms by which Bak and Bax permeabilise 
mitochondria during apoptosis. Journal of cell science 2009, 122 (Pt 16), 2801-8. 
 
Di Lorenzo, A.; Bedford, M. T., Histone arginine methylation. FEBS letters 2011, 585 
(13), 2024-31. 
 
Dormann, D.; Rodde, R.; Edbauer, D.; Bentmann, E.; Fischer, I.; Hruscha, A.; Than, M. 
E.; Mackenzie, I. R.; Capell, A.; Schmid, B.; Neumann, M.; Haass, C., ALS-
associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated 
nuclear import. The EMBO journal 2010, 29 (16), 2841-57. 
 
Dowden, J.; Hong, W.; Parry, R. V.; Pike, R. A.; Ward, S. G., Toward the development 
of potent and selective bisubstrate inhibitors of protein arginine 
methyltransferases. Bioorganic & medicinal chemistry letters 2010, 20 (7), 2103-
5. 
 
Egloff, S.; Murphy, S., Cracking the RNA polymerase II CTD code. Trends Genet 2008, 






El-Andaloussi, N.; Valovka, T.; Toueille, M.; Steinacher, R.; Focke, F.; Gehrig, P.; 
Covic, M.; Hassa, P. O.; Schar, P.; Hubscher, U.; Hottiger, M. O., Arginine 
methylation regulates DNA polymerase beta. Molecular cell 2006, 22 (1), 51-62. 
 
Ernst, P.; Wang, J.; Huang, M.; Goodman, R. H.; Korsmeyer, S. J., MLL and CREB bind 
cooperatively to the nuclear coactivator CREB-binding protein. Molecular and 
cellular biology 2001, 21 (7), 2249-58. 
 
Feng, Q.; He, B.; Jung, S. Y.; Song, Y.; Qin, J.; Tsai, S. Y.; Tsai, M. J.; O'Malley, B. W., 
Biochemical control of CARM1 enzymatic activity by phosphorylation. The 
Journal of biological chemistry 2009, 284 (52), 36167-74. 
 
Feng, Q.; Yi, P.; Wong, J.; O'Malley, B. W., Signaling within a coactivator complex: 
methylation of SRC-3/AIB1 is a molecular switch for complex disassembly. 
Molecular and cellular biology 2006, 26 (21), 7846-57. 
 
Feng, Y.; Li, M.; Wang, B.; Zheng, Y. G., Discovery and mechanistic study of a class of 
protein arginine methylation inhibitors. Journal of medicinal chemistry 2010, 53 
(16), 6028-39. 
 
Feng, Y.; Xie, N.; Wu, J.; Yang, C.; Zheng, Y. G., Inhibitory study of protein arginine 
methyltransferase 1 using a fluorescent approach. Biochemical and biophysical 
research communications 2009, 379 (2), 567-72. 
 
Fielenbach, N.; Guardavaccaro, D.; Neubert, K.; Chan, T.; Li, D.; Feng, Q.; Hutter, H.; 
Pagano, M.; Antebi, A., DRE-1: an evolutionarily conserved F box protein that 
regulates C. elegans developmental age. Developmental cell 2007, 12 (3), 443-55. 
 
Fischle, W., Talk is cheap--cross-talk in establishment, maintenance, and readout of 
chromatin modifications. Genes & development 2008, 22 (24), 3375-82. 
 
Fischle, W.; Wang, Y.; Allis, C. D., Histone and chromatin cross-talk. Current opinion in 
cell biology 2003, 15 (2), 172-83. 
 
Fisk, J. C.; Sayegh, J.; Zurita-Lopez, C.; Menon, S.; Presnyak, V.; Clarke, S. G.; Read, L. 
K., A type III protein arginine methyltransferase from the protozoan parasite 
Trypanosoma brucei. The Journal of biological chemistry 2009, 284 (17), 11590-
600. 
 
Fong, N.; Bentley, D. L., Capping, splicing, and 3' processing are independently 
stimulated by RNA polymerase II: different functions for different segments of 
the CTD. Genes & development 2001, 15 (14), 1783-95. 
 
Frankel, A.; Clarke, S., PRMT3 is a distinct member of the protein arginine N-
methyltransferase family. Conferral of substrate specificity by a zinc-finger 






Frankel, A.; Yadav, N.; Lee, J.; Branscombe, T. L.; Clarke, S.; Bedford, M. T., The novel 
human protein arginine N-methyltransferase PRMT6 is a nuclear enzyme 
displaying unique substrate specificity. The Journal of biological chemistry 2002, 
277 (5), 3537-43. 
 
Friesen, W. J.; Wyce, A.; Paushkin, S.; Abel, L.; Rappsilber, J.; Mann, M.; Dreyfuss, G., 
A novel WD repeat protein component of the methylosome binds Sm proteins. 
The Journal of biological chemistry 2002, 277 (10), 8243-7. 
 
Fujii, R.; Takumi, T., TLS facilitates transport of mRNA encoding an actin-stabilizing 
protein to dendritic spines. Journal of cell science 2005, 118 (Pt 24), 5755-65. 
 
Fujimoto, K.; Matsuura, K.; Hu-Wang, E.; Lu, R.; Shi, Y. B., Thyroid hormone activates 
protein arginine methyltransferase 1 expression by directly inducing c-Myc 
transcription during Xenopus intestinal stem cell development. The Journal of 
biological chemistry 2012, 287 (13), 10039-50. 
 
Fuqua, S. A.; Wiltschke, C.; Zhang, Q. X.; Borg, A.; Castles, C. G.; Friedrichs, W. E.; 
Hopp, T.; Hilsenbeck, S.; Mohsin, S.; O'Connell, P.; Allred, D. C., A 
hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. 
Cancer Res 2000, 60 (15), 4026-9. 
 
Gal, J.; Zhang, J.; Kwinter, D. M.; Zhai, J.; Jia, H.; Jia, J.; Zhu, H., Nuclear localization 
sequence of FUS and induction of stress granules by ALS mutants. Neurobiology 
of aging 2011, 32 (12), 2323 e27-40. 
 
Ganesh, L.; Yoshimoto, T.; Moorthy, N. C.; Akahata, W.; Boehm, M.; Nabel, E. G.; 
Nabel, G. J., Protein methyltransferase 2 inhibits NF-kappaB function and 
promotes apoptosis. Molecular and cellular biology 2006, 26 (10), 3864-74. 
 
Gilbreth, M.; Yang, P.; Wang, D.; Frost, J.; Polverino, A.; Cobb, M. H.; Marcus, S., The 
highly conserved skb1 gene encodes a protein that interacts with Shk1, a fission 
yeast Ste20/PAK homolog. Proceedings of the National Academy of Sciences of 
the United States of America 1996, 93 (24), 13802-7. 
 
Goulet, I.; Gauvin, G.; Boisvenue, S.; Cote, J., Alternative splicing yields protein 
arginine methyltransferase 1 isoforms with distinct activity, substrate specificity, 
and subcellular localization. The Journal of biological chemistry 2007, 282 (45), 
33009-21. 
 
Greer, E. L.; Brunet, A., FOXO transcription factors at the interface between longevity 
and tumor suppression. Oncogene 2005, 24 (50), 7410-25. 
 





Jacquemin-Sablon, A., Characterization of prmt7alpha and beta isozymes from 
Chinese hamster cells sensitive and resistant to topoisomerase II inhibitors. 
Biochimica et biophysica acta 2006, 1760 (11), 1646-56. 
 
Guccione, E.; Bassi, C.; Casadio, F.; Martinato, F.; Cesaroni, M.; Schuchlautz, H.; 
Luscher, B.; Amati, B., Methylation of histone H3R2 by PRMT6 and H3K4 by an 
MLL complex are mutually exclusive. Nature 2007, 449 (7164), 933-7. 
 
Guillen Schlippe, Y. V.; Hedstrom, L., A twisted base? The role of arginine in enzyme-
catalyzed proton abstractions. Archives of biochemistry and biophysics 2005, 433 
(1), 266-78. 
 
Guo, Q.; Bedford, M. T.; Fast, W., Discovery of peptidylarginine deiminase-4 substrates 
by protein array: antagonistic citrullination and methylation of human ribosomal 
protein S2. Molecular bioSystems 2011, 7 (7), 2286-95. 
 
Guo, Z.; Zheng, L.; Xu, H.; Dai, H.; Zhou, M.; Pascua, M. R.; Chen, Q. M.; Shen, B., 
Methylation of FEN1 suppresses nearby phosphorylation and facilitates PCNA 
binding. Nat Chem Biol 2010, 6 (10), 766-73. 
 
Hagiwara, T.; Hidaka, Y.; Yamada, M., Deimination of histone H2A and H4 at arginine 3 
in HL-60 granulocytes. Biochemistry 2005, 44 (15), 5827-34. 
 
Harada, H.; Becknell, B.; Wilm, M.; Mann, M.; Huang, L. J.; Taylor, S. S.; Scott, J. D.; 
Korsmeyer, S. J., Phosphorylation and inactivation of BAD by mitochondria-
anchored protein kinase A. Molecular cell 1999, 3 (4), 413-22. 
 
Hart, G. W.; Slawson, C.; Ramirez-Correa, G.; Lagerlof, O., Cross Talk Between O-
GlcNAcylation and Phosphorylation: Roles in Signaling, Transcription, 
and Chronic Disease. Annu Rev Biochem 2010, 80, 825-58. 
 
Heinke, R.; Spannhoff, A.; Meier, R.; Trojer, P.; Bauer, I.; Jung, M.; Sippl, W., Virtual 
screening and biological characterization of novel histone arginine 
methyltransferase PRMT1 inhibitors. ChemMedChem 2009, 4 (1), 69-77. 
 
Henneke, G.; Koundrioukoff, S.; Hubscher, U., Phosphorylation of human Fen1 by 
cyclin-dependent kinase modulates its role in replication fork regulation. 
Oncogene 2003, 22 (28), 4301-13. 
 
Herrmann, F.; Fackelmayer, F. O., Nucleo-cytoplasmic shuttling of protein arginine 
methyltransferase 1 (PRMT1) requires enzymatic activity. Genes to cells : 
devoted to molecular & cellular mechanisms 2009, 14 (3), 309-17. 
 
Herrmann, F.; Lee, J.; Bedford, M. T.; Fackelmayer, F. O., Dynamics of human protein 
arginine methyltransferase 1(PRMT1) in vivo. The Journal of biological 






Hidaka, Y.; Hagiwara, T.; Yamada, M., Methylation of the guanidino group of arginine 
residues prevents citrullination by peptidylarginine deiminase IV. FEBS letters 
2005, 579 (19), 4088-92. 
 
Higashimoto, K.; Kuhn, P.; Desai, D.; Cheng, X.; Xu, W., Phosphorylation-mediated 
inactivation of coactivator-associated arginine methyltransferase 1. Proceedings 
of the National Academy of Sciences of the United States of America 2007, 104 
(30), 12318-23. 
 
Hornbeck, P. V.; Kornhauser, J. M.; Tkachev, S.; Zhang, B.; Skrzypek, E.; Murray, B.; 
Latham, V.; Sullivan, M., PhosphoSitePlus: a comprehensive resource for 
investigating the structure and function of experimentally determined post-
translational modifications in man and mouse. Nucleic acids research 2012, 40 
(Database issue), D261-70. 
 
Hoyert, D. L. a. X., Jiaquan, Deaths: Preliminary Data for 2011. National Vital Statistics 
and Reports 2012, 61 (6), 1-51. 
 
Huang, H.; Regan, K. M.; Wang, F.; Wang, D.; Smith, D. I.; van Deursen, J. M.; Tindall, 
D. J., Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated 
degradation. Proceedings of the National Academy of Sciences of the United 
States of America 2005, 102 (5), 1649-54. 
 
Huang, S.; Litt, M.; Felsenfeld, G., Methylation of histone H4 by arginine 
methyltransferase PRMT1 is essential in vivo for many subsequent histone 
modifications. Genes & development 2005, 19 (16), 1885-93. 
 
Hyllus, D.; Stein, C.; Schnabel, K.; Schiltz, E.; Imhof, A.; Dou, Y.; Hsieh, J.; Bauer, U. 
M., PRMT6-mediated methylation of R2 in histone H3 antagonizes H3 K4 
trimethylation. Genes & development 2007, 21 (24), 3369-80. 
 
Iberg, A. N.; Espejo, A.; Cheng, D.; Kim, D.; Michaud-Levesque, J.; Richard, S.; 
Bedford, M. T., Arginine methylation of the histone H3 tail impedes effector 
binding. The Journal of biological chemistry 2008, 283 (6), 3006-10. 
 
Ito, D.; Seki, M.; Tsunoda, Y.; Uchiyama, H.; Suzuki, N., Nuclear transport impairment 
of amyotrophic lateral sclerosis-linked mutations in FUS/TLS. Annals of 
neurology 2011, 69 (1), 152-62. 
 
Iwasaki, H.; Yada, T., Protein arginine methylation regulates insulin signaling in L6 
skeletal muscle cells. Biochemical and biophysical research communications 
2007, 364 (4), 1015-21. 
 





protein arginine N-methyltransferase 5 activity in a substrate-specific manner. 
Biochemical and biophysical research communications 2005, 329 (2), 522-30. 
 
Jobert, L.; Argentini, M.; Tora, L., PRMT1 mediated methylation of TAF15 is required 
for its positive gene regulatory function. Experimental cell research 2009, 315 
(7), 1273-86. 
 
Jones, J. E.; Causey, C. P.; Knuckley, B.; Slack-Noyes, J. L.; Thompson, P. R., Protein 
arginine deiminase 4 (PAD4): Current understanding and future therapeutic 
potential. Current opinion in drug discovery & development 2009, 12 (5), 616-27. 
 
Karsten, W. E.; Lai, C. J.; Cook, P. F., Inverse solvent isotope effects in the NAD-Malic 
enzyme reaction are the result of the viscosity difference between D2O and H2O:  
Implications for solvent isotope effect studies. Journal of the American Chemical 
Society 1995, 117, 5914-5918. 
 
Katsanis, N.; Yaspo, M. L.; Fisher, E. M., Identification and mapping of a novel human 
gene, HRMT1L1, homologous to the rat protein arginine N-methyltransferase 1 
(PRMT1) gene. Mammalian genome : official journal of the International 
Mammalian Genome Society 1997, 8 (7), 526-9. 
 
Katz, J. E.; Dlakic, M.; Clarke, S., Automated identification of putative 
methyltransferases from genomic open reading frames. Molecular & cellular 
proteomics : MCP 2003, 2 (8), 525-40. 
 
Kearney, P. L.; Bhatia, M.; Jones, N. G.; Yuan, L.; Glascock, M. C.; Catchings, K. L.; 
Yamada, M.; Thompson, P. R., Kinetic characterization of protein arginine 
deiminase 4: a transcriptional corepressor implicated in the onset and progression 
of rheumatoid arthritis. Biochemistry 2005, 44 (31), 10570-82. 
 
Khoury, G. A.; Baliban, R. C.; Floudas, C. A., Proteome-wide post-translational 
modification statistics: frequency analysis and curation of the swiss-prot database. 
Scientific reports 2011, 1. 
 
Kinexus http://www.kinexus.ca/pdf/graphs_charts/ProteinSerKinaseSpecificity.pdf 
(accessed May 1). 
 
Kino, Y.; Washizu, C.; Aquilanti, E.; Okuno, M.; Kurosawa, M.; Yamada, M.; Doi, H.; 
Nukina, N., Intracellular localization and splicing regulation of FUS/TLS are 
variably affected by amyotrophic lateral sclerosis-linked mutations. Nucleic acids 
research 2011, 39 (7), 2781-98. 
 
Kleinschmidt, M. A.; Streubel, G.; Samans, B.; Krause, M.; Bauer, U. M., The protein 
arginine methyltransferases CARM1 and PRMT1 cooperate in gene regulation. 






Knuckley, B.; Bhatia, M.; Thompson, P. R., Protein arginine deiminase 4: evidence for a 
reverse protonation mechanism. Biochemistry 2007, 46 (22), 6578-87. 
 
Koh, S. S.; Chen, D.; Lee, Y. H.; Stallcup, M. R., Synergistic enhancement of nuclear 
receptor function by p160 coactivators and two coactivators with protein 
methyltransferase activities. The Journal of biological chemistry 2001, 276 (2), 
1089-98. 
 
Kousaka, A.; Mori, Y.; Koyama, Y.; Taneda, T.; Miyata, S.; Tohyama, M., The 
distribution and characterization of endogenous protein arginine N-
methyltransferase 8 in mouse CNS. Neuroscience 2009, 163 (4), 1146-57. 
 
Kouzarides, T., Chromatin modifications and their function. Cell 2007, 128 (4), 693-705. 
Kowenz-Leutz, E.; Pless, O.; Dittmar, G.; Knoblich, M.; Leutz, A., Crosstalk 
between C/EBPbeta phosphorylation, arginine methylation, and 
SWI/SNF/Mediator implies an indexing transcription factor code. The EMBO 
journal 2010, 29 (6), 1105-15. 
 
Krause, C. D.; Yang, Z. H.; Kim, Y. S.; Lee, J. H.; Cook, J. R.; Pestka, S., Protein 
arginine methyltransferases: evolution and assessment of their pharmacological 
and therapeutic potential. Pharmacology & therapeutics 2007, 113 (1), 50-87. 
 
Kuhn, P.; Chumanov, R.; Wang, Y.; Ge, Y.; Burgess, R. R.; Xu, W., Automethylation of 
CARM1 allows coupling of transcription and mRNA splicing. Nucleic acids 
research 2011, 39 (7), 2717-26. 
 
Kwak, Y. T.; Guo, J.; Prajapati, S.; Park, K. J.; Surabhi, R. M.; Miller, B.; Gehrig, P.; 
Gaynor, R. B., Methylation of SPT5 regulates its interaction with RNA 
polymerase II and transcriptional elongation properties. Molecular cell 2003, 11 
(4), 1055-66. 
 
Kwiatkowski, T. J., Jr.; Bosco, D. A.; Leclerc, A. L.; Tamrazian, E.; Vanderburg, C. R.; 
Russ, C.; Davis, A.; Gilchrist, J.; Kasarskis, E. J.; Munsat, T.; Valdmanis, P.; 
Rouleau, G. A.; Hosler, B. A.; Cortelli, P.; de Jong, P. J.; Yoshinaga, Y.; Haines, 
J. L.; Pericak-Vance, M. A.; Yan, J.; Ticozzi, N.; Siddique, T.; McKenna-Yasek, 
D.; Sapp, P. C.; Horvitz, H. R.; Landers, J. E.; Brown, R. H., Jr., Mutations in the 
FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. 
Science 2009, 323 (5918), 1205-8. 
 
Kzhyshkowska, J.; Schutt, H.; Liss, M.; Kremmer, E.; Stauber, R.; Wolf, H.; Dobner, T., 
Heterogeneous nuclear ribonucleoprotein E1B-AP5 is methylated in its Arg-Gly-
Gly (RGG) box and interacts with human arginine methyltransferase HRMT1L1. 
The Biochemical journal 2001, 358 (Pt 2), 305-14. 
 





methyltransferase 2: formation of monomethyl- and asymmetric dimethyl-
arginine residues on histone H4. The Biochemical journal 2009, 421 (2), 253-61. 
 
Lakowski, T. M.; t Hart, P.; Ahern, C. A.; Martin, N. I.; Frankel, A., Neta-substituted 
arginyl peptide inhibitors of protein arginine N-methyltransferases. ACS chemical 
biology 2010, 5 (11), 1053-63. 
 
Landim, M. B.; Casella Filho, A.; Chagas, A. C., Asymmetric dimethylarginine (ADMA) 
and endothelial dysfunction: implications for atherogenesis. Clinics (Sao Paulo) 
2009, 64 (5), 471-8. 
 
Lange, S.; Gogel, S.; Leung, K. Y.; Vernay, B.; Nicholas, A. P.; Causey, C. P.; 
Thompson, P. R.; Greene, N. D.; Ferretti, P., Protein deiminases: new players in 
the developmentally regulated loss of neural regenerative ability. Developmental 
biology 2011, 355 (2), 205-14. 
 
Law, W. J.; Cann, K. L.; Hicks, G. G., TLS, EWS and TAF15: a model for 
transcriptional integration of gene expression. Briefings in functional genomics & 
proteomics 2006, 5 (1), 8-14. 
 
Le Romancer, M.; Treilleux, I.; Leconte, N.; Robin-Lespinasse, Y.; Sentis, S.; 
Bouchekioua-Bouzaghou, K.; Goddard, S.; Gobert-Gosse, S.; Corbo, L., 
Regulation of estrogen rapid signaling through arginine methylation by PRMT1. 
Molecular cell 2008, 31 (2), 212-21. 
 
Leatherbarrow, R. J. GraFit version 5.0, Erathicus Software: Staines, U.K., 2004. 
 
Lee, J.; Sayegh, J.; Daniel, J.; Clarke, S.; Bedford, M. T., PRMT8, a new membrane-
bound tissue-specific member of the protein arginine methyltransferase family. 
The Journal of biological chemistry 2005, 280 (38), 32890-6. 
 
Lee, J. H.; Cook, J. R.; Yang, Z. H.; Mirochnitchenko, O.; Gunderson, S. I.; Felix, A. M.; 
Herth, N.; Hoffmann, R.; Pestka, S., PRMT7, a new protein arginine 
methyltransferase that synthesizes symmetric dimethylarginine. The Journal of 
biological chemistry 2005, 280 (5), 3656-64. 
 
Lee, J. S.; Smith, E.; Shilatifard, A., The language of histone crosstalk. Cell 2010, 142 
(5), 682-5. 
 
Leiper, J.; Murray-Rust, J.; McDonald, N.; Vallance, P., S-nitrosylation of 
dimethylarginine dimethylaminohydrolase regulates enzyme activity: further 
interactions between nitric oxide synthase and dimethylarginine 
dimethylaminohydrolase. Proceedings of the National Academy of Sciences of the 
United States of America 2002, 99 (21), 13527-32. 
 





for antibacterial innate immunity mediated by neutrophil extracellular traps. The 
Journal of experimental medicine 2010, 207 (9), 1853-62. 
 
Lin, W. J.; Gary, J. D.; Yang, M. C.; Clarke, S.; Herschman, H. R., The mammalian 
immediate-early TIS21 protein and the leukemia-associated BTG1 protein interact 
with a protein-arginine N-methyltransferase. The Journal of biological chemistry 
1996, 271 (25), 15034-44. 
 
Liu, F.; Zhao, X.; Perna, F.; Wang, L.; Koppikar, P.; Abdel-Wahab, O.; Harr, M. W.; 
Levine, R. L.; Xu, H.; Tefferi, A.; Deblasio, A.; Hatlen, M.; Menendez, S.; 
Nimer, S. D., JAK2V617F-mediated phosphorylation of PRMT5 downregulates 
its methyltransferase activity and promotes myeloproliferation. Cancer cell 2011, 
19 (2), 283-94. 
 
Lo, W. S.; Trievel, R. C.; Rojas, J. R.; Duggan, L.; Hsu, J. Y.; Allis, C. D.; Marmorstein, 
R.; Berger, S. L., Phosphorylation of serine 10 in histone H3 is functionally linked 
in vitro and in vivo to Gcn5-mediated acetylation at lysine 14. Molecular cell 
2000, 5 (6), 917-26. 
 
Luo, Y.; Arita, K.; Bhatia, M.; Knuckley, B.; Lee, Y. H.; Stallcup, M. R.; Sato, M.; 
Thompson, P. R., Inhibitors and inactivators of protein arginine deiminase 4: 
functional and structural characterization. Biochemistry 2006, 45 (39), 11727-36. 
 
Luo, Y.; Knuckley, B.; Lee, Y. H.; Stallcup, M. R.; Thompson, P. R., A 
fluoroacetamidine-based inactivator of protein arginine deiminase 4: design, 
synthesis, and in vitro and in vivo evaluation. Journal of the American Chemical 
Society 2006, 128 (4), 1092-3. 
 
Ma, H.; Baumann, C. T.; Li, H.; Strahl, B. D.; Rice, R.; Jelinek, M. A.; Aswad, D. W.; 
Allis, C. D.; Hager, G. L.; Stallcup, M. R., Hormone-dependent, CARM1-
directed, arginine-specific methylation of histone H3 on a steroid-regulated 
promoter. Current biology : CB 2001, 11 (24), 1981-5. 
 
Ma, X. J.; Lu, Q.; Grunstein, M., A search for proteins that interact genetically with 
histone H3 and H4 amino termini uncovers novel regulators of the Swe1 kinase in 
Saccharomyces cerevisiae. Genes & development 1996, 10 (11), 1327-40. 
 
Mai, A.; Valente, S.; Cheng, D.; Perrone, A.; Ragno, R.; Simeoni, S.; Sbardella, G.; 
Brosch, G.; Nebbioso, A.; Conte, M.; Altucci, L.; Bedford, M. T., Synthesis and 
biological validation of novel synthetic histone/protein methyltransferase 
inhibitors. ChemMedChem 2007, 2 (7), 987-91. 
 
Mallappa, C.; Hu, Y. J.; Shamulailatpam, P.; Tae, S.; Sif, S.; Imbalzano, A. N., The 
expression of myogenic microRNAs indirectly requires protein arginine 
methyltransferase (Prmt)5 but directly requires Prmt4. Nucleic acids research 






Mathioudaki, K.; Papadokostopoulou, A.; Scorilas, A.; Xynopoulos, D.; Agnanti, N.; 
Talieri, M., The PRMT1 gene expression pattern in colon cancer. British journal 
of cancer 2008, 99 (12), 2094-9. 
 
Matsuzaki, H.; Daitoku, H.; Hatta, M.; Tanaka, K.; Fukamizu, A., Insulin-induced 
phosphorylation of FKHR (Foxo1) targets to proteasomal degradation. 
Proceedings of the National Academy of Sciences of the United States of America 
2003, 100 (20), 11285-90. 
 
Mayer, B. J.; Baltimore, D., Signalling through SH2 and SH3 domains. Trends in cell 
biology 1993, 3 (1), 8-13. 
 
McElwee, J. L.; Mohanan, S.; Griffith, O. L.; Breuer, H. C.; Anguish, L. J.; Cherrington, 
B. D.; Palmer, A. M.; Howe, L. R.; Subramanian, V.; Causey, C. P.; Thompson, 
P. R.; Gray, J. W.; Coonrod, S. A., Identification of PADI2 as a potential breast 
cancer biomarker and therapeutic target. BMC cancer 2012, 12, 500. 
 
Meyer, R.; Wolf, S. S.; Obendorf, M., PRMT2, a member of the protein arginine 
methyltransferase family, is a coactivator of the androgen receptor. The Journal of 
steroid biochemistry and molecular biology 2007, 107 (1-2), 1-14. 
 
Miranda, T. B.; Miranda, M.; Frankel, A.; Clarke, S., PRMT7 is a member of the protein 
arginine methyltransferase family with a distinct substrate specificity. The Journal 
of biological chemistry 2004, 279 (22), 22902-7. 
 
Miranda, T. B.; Webb, K. J.; Edberg, D. D.; Reeves, R.; Clarke, S., Protein arginine 
methyltransferase 6 specifically methylates the nonhistone chromatin protein 
HMGA1a. Biochemical and biophysical research communications 2005, 336 (3), 
831-5. 
 
Misteli, T.; Spector, D. L., RNA polymerase II targets pre-mRNA splicing factors to 
transcription sites in vivo. Molecular cell 1999, 3 (6), 697-705. 
 
Mitchell, J. D.; Borasio, G. D., Amyotrophic lateral sclerosis. Lancet 2007, 369 (9578), 
2031-41. 
 
Mowen, K. A.; Tang, J.; Zhu, W.; Schurter, B. T.; Shuai, K.; Herschman, H. R.; David, 
M., Arginine methylation of STAT1 modulates IFNalpha/beta-induced 
transcription. Cell 2001, 104 (5), 731-41. 
 
Nakajima, T.; Kinoshita, S.; Sasagawa, T.; Sasaki, K.; Naruto, M.; Kishimoto, T.; Akira, 
S., Phosphorylation at threonine-235 by a ras-dependent mitogen-activated 
protein kinase cascade is essential for transcription factor NF-IL6. Proceedings of 







Nakashima, K.; Hagiwara, T.; Ishigami, A.; Nagata, S.; Asaga, H.; Kuramoto, M.; 
Senshu, T.; Yamada, M., Molecular characterization of peptidylarginine 
deiminase in HL-60 cells induced by retinoic acid and 1alpha,25-
dihydroxyvitamin D(3). The Journal of biological chemistry 1999, 274 (39), 
27786-92. 
 
Neeli, I.; Khan, S. N.; Radic, M., Histone deimination as a response to inflammatory 
stimuli in neutrophils. J Immunol 2008, 180 (3), 1895-902. 
 
Nicholson, T. B.; Chen, T.; Richard, S., The physiological and pathophysiological role of 
PRMT1-mediated protein arginine methylation. Pharmacological research : the 
official journal of the Italian Pharmacological Society 2009, 60 (6), 466-74. 
 
Nishioka, K.; Reinberg, D., Methods and tips for the purification of human histone 
methyltransferases. Methods 2003, 31 (1), 49-58. 
 
Obianyo, O.; Causey, C. P.; Osborne, T. C.; Jones, J. E.; Lee, Y. H.; Stallcup, M. R.; 
Thompson, P. R., A chloroacetamidine-based inactivator of protein arginine 
methyltransferase 1: design, synthesis, and in vitro and in vivo evaluation. 
Chembiochem : a European journal of chemical biology 2010, 11 (9), 1219-23. 
 
Obianyo, O.; Osborne, T. C.; Thompson, P. R., Kinetic mechanism of protein 
arginine methyltransferase 1. Biochemistry 2008, 47 (39), 10420-7. 
 
Obianyo, O.; Thompson, P. R., Kinetic mechanism of protein arginine methyltransferase 
6 (PRMT6). The Journal of biological chemistry 2012, 287 (8), 6062-71. 
 
Osborne, T.; Roska, R. L.; Rajski, S. R.; Thompson, P. R., In situ generation of a 
bisubstrate analogue for protein arginine methyltransferase 1. Journal of the 
American Chemical Society 2008, 130 (14), 4574-5. 
 
Osborne, T. C.; Obianyo, O.; Zhang, X.; Cheng, X.; Thompson, P. R., Protein arginine 
methyltransferase 1: positively charged residues in substrate peptides distal to the 
site of methylation are important for substrate binding and catalysis. Biochemistry 
2007, 46 (46), 13370-81. 
 
Ostareck-Lederer, A.; Ostareck, D. H.; Rucknagel, K. P.; Schierhorn, A.; Moritz, B.; 
Huttelmaier, S.; Flach, N.; Handoko, L.; Wahle, E., Asymmetric arginine 
dimethylation of heterogeneous nuclear ribonucleoprotein K by protein-arginine 
methyltransferase 1 inhibits its interaction with c-Src. The Journal of biological 
chemistry 2006, 281 (16), 11115-25. 
 
Pahlich, S.; Zakaryan, R. P.; Gehring, H., Identification of proteins interacting with 
protein arginine methyltransferase 8: the Ewing sarcoma (EWS) protein binds 






Pal, S.; Baiocchi, R. A.; Byrd, J. C.; Grever, M. R.; Jacob, S. T.; Sif, S., Low levels of 
miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle 
cell lymphoma. The EMBO journal 2007, 26 (15), 3558-69. 
 
Pal, S.; Vishwanath, S. N.; Erdjument-Bromage, H.; Tempst, P.; Sif, S., Human 
SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively 
regulates expression of ST7 and NM23 tumor suppressor genes. Molecular and 
cellular biology 2004, 24 (21), 9630-45. 
 
Pawlak, M. R.; Banik-Maiti, S.; Pietenpol, J. A.; Ruley, H. E., Protein arginine 
methyltransferase I: substrate specificity and role in hnRNP assembly. Journal of 
cellular biochemistry 2002, 87 (4), 394-407. 
 
Pawlak, M. R.; Scherer, C. A.; Chen, J.; Roshon, M. J.; Ruley, H. E., Arginine N-
methyltransferase 1 is required for early postimplantation mouse development, 
but cells deficient in the enzyme are viable. Molecular and cellular biology 2000, 
20 (13), 4859-69. 
 
Pawson, T.; Gish, G. D., SH2 and SH3 domains: from structure to function. Cell 1992, 71 
(3), 359-62. 
 
Pollack, B. P.; Kotenko, S. V.; He, W.; Izotova, L. S.; Barnoski, B. L.; Pestka, S., The 
human homologue of the yeast proteins Skb1 and Hsl7p interacts with Jak kinases 
and contains protein methyltransferase activity. The Journal of biological 
chemistry 1999, 274 (44), 31531-42. 
 
Qi, C.; Chang, J.; Zhu, Y.; Yeldandi, A. V.; Rao, S. M.; Zhu, Y. J., Identification of 
protein arginine methyltransferase 2 as a coactivator for estrogen receptor alpha. 
The Journal of biological chemistry 2002, 277 (32), 28624-30. 
 
Ragno, R.; Simeoni, S.; Castellano, S.; Vicidomini, C.; Mai, A.; Caroli, A.; Tramontano, 
A.; Bonaccini, C.; Trojer, P.; Bauer, I.; Brosch, G.; Sbardella, G., Small molecule 
inhibitors of histone arginine methyltransferases: homology modeling, molecular 
docking, binding mode analysis, and biological evaluations. Journal of medicinal 
chemistry 2007, 50 (6), 1241-53. 
 
Raijmakers, R.; Zendman, A. J.; Egberts, W. V.; Vossenaar, E. R.; Raats, J.; Soede-
Huijbregts, C.; Rutjes, F. P.; van Veelen, P. A.; Drijfhout, J. W.; Pruijn, G. J., 
Methylation of arginine residues interferes with citrullination by peptidylarginine 
deiminases in vitro. Journal of molecular biology 2007, 367 (4), 1118-1129. 
 
Ren, J.; Wang, Y.; Liang, Y.; Zhang, Y.; Bao, S.; Xu, Z., Methylation of ribosomal 
protein S10 by protein-arginine methyltransferase 5 regulates ribosome 






Rezai-Zadeh, N.; Zhang, X.; Namour, F.; Fejer, G.; Wen, Y. D.; Yao, Y. L.; Gyory, I.; 
Wright, K.; Seto, E., Targeted recruitment of a histone H4-specific 
methyltransferase by the transcription factor YY1. Genes & development 2003, 17 
(8), 1019-29. 
 
Robin-Lespinasse, Y.; Sentis, S.; Kolytcheff, C.; Rostan, M. C.; Corbo, L.; Le Romancer, 
M., hCAF1, a new regulator of PRMT1-dependent arginine methylation. Journal 
of cell science 2007, 120 (Pt 4), 638-47. 
 
Rouault, J. P.; Prevot, D.; Berthet, C.; Birot, A. M.; Billaud, M.; Magaud, J. P.; Corbo, 
L., Interaction of BTG1 and p53-regulated BTG2 gene products with mCaf1, the 
murine homolog of a component of the yeast CCR4 transcriptional regulatory 
complex. The Journal of biological chemistry 1998, 273 (35), 22563-9. 
 
Rust, H. L.; Thompson, P. R., Kinase consensus sequences: a breeding ground for 
crosstalk. ACS chemical biology 2011, 6 (9), 881-92. 
 
Rust, H. L.; Zurita-Lopez, C. I.; Clarke, S.; Thompson, P. R., Mechanistic studies on 
transcriptional coactivator protein arginine methyltransferase 1. Biochemistry 
2011, 50 (16), 3332-45. 
 
Sakamaki, J.; Daitoku, H.; Ueno, K.; Hagiwara, A.; Yamagata, K.; Fukamizu, A., 
Arginine methylation of BCL-2 antagonist of cell death (BAD) counteracts its 
phosphorylation and inactivation by Akt. Proceedings of the National Academy of 
Sciences of the United States of America 2011, 108 (15), 6085-90. 
 
Sassone-Corsi, P.; Mizzen, C. A.; Cheung, P.; Crosio, C.; Monaco, L.; Jacquot, S.; 
Hanauer, A.; Allis, C. D., Requirement of Rsk-2 for epidermal growth factor-
activated phosphorylation of histone H3. Science 1999, 285 (5429), 886-91. 
 
Sayegh, J.; Webb, K.; Cheng, D.; Bedford, M. T.; Clarke, S. G., Regulation of protein 
arginine methyltransferase 8 (PRMT8) activity by its N-terminal domain. The 
Journal of biological chemistry 2007, 282 (50), 36444-53. 
 
Schreiber, S. L.; Bernstein, B. E., Signaling network model of chromatin. Cell 2002, 111 
(6), 771-8. 
 
Schurter, B. T.; Koh, S. S.; Chen, D.; Bunick, G. J.; Harp, J. M.; Hanson, B. L.; 
Henschen-Edman, A.; Mackay, D. R.; Stallcup, M. R.; Aswad, D. W., 
Methylation of histone H3 by coactivator-associated arginine methyltransferase 1. 
Biochemistry 2001, 40 (19), 5747-56. 
 
Scorilas, A.; Black, M. H.; Talieri, M.; Diamandis, E. P., Genomic organization, physical 
mapping, and expression analysis of the human protein arginine methyltransferase 







Scott, H. S.; Antonarakis, S. E.; Lalioti, M. D.; Rossier, C.; Silver, P. A.; Henry, M. F., 
Identification and characterization of two putative human arginine 
methyltransferases (HRMT1L1 and HRMT1L2). Genomics 1998, 48 (3), 330-40. 
 
Sgarra, R.; Lee, J.; Tessari, M. A.; Altamura, S.; Spolaore, B.; Giancotti, V.; Bedford, M. 
T.; Manfioletti, G., The AT-hook of the chromatin architectural transcription 
factor high mobility group A1a is arginine-methylated by protein arginine 
methyltransferase 6. The Journal of biological chemistry 2006, 281 (7), 3764-72. 
 
Shaw, C. E.; Enayat, Z. E.; Powell, J. F.; Anderson, V. E.; Radunovic, A.; al-Sarraj, S.; 
Leigh, P. N., Familial amyotrophic lateral sclerosis. Molecular pathology of a 
patient with a SOD1 mutation. Neurology 1997, 49 (6), 1612-6. 
 
Shen, B.; Singh, P.; Liu, R.; Qiu, J.; Zheng, L.; Finger, L. D.; Alas, S., Multiple but 
dissectible functions of FEN-1 nucleases in nucleic acid processing, genome 
stability and diseases. BioEssays : news and reviews in molecular, cellular and 
developmental biology 2005, 27 (7), 717-29. 
 
Shia, W. J.; Okumura, A. J.; Yan, M.; Sarkeshik, A.; Lo, M. C.; Matsuura, S.; Komeno, 
Y.; Zhao, X.; Nimer, S. D.; Yates, J. R., 3rd; Zhang, D. E., PRMT1 interacts with 
AML1-ETO to promote its transcriptional activation and progenitor cell 
proliferative potential. Blood 2012, 119 (21), 4953-62. 
 
Shogren-Knaak, M.; Ishii, H.; Sun, J. M.; Pazin, M. J.; Davie, J. R.; Peterson, C. L., 
Histone H4-K16 acetylation controls chromatin structure and protein interactions. 
Science 2006, 311 (5762), 844-7. 
 
Sims, R. J., 3rd; Rojas, L. A.; Beck, D.; Bonasio, R.; Schuller, R.; Drury, W. J., 3rd; 
Eick, D.; Reinberg, D., The C-terminal domain of RNA polymerase II is modified 
by site-specific methylation. Science 2011, 332 (6025), 99-103. 
 
Singh, V.; Miranda, T. B.; Jiang, W.; Frankel, A.; Roemer, M. E.; Robb, V. A.; Gutmann, 
D. H.; Herschman, H. R.; Clarke, S.; Newsham, I. F., DAL-1/4.1B tumor 
suppressor interacts with protein arginine N-methyltransferase 3 (PRMT3) and 
inhibits its ability to methylate substrates in vitro and in vivo. Oncogene 2004, 23 
(47), 7761-71. 
 
Slade, D. J.; Subramanian, V.; Fuhrmann, J.; Thompson, P. R., Chemical and biological 
methods to detect posttranslational modifications of arginine. Biopolymers 2013. 
 
So, C. W.; Cleary, M. L., MLL-AFX requires the transcriptional effector domains of 
AFX to transform myeloid progenitors and transdominantly interfere with 
forkhead protein function. Molecular and cellular biology 2002, 22 (18), 6542-52. 
 





GAS7 transforms multipotent hematopoietic progenitors and induces mixed 
lineage leukemias in mice. Cancer cell 2003, 3 (2), 161-71. 
 
Spannhoff, A.; Heinke, R.; Bauer, I.; Trojer, P.; Metzger, E.; Gust, R.; Schule, R.; 
Brosch, G.; Sippl, W.; Jung, M., Target-based approach to inhibitors of histone 
arginine methyltransferases. Journal of medicinal chemistry 2007, 50 (10), 2319-
25. 
 
Spannhoff, A.; Machmur, R.; Heinke, R.; Trojer, P.; Bauer, I.; Brosch, G.; Schule, R.; 
Hanefeld, W.; Sippl, W.; Jung, M., A novel arginine methyltransferase inhibitor 
with cellular activity. Bioorganic & medicinal chemistry letters 2007, 17 (15), 
4150-3. 
 
Strahl, B. D.; Briggs, S. D.; Brame, C. J.; Caldwell, J. A.; Koh, S. S.; Ma, H.; Cook, R. 
G.; Shabanowitz, J.; Hunt, D. F.; Stallcup, M. R.; Allis, C. D., Methylation of 
histone H4 at arginine 3 occurs in vivo and is mediated by the nuclear receptor 
coactivator PRMT1. Current biology : CB 2001, 11 (12), 996-1000. 
 
Suganuma, T.; Workman, J. L., Crosstalk among Histone Modifications. Cell 2008, 135 
(4), 604-7. 
 
Swiercz, R.; Person, M. D.; Bedford, M. T., Ribosomal protein S2 is a substrate for 
mammalian PRMT3 (protein arginine methyltransferase 3). The Biochemical 
journal 2005, 386 (Pt 1), 85-91. 
 
Takahashi, Y.; Daitoku, H.; Hirota, K.; Tamiya, H.; Yokoyama, A.; Kako, K.; 
Nagashima, Y.; Nakamura, A.; Shimada, T.; Watanabe, S.; Yamagata, K.; 
Yasuda, K.; Ishii, N.; Fukamizu, A., Asymmetric arginine dimethylation 
determines life span in C. elegans by regulating forkhead transcription factor 
DAF-16. Cell metabolism 2011, 13 (5), 505-16. 
 
Tan, Y.; Demeter, M. R.; Ruan, H.; Comb, M. J., BAD Ser-155 phosphorylation 
regulates BAD/Bcl-XL interaction and cell survival. The Journal of biological 
chemistry 2000, 275 (33), 25865-9. 
 
Taneda, T.; Miyata, S.; Kousaka, A.; Inoue, K.; Koyama, Y.; Mori, Y.; Tohyama, M., 
Specific regional distribution of protein arginine methyltransferase 8 (PRMT8) in 
the mouse brain. Brain research 2007, 1155, 1-9. 
 
Tang, J.; Frankel, A.; Cook, R. J.; Kim, S.; Paik, W. K.; Williams, K. R.; Clarke, S.; 
Herschman, H. R., PRMT1 is the predominant type I protein arginine 
methyltransferase in mammalian cells. The Journal of biological chemistry 2000, 
275 (11), 7723-30. 
 





methyltransferase that differs from PRMT1 in its oligomerization, subcellular 
localization, substrate specificity, and regulation. The Journal of biological 
chemistry 1998, 273 (27), 16935-45. 
 
Tee, W. W.; Pardo, M.; Theunissen, T. W.; Yu, L.; Choudhary, J. S.; Hajkova, P.; Surani, 
M. A., Prmt5 is essential for early mouse development and acts in the cytoplasm 
to maintain ES cell pluripotency. Genes & development 2010, 24 (24), 2772-7. 
 
Teyssier, C.; Chen, D.; Stallcup, M. R., Requirement for multiple domains of the protein 
arginine methyltransferase CARM1 in its transcriptional coactivator function. The 
Journal of biological chemistry 2002, 277 (48), 46066-72. 
 
Teyssier, C.; Ma, H.; Emter, R.; Kralli, A.; Stallcup, M. R., Activation of nuclear receptor 
coactivator PGC-1alpha by arginine methylation. Genes & development 2005, 19 
(12), 1466-73. 
 
Thompson, P. R.; Fast, W., Histone citrullination by protein arginine deiminase: is 
arginine methylation a green light or a roadblock? ACS chemical biology 2006, 1 
(7), 433-41. 
 
Thompson, P. R.; Kurooka, H.; Nakatani, Y.; Cole, P. A., Transcriptional coactivator 
protein p300. Kinetic characterization of its histone acetyltransferase activity. The 
Journal of biological chemistry 2001, 276 (36), 33721-9. 
 
Tradewell, M. L.; Yu, Z.; Tibshirani, M.; Boulanger, M. C.; Durham, H. D.; Richard, S., 
Arginine methylation by PRMT1 regulates nuclear-cytoplasmic localization and 
toxicity of FUS/TLS harbouring ALS-linked mutations. Human molecular 
genetics 2012, 21 (1), 136-49. 
 
Tran, C. T.; Leiper, J. M.; Vallance, P., The DDAH/ADMA/NOS pathway. 
Atherosclerosis. Supplements 2003, 4 (4), 33-40. 
 
Troffer-Charlier, N.; Cura, V.; Hassenboehler, P.; Moras, D.; Cavarelli, J., Functional 
insights from structures of coactivator-associated arginine methyltransferase 1 
domains. The EMBO journal 2007, 26 (20), 4391-401. 
 
Vallance, P.; Leiper, J., Cardiovascular biology of the asymmetric 
dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. 
Arteriosclerosis, thrombosis, and vascular biology 2004, 24 (6), 1023-30. 
 
Vallance, P.; Leone, A.; Calver, A.; Collier, J.; Moncada, S., Accumulation of an 
endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 
1992, 339 (8793), 572-5. 
 





Hu, X.; Smith, B.; Ruddy, D.; Wright, P.; Ganesalingam, J.; Williams, K. L.; 
Tripathi, V.; Al-Saraj, S.; Al-Chalabi, A.; Leigh, P. N.; Blair, I. P.; Nicholson, G.; 
de Belleroche, J.; Gallo, J. M.; Miller, C. C.; Shaw, C. E., Mutations in FUS, an 
RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. 
Science 2009, 323 (5918), 1208-11. 
 
Verbiest, V.; Montaudon, D.; Tautu, M. T.; Moukarzel, J.; Portail, J. P.; Markovits, J.; 
Robert, J.; Ichas, F.; Pourquier, P., Protein arginine (N)-methyl transferase 7 
(PRMT7) as a potential target for the sensitization of tumor cells to 
camptothecins. FEBS letters 2008, 582 (10), 1483-9. 
 
Virdee, K.; Parone, P. A.; Tolkovsky, A. M., Phosphorylation of the pro-apoptotic 
protein BAD on serine 155, a novel site, contributes to cell survival. Current 
biology : CB 2000, 10 (18), 1151-4. 
 
Waldmann, T.; Izzo, A.; Kamieniarz, K.; Richter, F.; Vogler, C.; Sarg, B.; Lindner, H.; 
Young, N. L.; Mittler, G.; Garcia, B. A.; Schneider, R., Methylation of H2AR29 
is a novel repressive PRMT6 target. Epigenetics & chromatin 2011, 4, 11. 
 
Wang, H.; Huang, Z. Q.; Xia, L.; Feng, Q.; Erdjument-Bromage, H.; Strahl, B. D.; 
Briggs, S. D.; Allis, C. D.; Wong, J.; Tempst, P.; Zhang, Y., Methylation of 
histone H4 at arginine 3 facilitating transcriptional activation by nuclear hormone 
receptor. Science 2001, 293 (5531), 853-7. 
 
Wang, H. G.; Pathan, N.; Ethell, I. M.; Krajewski, S.; Yamaguchi, Y.; Shibasaki, F.; 
McKeon, F.; Bobo, T.; Franke, T. F.; Reed, J. C., Ca2+-induced apoptosis 
through calcineurin dephosphorylation of BAD. Science 1999, 284 (5412), 339-
43. 
 
Wang, L.; Pal, S.; Sif, S., Protein arginine methyltransferase 5 suppresses the 
transcription of the RB family of tumor suppressors in leukemia and lymphoma 
cells. Molecular and cellular biology 2008, 28 (20), 6262-77. 
 
Wang, S.; Tan, X.; Yang, B.; Yin, B.; Yuan, J.; Qiang, B.; Peng, X., The role of protein 
arginine-methyltransferase 1 in gliomagenesis. BMB reports 2012, 45 (8), 470-5. 
 
Wang, X.; Arai, S.; Song, X.; Reichart, D.; Du, K.; Pascual, G.; Tempst, P.; Rosenfeld, 
M. G.; Glass, C. K.; Kurokawa, R., Induced ncRNAs allosterically modify RNA-
binding proteins in cis to inhibit transcription. Nature 2008, 454 (7200), 126-30. 
 
Wang, X.; Huang, Y.; Zhao, J.; Zhang, Y.; Lu, J.; Huang, B., Suppression of PRMT6-
mediated arginine methylation of p16 protein potentiates its ability to arrest A549 
cell proliferation. The international journal of biochemistry & cell biology 2012, 
44 (12), 2333-41. 
 





Han, H.; Grigoryev, S. A.; Allis, C. D.; Coonrod, S. A., Histone 
hypercitrullination mediates chromatin decondensation and neutrophil 
extracellular trap formation. The Journal of cell biology 2009, 184 (2), 205-13. 
 
Wang, Y.; Wysocka, J.; Sayegh, J.; Lee, Y. H.; Perlin, J. R.; Leonelli, L.; Sonbuchner, L. 
S.; McDonald, C. H.; Cook, R. G.; Dou, Y.; Roeder, R. G.; Clarke, S.; Stallcup, 
M. R.; Allis, C. D.; Coonrod, S. A., Human PAD4 regulates histone arginine 
methylation levels via demethylimination. Science 2004, 306 (5694), 279-83. 
 
Wang, Z.; Udeshi, N. D.; Slawson, C.; Compton, P. D.; Sakabe, K.; Cheung, W. D.; 
Shabanowitz, J.; Hunt, D. F.; Hart, G. W., Extensive crosstalk between O-
GlcNAcylation and phosphorylation regulates cytokinesis. Sci Signal 2010, 3 
(104), ra2. 
 
Weerapana, E.; Wang, C.; Simon, G. M.; Richter, F.; Khare, S.; Dillon, M. B.; 
Bachovchin, D. A.; Mowen, K.; Baker, D.; Cravatt, B. F., Quantitative reactivity 
profiling predicts functional cysteines in proteomes. Nature 2010, 468 (7325), 
790-5. 
 
Willis, V. C.; Gizinski, A. M.; Banda, N. K.; Causey, C. P.; Knuckley, B.; Cordova, K. 
N.; Luo, Y.; Levitt, B.; Glogowska, M.; Chandra, P.; Kulik, L.; Robinson, W. H.; 
Arend, W. P.; Thompson, P. R.; Holers, V. M., N-alpha-benzoyl-N5-(2-chloro-1-
iminoethyl)-L-ornithine amide, a protein arginine deiminase inhibitor, reduces the 
severity of murine collagen-induced arthritis. J Immunol 2011, 186 (7), 4396-404. 
 
Wolf, S. S., The protein arginine methyltransferase family: an update about function, new 
perspectives and the physiological role in humans. Cellular and molecular life 
sciences : CMLS 2009, 66 (13), 2109-21. 
 
Wood, D. D.; Ackerley, C. A.; Brand, B.; Zhang, L.; Raijmakers, R.; Mastronardi, F. G.; 
Moscarello, M. A., Myelin localization of peptidylarginine deiminases 2 and 4: 
comparison of PAD2 and PAD4 activities. Laboratory investigation; a journal of 
technical methods and pathology 2008, 88 (4), 354-64. 
 
Xie, J.; Supekova, L.; Schultz, P. G., A genetically encoded metabolically stable 
analogue of phosphotyrosine in Escherichia coli. ACS chemical biology 2007, 2 
(7), 474-8. 
 
Xu, W.; Chen, H.; Du, K.; Asahara, H.; Tini, M.; Emerson, B. M.; Montminy, M.; Evans, 
R. M., A transcriptional switch mediated by cofactor methylation. Science 2001, 
294 (5551), 2507-11. 
 
Xu, W.; Cho, H.; Kadam, S.; Banayo, E. M.; Anderson, S.; Yates, J. R., 3rd; Emerson, B. 
M.; Evans, R. M., A methylation-mediator complex in hormone signaling. Genes 






Yadav, N.; Lee, J.; Kim, J.; Shen, J.; Hu, M. C.; Aldaz, C. M.; Bedford, M. T., Specific 
protein methylation defects and gene expression perturbations in coactivator-
associated arginine methyltransferase 1-deficient mice. Proceedings of the 
National Academy of Sciences of the United States of America 2003, 100 (11), 
6464-8. 
 
Yamagata, K.; Daitoku, H.; Takahashi, Y.; Namiki, K.; Hisatake, K.; Kako, K.; Mukai, 
H.; Kasuya, Y.; Fukamizu, A., Arginine methylation of FOXO transcription 
factors inhibits their phosphorylation by Akt. Molecular cell 2008, 32 (2), 221-31. 
 
Yamaguchi, A.; Kitajo, K., The effect of PRMT1-mediated arginine methylation on the 
subcellular localization, stress granules, and detergent-insoluble aggregates of 
FUS/TLS. PloS one 2012, 7 (11), e49267. 
 
Yang, E.; Zha, J.; Jockel, J.; Boise, L. H.; Thompson, C. B.; Korsmeyer, S. J., Bad, a 
heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell 
death. Cell 1995, 80 (2), 285-91. 
 
Yang, J.; Cron, P.; Good, V. M.; Thompson, V.; Hemmings, B. A.; Barford, D., Crystal 
structure of an activated Akt/protein kinase B ternary complex with GSK3-
peptide and AMP-PNP. Nat Struct Biol 2002, 9 (12), 940-4. 
 
Yang, Y.; Bedford, M. T., Protein arginine methyltransferases and cancer. Nature 
reviews. Cancer 2013, 13 (1), 37-50. 
 
Yoshimatsu, M.; Toyokawa, G.; Hayami, S.; Unoki, M.; Tsunoda, T.; Field, H. I.; Kelly, 
J. D.; Neal, D. E.; Maehara, Y.; Ponder, B. A.; Nakamura, Y.; Hamamoto, R., 
Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is 
involved in various types of human cancers. International journal of cancer. 
Journal international du cancer 2011, 128 (3), 562-73. 
 
Young, T. S.; Ahmad, I.; Yin, J. A.; Schultz, P. G., An enhanced system for unnatural 
amino acid mutagenesis in E. coli. Journal of molecular biology 2010, 395 (2), 
361-74. 
 
Yu, Z.; Chen, T.; Hebert, J.; Li, E.; Richard, S., A mouse PRMT1 null allele defines an 
essential role for arginine methylation in genome maintenance and cell 
proliferation. Molecular and cellular biology 2009, 29 (11), 2982-96. 
 
Yue, W. W.; Hassler, M.; Roe, S. M.; Thompson-Vale, V.; Pearl, L. H., Insights into 
histone code syntax from structural and biochemical studies of CARM1 
methyltransferase. The EMBO journal 2007, 26 (20), 4402-12. 
 
Zha, J.; Harada, H.; Yang, E.; Jockel, J.; Korsmeyer, S. J., Serine phosphorylation of 
death agonist BAD in response to survival factor results in binding to 14-3-3 not 






Zhang, X., Gamble, M. J., Stadler, S., Cherrington, B. D., Causey, C. P., Thompson, P. 
R., Roberson, M. S., Kraus, W. L., and Coonrod, S. A., Genome-Wide Analysis 
Reveals PADI4 Cooperates with Elk-1 to Activate c-Fos Expression in Breast 
Cancer Cells. PLOS Genetics 2011, 7 (6), e1002112. 
 
Zhang, X.; Bolt, M.; Guertin, M. J.; Chen, W.; Zhang, S.; Cherrington, B. D.; Slade, D. 
J.; Dreyton, C. J.; Subramanian, V.; Bicker, K. L.; Thompson, P. R.; Mancini, M. 
A.; Lis, J. T.; Coonrod, S. A., Peptidylarginine deiminase 2-catalyzed histone H3 
arginine 26 citrullination facilitates estrogen receptor alpha target gene activation. 
Proceedings of the National Academy of Sciences of the United States of America 
2012, 109 (33), 13331-6. 
 
Zhang, X.; Cheng, X., Structure of the predominant protein arginine methyltransferase 
PRMT1 and analysis of its binding to substrate peptides. Structure 2003, 11 (5), 
509-20. 
 
Zhang, X.; Gan, L.; Pan, H.; Guo, S.; He, X.; Olson, S. T.; Mesecar, A.; Adam, S.; 
Unterman, T. G., Phosphorylation of serine 256 suppresses transactivation by 
FKHR (FOXO1) by multiple mechanisms. Direct and indirect effects on 
nuclear/cytoplasmic shuttling and DNA binding. The Journal of biological 
chemistry 2002, 277 (47), 45276-84. 
 
Zhang, X.; Zhou, L.; Cheng, X., Crystal structure of the conserved core of protein 
arginine methyltransferase PRMT3. The EMBO journal 2000, 19 (14), 3509-19. 
 
Zoccali, C.; Bode-Boger, S.; Mallamaci, F.; Benedetto, F.; Tripepi, G.; Malatino, L.; 
Cataliotti, A.; Bellanuova, I.; Fermo, I.; Frolich, J.; Boger, R., Plasma 
concentration of asymmetrical dimethylarginine and mortality in patients with 
end-stage renal disease: a prospective study. Lancet 2001, 358 (9299), 2113-7. 
 
Zou, L.; Zhang, H.; Du, C.; Liu, X.; Zhu, S.; Zhang, W.; Li, Z.; Gao, C.; Zhao, X.; Mei, 
M.; Bao, S.; Zheng, H., Correlation of SRSF1 and PRMT1 expression with 
clinical status of pediatric acute lymphoblastic leukemia. Journal of hematology 
& oncology 2012, 5, 42. 
 
Zurita-Lopez, C. I.; Sandberg, T.; Kelly, R.; Clarke, S. G., Human protein arginine 
methyltransferase 7 (PRMT7) is a type III enzyme forming omega-NG-
monomethylated arginine residues. The Journal of biological chemistry 2012, 287 
(11), 7859-70. 
 
 
 
 
 
187 
 
 
 
 
 
 
188 
 
 
